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Abstract: 
The aim of this work was to establish meaningful clinical end-points and surrogate 
markers for diabetic macular ischaemia, a condition for which there is no treatment. 
The relationship between diabetic eye disease and circulating cellular mediators of 
angiogenesis and inflammation was further explored with a view to developing 
therapy in the longer term.  
Visual loss in diabetic macular ischaemia was observed to occur only in moderate to 
severe disease, progresses at a rate of 5-10% increase in area per year and associated 
with thinning of the retinal nerve fibre layer. Direct visualisation of cells in the 
vitreous was achieved using optical coherence tomography. Novel methods for this 
were further developed in inflammatory eye disease, with a view for application in 
diabetic eye disease.  A method for in vivo labelling of cells using ICG to enhance 
visualisation was described. In the field of regenerative medicine, this technique may 
allow direct visualisation of cell-mediated inflammation regardless of the type of cell 
or tissue transplanted. EPC and monocyte profiles were analysed in the context of 
diabetic eye disease. Elevated levels of EPCs as defined by CD34+ CD309+ were 
observed in diabetes, but no associations were observed with progression. There 
were no initial associations between monocyte subsets and diabetic eye disease 
severity at the outset but differences were observed in the context of progression. 
Observations from this work support the notion that inflammation plays an 
important role in diabetic eye disease and will inform development of new 
treatments in this field.  
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1. General introduction 
1.1 Diabetic retinopathy 
1.1.1 Historical perspective 
Diabetes was one of the first diseases to be described in medicine. In 1500 BC, it was 
mentioned in an Egyptian manuscript as the excessive passing of urine. The 
knowledge of diabetes did not increase for over a thousand years, and over the turn 
of the 1st century it continued to be described as an incurable condition with “honey 
urine” for which its name was derived; Diabetes, a Greek work meaning to “pass 
through” or “siphon”, and Mellitus, Latin for “sweet” or “honeyed”. It was not until 
the discovery of insulin by Frederick Banting and Charles Best in 1922, that patients 
with diabetes had a substantial increase in survival and life expectancy.(1) With the 
development of modern insulin and glucose monitoring devices, patients with 
diabetes are now living longer, and in doing so, are at a greater risk of developing 
diabetes-related complications. It is estimated that over half of these individuals will 
at some point in the course of their disease develop diabetic retinopathy, 
representing an insurmountable burden on healthcare systems worldwide.(2-5) By 
the year 2030, there will be an estimated 552 million people diagnosed with diabetes 
globally. 
 Vision loss as a consequence of diabetes is now well known. However, it was 
only the invention of the direct ophthalmoscope that allowed the first description of 
diabetic retinopathy in 1856, when Eduard Jaeger reported his then controversial 
observations of “yellowish spots and extravasations” in the central macular of a 
diabetic patient.(6) However, a causal relationship between diabetes and diabetic 
vascular changes in the retina was treated with skepticism by European 
ophthalmologists, largely because of open opposition by Albrecht von Graefe, an 
influential German ophthalmologist in his time. Diabetic retinopathy, as a disease 
entity only gained acceptance after 1872 when Edward Nettleship published the first 
histopathological proof in his seminal paper “On oedema or cystic disease of the 
retina”.(7) 
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1.1.2 Epidemiology 
In the 21st century, diabetic retinopathy is now recognised as the most common 
microvascular complication of diabetes and the leading cause of blindness in 
working-age persons. As such, it is a condition that is of an important public health 
concern with significant economic consequences. Our knowledge of the onset, 
progression, and impact of diabetic retinopathy derives from large epidemiological 
studies such as the Wisconsin Epidemiologic Study of Diabetes (WESDR)(4, 5, 8), 
Beaver Dam Eye Study (BDES) (9), and Blue Mountains Eye Study (BMES) (10, 11).  
The WESDR, a population-based cohort study, shows that the prevalence of 
diabetic retinopathy in type 1 diabetes range from 17% (less than 5 years duration of 
disease) to 100% (more than 15 years duration of disease). In the corresponding type 
2 population, the prevalence ranged from 29% to 78%. The factors that influenced 
the development of diabetic retinopathy were confirmed in two landmark clinic 
trials; the Diabetes Control and Complications Trial (DCCT) for type 1 diabetes (12), 
and the UK Prospective Diabetes Study (UKPDS) for type 2 diabetes (13), and include 
glycaemic control, duration of diabetes, dyslipidaemia, and blood pressure.(14, 15) Of 
note, both inflammation and vascular endothelial dysfunction have also been 
associated with the presence of diabetic retinopathy in large population-based 
studies. Serum levels of C-reactive protein (CRP), soluble intercellular adhesion 
molecule-1 (sICAM-1), and urinary albumin:creatinine ratio (16) , as well as 
chemokines such as stromal cell-derived factor (SDF)-1 alpha, RANTES, and monocyte 
chemoattractant protein (MCP)-1 (12), have been associated with diabetic 
retinopathy prevalence and severity.  
 
1.2 Phenotypic manifestations of diabetic retinopathy 
The abnormalities observed in the retina in diabetic retinopathy can be conceptually 
classified according to the behaviour of the retinal vasculature- (1) hyperperfusion 
(leakage and oedema), which results in the development of lesions such as macular 
oedema, peripheral hard exudates and microaneurysms, and (2) hypoperfusion 
(ischaemia), which results in enlargement of the foveal avascular zone (FAZ) in the 
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macula, and capillary non perfusion and retinal neovascularisation in the retinal 
periphery.  
Historically, classification for diabetic retinopathy was developed for the 
purposes of communication between researchers and clinicians. In 1968, the “Airlie 
House” classification was developed by the US public health service, based on five 
standard colour photographic fields.(17) Vascular lesions were classified into three 
categories; absent, mild to moderate, and severe. This system was deemed over-
simplistic, with only three categories of severity, in particular, the broad category of 
“mild to moderate”. Subsequently, the Diabetic Retinopathy Study (DRS), whose 
principal aim was to determine the efficacy of retinal laser photocoagulation in 
preventing severe vision loss in “high-risk” proliferative diabetic retinopathy, created 
the modified Airlie House classification system.(18) This included a further 2 colour 
photographic fields and separation of severity grades in order to allow the 
researchers to grade more consistently. Although the DRS, a landmark study in the 
field of diabetic retinopathy treatment, showed that visual function was preserved 
with laser treatment of those with “high-risk” retinal features, it failed to examine 
whether those with early features of proliferative diabetic retinopathy would benefit 
from similar therapy.  
The Early Treatment Diabetic Retinopathy Study (ETDRS) was designed in the 
1970s to answer this question, and the efficacy of laser photocoagulation for macular 
oedema. In the ETDRS, classification of diabetic retinopathy features were further 
split to include 17 factors, examples of which include microaneurysms, intraretinal 
microvascular abnormalities (IRMA), new vessels, hard exudates, cotton wool spots, 
venous beading/narrowing/sheathing, perivascular exudates, fibrosis. Combined with 
several severity steps, this presented a complicated grading scheme of over 100 
grades. In spite of this, the ETDRS diabetic retinopathy scale remains the gold-
standard for grading for researchers and clinicians alike.(19) An attempt to simplify 
the ETDRS grading system was developed by the Global Diabetic Retinopathy Project 
Group- the International Classification Scheme.(20) This international collaborative 
effort towards consensus regarding disease severity classification was designed to 
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detect both proliferative diabetic retinopathy and diabetic macular oedema at a 
threshold, which required laser therapy, for the purposes of facilitating 
communication and discussion amongst clinicians who attend to these patients. 
It is important to note that the historical classification of diabetic retinopathy 
is based solely on colour photography. Fluorescein angiography, although performed 
in ETDRS, had poor agreement in grading of the FAZ size (74% agreement), FAZ 
outline and perifoveal capillary loss (47% agreement)(21). Because of the 
questionable reproducibility of grading, the resources required, and invasive nature 
of fluorescein angiography, it has not been used in more recent clinical trials of 
diabetic retinopathy such as the Diabetic Retinopathy Clinical Research Network 
(DRCR.net).(22) A fundamentally new way of assessing retinal disease was introduced 
by the advent of optical coherence tomography (OCT) was a completely different 
story. Its non-invasive nature, rapid acquisition, and cross-sectional view of the 
retina, has led to widespread use in both research and clinical practice. As such, the 
future of diabetic retinopathy classification is likely to incorporate multi-modal, non-
invasive imaging technology, such as OCT, but also OCT angiography, and ultra 
widefield fundus photography. 
 
1.2.1 Retinal Neovascularisation 
Retinal neovascularisation in the diabetes occurs as a result of areas of retinal non-
perfusion. It can occur at the optic nerve head; neovascularisation at the disk (NVD) 
or along retinal veins and postcapillary venules; neovascularisation elsewhere (NVE).  
In diabetic retinopathy, neovascularisation may also occur in the anterior segment in 
the form of new vessels in the iris, or iris rubeosis, with resultant bleeding into the 
anterior chamber of the eye, and/or blockage of the trabecular meshwork (drainage 
angle) and elevated intraocular pressure. The new blood vessels grow along the 
retina and vitreous gel. They have thin fragile walls, leak plasma (as observed using 
fluorescein angiography), and may bleed into the vitreous cavity. Visual loss from 
retinal neovascularisation can occur with vitreous haemorrhage, or later fibrosis of 
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new vessels with and consequent tractional forces on the retina causing retinal 
breaks and detachment. 
 The spectrum of disease in retinal neovascularisation is wide. Clinically, it can 
be classified as non-proliferative or proliferative diabetic retinopathy (PDR).(19, 20) 
PDR, which occurs in up to 50% in type 1, and 15% in type 2 diabetes, remains a 
major cause of visual disability in this age group.(4) Therefore, the timely detection of 
neovascularisation and the monitoring of new vessel activity is important in 
managing these patients. In the landmark clinical trials of the DRS and ETDRS, colour 
photography was used to detect retinal neovascularisation with fluorescein 
angiography (examples of which can be seen in Figure 1.1a-d) as an adjunct for the 
classification of disease severity, guiding laser therapy and evaluating the response to 
treatment.(21, 23, 24) In current large multicenter clinical trials, fluorescein 
angiography is usually not required, and performed at the investigator’s 
discretion.(25) In clinical practice however, it is often used to ascertain new vessel 
activity in the context of evaluating the response to treatment. As fluorescein 
angiography is an invasive procedure, it is not performed with the same frequency as 
OCT. 
OCT, first described by Huang et al., in 1991, obtains a cross-sectional image 
of the retina, using a non-invasive technique with micrometre resolution.(26, 27) In 
the last decade, this technology has advanced rapidly, and currently, spectral-domain 
OCT (SD-OCT), which uses spectral interferometry and a Fourier transform algorithm, 
has an increased sensitivity, higher scan acquisition rate, and potentially greater 
depth penetration.(27) The evolution of SD-OCT has changed how diabetic 
retinopathy is investigated, and has been widely adopted for the assessment of 
diabetic macular oedema, both in clinical practice and clinical trials. This non-invasive 
technique has not only allowed for more frequent assessment and close monitoring 
of patients with diabetic retinopathy, but has also increased our understanding of 
how the disease affects the different layers of the retina and choroid, in particular, 
for the identification of retinal thickening, intra-retinal oedema and changes of the 
vitreoretinal interface.(28-31) 
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Figure 1.1. Retinal neovascularisation.  
(a) Colour fundus photograph of a patient with active neovascularisation elsewhere (NVE). (b) 
Magnification of the annotated area in 2a showing the NVE in detail. (c) Early phase fluorescein 
angiogram demonstrating temporal capillary non-perfusion and leakage from the NVE complex, which 
(d) increased in size and intensity through the study, corresponding to active disease. (e-f) Green 
horizontal lines represent spectral-domain optical coherence tomography B-scans through the NVE. (e) 
Depicted area is enlarged and shows a flat NVE complex with vitreous invasion (red) and associated 
vitreous hyperreflective dots (green). (f) Magnification of the delineated area shows in more detail the 
dilated tips of the NVE (red) and the hyperreflective dots (green). Figure prepared from my own data. 
 
There is limited evidence regarding the usefulness of SD-OCT for the 
investigation of the morphologic features of PDR, namely NVD and NVE. Although 
vitreoretinal changes may be observed when extramacular SD-OCT scans are 
obtained through new vessels, there have been no studies that address its potential 
to assess new vessel activity.(32) Identifying SD-OCT derived features of new vessel 
activity will enable the clinician to more closely monitor patients, and consequently 
tailor management decisions according to the individual’s response to treatment – 
i.e., during a course of pan-retinal laser photocoagulation, or intravitreal 
pharmacotherapy. An example of an OCT image of an active neovascular complex is 
demonstrated in Figure 1.1, showing invasion into the vitreous cavity hyperreflective 
dots above the lesion, which may indicate sub-clinical bleeds into the vitreous cavity 
or inflammatory cells homing to these sites of neovascularisation. 
 
1.2.2 Macular ischaemia 
Diabetic macular ischaemia (DMI) is characterized by disruption to the FAZ, loss of 
capillaries in the perifoveal and non-contiguous areas of the macula. The presence of 
DMI is recognised as an important cause of visual loss in diabetic retinopathy, and 
implicated in poor treatment outcomes in diabetic macular oedema (DMO) and 
PDR.(24, 33, 34) Furthermore, macular ischaemia has been observed to be a risk 
factor for the development of PDR, DMO, and a poor visual outcome after 
vitrectomy.(24, 35, 36)  At the present time, there is no effective treatment for DMI, 
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and consequently, major population studies, and clinical trials for targeting DMO, 
have not been geared towards identifying macular ischaemia.(5, 37)  
The paucity of information evaluating DMI may be explained, in part, by the 
requirement of an invasive procedure, fluorescein angiography, for its diagnosis. 
Despite the risk, albeit small, of serious adverse effects, fluorescein angiography is 
the current gold standard as it allows excellent visualization of the foveal capillary 
network. The EDTRS first described standardized grading of DMI using angiography; 
in their system, severity of DMI is assessed on the basis of criteria such as degree of 
capillary loss, capillary dilatation, the size and outline of the FAZ, perifoveal capillary 
spacing, and abnormalities of retinal arterioles.(21) Examples of the different DMI 
severity levels are shown in Figure 1.2. The EDTRS study only included a few cases of 
severe macular ischaemia (2.3% of eyes at baseline), and though limited by a 36% 
attrition rate, remains as the only large prospective study to grade specifically for 
DMI. Although some studies have adopted the EDTRS method of DMI grading,(38, 39) 
many others use only the FAZ area and outline, which has been shown to be a 
reliable measure of DMI, as a substitute for detailed ETDRS grading.(33, 40) As a 
result the effects of ischaemia outside the FAZ are often not accounted for.  
The clinical significance of DMI is that it confers a poor prognosis in diabetic 
retinopathy, complicates management decisions of DMO, may impart a poor 
response to treatment, and most importantly, has effects on visual function. 
Although previous studies have demonstrated the correlation of macular ischaemia 
with impaired visual acuity,(41) this relationship is not always straightforward. 
Morphological changes do not always correspond with functional endpoints and – in 
many cases – good visual acuity may be maintained even in the presence of 
seemingly advanced ischaemia.(42, 43) 
 
1.2.3 Retinal choroidopathy  
The choroidal circulation forms an integral part of metabolic exchange in the outer 
retina.(44) This is of particular significance in the macula, due to the lack of retinal 
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vasculature – the FAZ, and a high metabolic demand from an increased 
photoreceptor density. Dysfunction of the choroidal circulation has been long 
implicated in diabetic retinopathy and maculopathy.(45) Since the advent of 
enhanced depth OCT (EDI-OCT) imaging, allowing non-invasive examination of the 
choroid in vivo,(46) there has been renewed interest in diabetic choroidopathy as a 
disease entity.(47-50)  
Evidence for diabetic choroidopathy were first noted in histopathological 
studies, where abnormalities such as arteriosclerosis, choriocapillaris degeneration, 
focal scarring, and neovascularisation were observed.(51-53) This was followed by 
indocyanine green angiographic findings in the diabetic choroid, showing hyper- and 
hypofluorescent spots at the level of the choriocapillaris suggested to represent 
aneurysms or deficits in the choroidal vasculature.(54, 55) 
A number of preliminary studies have used OCT, either EDI-OCT or long-
wavelength OCT research prototype systems, to examine the choroid in patients with 
diabetic retinopathy. These studies have reported a thinner choroid compared to 
healthy eyes, with an increased disparity in eyes with a greater severity of diabetic 
retinopathy, the presence of macular oedema, and prior pan-retinal laser 
photocoagulation.(47-50) However, the thinning observed in eyes of patients with 
diabetic retinopathy has been described to exceed the magnitude of possible 
choriocapillaris atrophy in isolation.(47) It is therefore conceivable that choroidal 
vascular changes observed in patients with diabetes occur not only in the 
choriocapillaris, but also within its medium (Sattler’s) and large (Haller’s) vessel 
layers. To date, analysis of these choroidal vascular sublayers using OCT has been 
restricted to small studies using long wavelength OCT in normal subjects.(56, 57)   
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Figure 1.2. Diabetic macular ischaemia severity grades. 
(i) Examples of an early phase fundus fluorescein angiogram demonstrating (a) none, (b) questionable, 
(c) mild, (d) moderate, and (e) severe diabetic macular ischaemia. (ii) Annotated fluorescein 
angiogram, with the foveal avascular zone outlined in red. (iii) The foveal avascular zone outline alone 
on the left (red), and on the right, the foveal avascular zone area (white), and perifoveal vasculature 
(red). Figure prepared from my own data. 
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1.3 Cellular mediators in diabetic retinopathy 
In adults, neovascularisation – the growth of new blood vessels – is typically thought 
to occur via “angiogenesis” (i.e. by the proliferation, migration, and remodelling of 
fully differentiated endothelial cells in existing vascular networks).(58) However, 
since 1997, circulating endothelial progenitor cells (EPCs) have been found to 
contribute to this process – a form of “vasculogenesis” (the formation of blood 
vessels from individually migrating precursor cells), previously only described in the 
embryo.(59) Since this seminal finding, EPCs have been used to promote tissue 
vascularisation in a number of non-ocular models,(60) and the therapeutic 
opportunity they present, for patients with diabetic retinopathy, has been 
recognised.(61) A number of studies have demonstrated evidence of EPC dysfunction 
in patients with diabetes mellitus;(62-64) There are fewer EPCs in peripheral blood in 
patients with diabetes compared with healthy subjects and diabetic EPCs exhibit 
impaired mobilisation from the bone marrow, impaired migratory response to 
chemokines, proliferation, adhesion and deformability.(62-65) 
Diabetic retinopathy is a phenotypically heterogeneous disorder and the 
association between EPC number/function and each disease subtype is not yet 
known.(61) Therefore, as a first step in the application of EPCs for the treatment of 
diabetic retinopathy, characterisation of EPCs in each diabetic retinopathy subgroup 
is required. The knowledge acquired from such characterisation may provide useful 
prognostic information for these patients, as well as guiding the development of 
translational cellular therapies. 
 
1.3.1 Endothelial progenitor cells (EPCs) 
The EPC was first isolated in in human peripheral blood by Asahara et al using cell 
surface markers CD34 and vascular endothelial growth factor receptor (VEGFR2).(59) 
They observed that these cells were able to differentiate in to mature endothelial 
cells in culture, form vascular structures, and incorporate into sites of active 
angiogenesis restoring vascular integrity.(66, 67) EPCs are found mainly in the adult 
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bone marrow. In the peripheral circulation, these cells are relatively rare at 0.01% of 
peripheral blood mononuclear cells (PBMCs).(61, 66) However, their numbers 
increase in response to injury; such as inflammation or ischaemia where they are 
recruited to sites requiring vascular repair.(68) 
  EPCs have been previously defined by their surface markers and behaviour in 
culture. In its initial discovery, CD34+ and VEGFR2+ hematopoietic progenitor cells 
were shown to differentiate to an endothelial phenotype. However, CD34 is not 
exclusively expressed on haematopoietic stem cells but also on mature endothelial 
cells. CD133, an immature haematopoietic stem cell marker, was used to distinguish 
between the two.(69) There is also evidence showing that CD14+ myeloid cells are 
capable of transdifferentiating along the endothelial cell lineage, and can participate 
in the formation of new vessels in vivo.(69-74) Controversy remains, with respect to 
the identification and origin of EPCs from peripheral blood mononuclear cells. 
Putative sources that have been suggested include (1) hematopoietic stem cells, (2) 
myeloid cells and (3) circulating mature endothelial cells. (75, 76)  
 Controversy regarding the potential identity and origin of the EPC are further 
muddied by its progeny; the heterogeneous nature of the vascular endothelium is 
exemplified not only by its behaviour in health and disease, but also its variability in 
gene expression, morphology and function according to its location within the 
circulatory system.(77) However, such diversity is key to the specialised role of its 
function. In particular, the microvascular endothelium, among its many roles, 
regulates fluid and nutrient transport and acts as a gatekeeper for inflammation, 
adapting to local fluctuations in metabolism.(78) In diabetes, endothelial dysfunction 
and early senescence have been demonstrated in response to hyperglycaemic 
conditions (79), with impaired nitric oxide production(80) and increased circulating 
apoptotic microparticles found in the circulation of these patients.(81) The reparative 
function of the endothelium has also been shown to be impaired in diabetes. EPCs in 
diabetes have been observed to have impaired mobilization, migration, and homing 
to sites of injury.(82) In culture, a decreased proliferative capacity and shorten 
survival have been further observed.(82) Defects in intracellular signalling, a response 
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to inflammation, reactive oxygen species, and insulin have all been implicated.(83, 
84)  
 EPCs have been reported to be reduced in numbers in newly diagnosed type 2 
diabetes, with a partial recovery during the intervening years, before a dramatic 
reduction at 20 years after diagnosis.(85) Functional impairment of EPCs have also 
been associated with its affiliated complications. In animal models of critical limb 
ischaemia, collateralisation of vessels was enhanced by EPCs from control but not 
diabetic animals.(86) In diabetic kidney disease, renal transplantation has been 
shown to improve EPC function (in vitro migration and adhesion) but paradoxically 
decreased its numbers.(87) In diabetic neuropathy, intramuscular administration of 
EPCs has been shown to reverse impairment of sciatic nerve conduction velocity and 
blood flow in diabetic rats.(88) This was similarly observed in streptozotocin-induced 
diabetic mice after hind-limb injection of EPCs.(89) Interestingly, portions of injected 
EPCs were localised to the vasa nervorum suggesting that EPCs may reverse the 
effects of diabetic neuropathy. In fact, bone marrow neuropathy itself (in a rat model 
of type 2 diabetes), has been found to be a cause for the reduction of bone marrow 
release of EPCs.(90) Interestingly, these changes were observed prior to the 
development of diabetic retinopathy in this model. 
 In diabetic eye disease, EPCs have been observed in both type 1 and type 2 
diabetes to be reduced in number but have a higher clonogenic potential and an 
enhanced ability to differentiate into mature endothelial cells in culture.(91, 92) It 
has been suggested that this may, in part, explain the paradoxical “hyperactive” 
pathological angiogenesis that occurs in proliferative diabetic retinopathy, which 
occurs when there is profound areas of retinal ischaemia. In proliferative diabetic 
retinopathy, these aberrant new vessels display characteristics of “poorly-made’ 
vasculature; leaking, growing into the avascular vitreous, prone to fibrosis with 
consequent contraction that applies unwanted tractional forces which wrinkle, tear 
and detach the neural retina. Evidence from patients with type 1 diabetes, indicates 
that it may be a stage-related regulation of EPCs that occurs with duration of 
diabetes that plays a role in this phenomena. Reduced numbers of EPCs were 
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observed in patients with mild and moderate non-proliferative diabetic retinopathy, 
whereas “mature” EPCs which co-expressed CD34 and CD31 were dramatically 
increased in proliferative disease.(93) Indeed, these “mature” EPCs may have a 
causative role in the generation of aberrant new vessels, and reflect a phenotypic 
shift in patients who develop proliferative diabetic retinopathy. However, they may 
just as likely be a consequence of “abnormal” EPCs, either produced by the bone 
marrow or as a result of shedding from the neovascular complexes themselves. There 
are no studies that examine the relationship between EPCs and diabetic 
maculopathy.  
 
1.3.2 Circulatory Monocytes 
Under prolonged ischaemia, large numbers of circulating monocytes are attracted to 
sites of injury. The biological goal of this response is to promote healing of damaged 
tissue by removal of dead cells, aid in the replacement of necrotic areas by 
connective tissue (fibrosis), and ultimately restore vascularisation at a 
microcirculatory level. Circulating monocytes and their tissue decedents, 
macrophages, produce a myriad of cytokines to orchestrate this repair process. This 
has been observed in various conditions where tissues/organs are exposed to periods 
of prolonged ischaemia; myocardial infarction, stroke, critical limb ischaemia, and 
chronic renal disease.(94-97) In the retina, leukocytes have been long implicated in 
the pathogenesis of diabetic retinopathy. (98) More specifically, targeted suppression 
of circulating monocytes with clodronate liposomes has been observed to suppress 
pathological neovascularisation in rat models of proliferative retinopathy. (99) This 
suggests that alterations in monocyte profiles in diabetes may not only play a role in 
the pathogenesis of diabetic eye disease, but also differentially steer individual eyes 
toward divergent phenotypic manifestations of diabetic retinal or macular disease. 
 Monocytes populations show a great diversity within the circulation; in their 
proportions, cytokines secreted, and role they play in an inflammatory response. 
Presently, subsets of the monocyte population are defined by their differential 
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expression of CD14 (lipopolysaccharide receptor) and CD16 (Fc receptor). The major 
subset (~85%) is “classical monocyte” (also known as M2), which expresses CD14++ 
CD16- and produce large amounts of proinflammatory cytokines such as interleukin 
(IL)-1, IL-6, reactive oxygen species (ROS), prostaglandin E2, and plasminogen 
activator.(100, 101) The 2nd most common subset (~15%) is the “non-classical 
monocytes” (also known as M1), which express CD14low CD16+. These cells exhibit 
potent antigen-presenting capacity and produces interferon-α, tumour necrosis 
factor, and IL-12.(102) The smallest subset (<5%) is the “intermediate monocyte” 
(iM), which express CD14+ CD16+. It is unknown if intermediate monocytes have a 
discrete biological role or whether they are an “intermediate”, as the name suggests, 
in the journey of transition from classical to non-classical monocytes.(103) It has 
been observed that intermediate monocytes are increased in different disease states, 
such as rheumatoid arthritis, severe asthma, and sarcoidosis.(104-106) Interestingly, 
they are increased by intense physical activity, but found in lower percentages in 
physically active individuals.(107, 108) 
 In diabetes, phenotypes of circulating immune cells have been observed to 
occur in distinct frequencies in type 1 and type 2 disease, and monocytes in particular 
have been positively correlated with age, body mass index and insulin 
sensitivity.(109) Flow cytometric analysis have further shown that proportions of 
monocyte subsets differ in patients with type 1 diabetes compared with healthy 
controls, with significantly higher classical and non-classical subsets.(110) Both 
intermediate and non-classical subsets have also been observed to be predictive of 
the development of diabetic retinopathy in these patients.(110) Conversely, Fadini et 
al did not observe any difference in monocyte subsets in patients with type 2 
diabetes compared to controls.(111) However, a trend towards a decrease in classical 
monocytes was observed in patients with nephropathy or retinopathy. When the 
authors compared the ratio of non-classical to classical monocytes (M1/M2 ratio) a 
significant difference was observed with macroangiopathy but not microangiopathy. 
To the author’s knowledge, there are no studies that examine monocyte profiles in 
patients with different phenotypic manifestations of diabetic eye disease.  
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1.3.3 Implications for the clinical management of DR 
Diabetic retinopathy, a microvascular complication of diabetes mellitus, is the leading 
cause of blindness among people of working-age in the United Kingdom.(112) 
Diabetic retinopathy is a vasodegenerative disorder in which the sequence of 
pathologic changes has been well established: progressive dysfunction and death of 
the endothelial cells and pericytes is followed by vascular occlusion and ischaemia, 
with subsequent ischaemia-related events such as vascular leakage and/or retinal 
neovascularisation.(113) While both endothelial cells and pericytes undergo 
premature death in diabetic retinopathy, there is some evidence to suggest that the 
endothelium has a capacity for replication and repair, at least in the short-term.(114) 
Despite these findings, the balance of experimental and clinical evidence suggests 
that reparative neovascular processes in patients with diabetic retinopathy are 
limited – contrary to its perception as a pro-neovascular disorder, the proliferative 
phase of diabetic retinopathy only develops after long periods of ischaemia occurring 
in the context of impaired or absent vascular repair and remodelling.(115) In 
contrast, microvascular repair and remodelling is a notable feature of other 
ischaemic retinopathies such as retinal venous occlusion.(61) Thus, if reparative 
neovascularisation can be harnessed appropriately, the potential exists to contain or 
reverse the ischaemia that drives macular oedema and pathologic retinal 
neovascularisation in patients with diabetic retinopathy.  
It is widely accepted that neovascularisation occurs in 2 ways: angiogenesis, a 
process where new blood vessels form by the remodelling of fully differentiated 
endothelial cells in existing vascular networks (58), and vasculogenesis, which 
involves de novo formation of blood vessels (primarily during embryogenesis) from 
migrating precursor cells.(116) The discovery that in some instances these precursor 
cells may be derived from the adult bone marrow (59) presents a number of 
diagnostic and therapeutic opportunities; in particular, EPCs may have the ability to 
act as circulating biomarkers for disease onset and progression, as well as acting as 
promoters of reparative neovascularisation.(61)  
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Pioneering preclinical and clinical studies have shown that administration of 
EPCs can restore tissue vascularisation after ischaemic events in other parts of the 
body e.g. ischaemic limbs.(60) Thus, EPCs could conceivably fulfil a similar role in 
patients with diabetic retinopathy. However, a number of studies have shown that 
patients with diabetes mellitus have fewer numbers of circulating EPCs, with 
decreased function, relative to age-matched healthy controls.(62-64) These findings 
are consistent with the known impairment of reparative neovascular processes in 
patients with diabetic retinopathy.(115) However, diabetic retinopathy is a 
structurally heterogeneous disorder and the association between each disease 
subtype, and EPC number/dysfunction, is not yet known. Characterisation of EPCs in 
this manner thus represents a vital first step for their potential therapeutic 
application in this disease.  
Although there are no studies that have assessed the use of monocytes in 
diabetic retinopathy as a means for cell replacement therapy, multiple independent 
groups have demonstrated that CD14+ monocytes are integral to the efficacy of bone 
marrow or cord blood transplantation in regenerative medicine.(117) Mononuclear 
fractions of cord blood depleted of CD14+ monocytes have shown a reduced 
therapeutic value in a rat stroke model. In addition, the value of CD14+ monocytes 
did not depend on its source as interchangeable results were obtained with cells 
derived from peripheral blood. Similar results have been observed in hind limb 
ischaemia models with both human peripheral and mouse bone marrow derived 
monocytes.(118) The therapeutic value of monocytes has been increasing recognised 
over the past decade with some in the field postulating that there is more evidence 
for the therapeutic value of mature cells (monocytes) than stem cells.(119) A 
paradigm shift in regenerative medicine has moved in the direction of endogenous 
tissue repair by controlling host inflammatory pathways. However, this development 
has been largely confined to research in inflammatory and autoimmune diseases and 
has not been fully explored in predominantly microvascular diseases such as diabetic 
eye disease. Arguably, there is sufficient preliminary evidence and scope to consider 
the CD14+ monocyte as a potential candidate for cell therapy. 
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1.3.4 The effects of lipid-lowering therapy 
It is well accepted that dyslipidaemia increases the risk of retinopathy and its 
progression.(120, 121) However, findings from large randomized controlled trials 
have not been consistent. For example, the Collaborative Atorvastatin Diabetes Study 
(CARDS) (n=2830) failed to observe the reduction of progression of retinopathy in 
patients with type 2 diabetes.(122)  In contrast, the FIELD Study, which compared 
fenofibrate and placebo in stain-naïve patients with type 2 diabetes (n=9795) 
observed that in 5 years, patients on fenofibrate required less laser or retinopathy or 
maculopathy (3.6% versus 5.2%).(123) Furthermore, post-hoc analysis of the FIELD 
Study (n=1012) found a reduced incidence of 2-step progression of retinopathy (by 
ETDRS criteria), but only in those with retinopathy prior to trial enrolment (3.1% 
versus 14.6%).(124) The ACCORD trial (n=2856), where all patients were on open-
label simvastatin, similarly observed a reduced in progression of diabetic 
retinopathy.(125) Of note, the reduction obtained with fenofibrate combined with 
simvastatin was 40%, higher than the 33% reduction obtained in the intensive 
glycaemic control arm. This highlights the importance of consideration of statin 
therapy when studying patients with diabetic retinopathy.  
 Fenofibrate if a peroxisome proliferactor- activated receptor (PPAR)- α that is 
indicated for the treatment of hypertriglyceridemia and mixed lipidaemia. In addition 
to its main action fenofibrate has other non-lipid medicated mechanisms by which it 
could be effective in slowing the progression of diabetic retinopathy. This includes 
effects on endothelial cell apoptosis(126), angiogenesis (127), and its antioxidant and 
anti-inflammatory activity.(128-130) Of relevance to this thesis, fenofibrate has 
further been shown to alter gene transcription of apolipoprotein A1, a potent 
scavenger of reactive oxygen species in macrophages and fibroblasts in the liver.(131) 
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1.4 Why should we study cellular mediators in DR? 
It is well known that the process of neovascularisation occurs as a result of elevated 
vascular endothelial growth factor (VEGF) levels in the eye. More recently, the role of 
inflammation in the pathogenesis of diabetic retinopathy has gained wider 
acceptance. Elevated levels of inflammatory cytokines such as IL-4, IL-6, IL-8, IL17A, 
MCP-1, and tumour necrosis factor (TNF)α have been observed in vitreous samples 
from eyes with proliferative diabetic retinopathy compared to controls, along with 
raised circulating inflammatory biomarkers in these patients.(132-134) Furthermore, 
there is evidence to suggest that elevated levels of macrophage colony-stimulating 
factor (M-CSF) and IL-13, which are elevated in vitreous samples of patients with 
proliferative diabetic retinopathy, may result in M2 polarisation of 
macrophages.(135) A recent proof-of-concept clinical trial has observed that the use 
of a low-dose oral anti-inflammatory agent, doxycycline, has shown promising results 
in improvement of retinal function in eyes with severe nonproliferative, and 
proliferative diabetic retinopathy. (136) These suggest that cellular mediators play a 
large role in both severity and the phenotypic manifestation of diabetic eye disease. 
A greater understanding of the part inflammation play may aid in tailoring treatment 
regimes (steroid therapy, laser, anti-VEGF therapy or a combinations of these) to 
individual patients. The implications of which will have long-term consequences, both 
to the patients’ visual function, as well as quality of life. 
 
1.5 Thesis Hypothesis 
Effective biomarker research has increasingly become one of the cornerstones of 
early drug development in order to identify optimal biological doses for treatment. In 
fact, imaging-based biomarkers have also been applied to other fields such as 
cardiology and oncology to understand mechanisms of disease and predict outcomes 
of novel therapy. This thesis hypothesizes that the synergistic use of state-of-the-art 
retinal imaging techniques to visualise the eye and its associated blood vessels, 
combined with putative cellular mediators of diabetic retinopathy; EPCs and 
37 
 
 
monocytes, will make a powerful biomarker for the identification, definition, and 
prognosis of diabetic eye disease. 
 
1.6 Thesis Aims 
Recent research has shown that diabetes can affect both EPCs and monocytes with 
significant overlap between both cell types. The relationships between these cells 
and the phenotypic manifestations of diabetic eye disease are less well known. This 
project aims to firstly, characterise a clinical phenotype of diabetic eye disease- 
diabetic macular ischaemia, for which no therapy is currently available, as it is likely 
to represent a cohort of patients who would be suitable for replacement cell therapy. 
Secondly, novel methods for monitoring inflammation were investigated in the 
retinae of both animal models and humans, in an attempt to develop quantitative 
outcome measures that may be applicable to a clinical trial. And finally, examine the 
characteristics of EPCs and circulating monocytes in different diabetic eye disease 
phenotypes in order to identify if relationships exists between these entities. Overall 
this work may contribute, in the near future, to the development of a suitable cell 
replacement therapy in diabetic eye disease. 
 
1.   To elucidate the natural history of diabetic macular ischaemia, for which there is 
no existing therapy. Understanding the natural progression of disease will be 
important as patients with diabetic macular ischaemia may be ideal candidates for 
regenerative therapy in the future. 
2.  To validate methods of retinal image analysis; which will be used for the 
characterisation of diabetic macular ischaemia. 
3.  To explore different imaging techniques of measuring inflammation in the retina. 
4.  To profile circulating endothelial progenitor cells and monocytes of patients with 
diabetic eye disease and explore their relationships with retinal disease phenotype. 
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2. Clinical Imaging in diabetic macular ischaemia 
2.1 Introduction: 
DMI was first established using fluorescein angiography (FA) in the ETDRS.(21, 43, 
137) Due to the requirement of angiography for its evaluation, DMI has not been 
studied in the pivotal epidemiological studies of diabetic retinopathy, and is 
consequently not well understood.(9, 138, 139) Increasing our understanding of how 
quickly DMI progresses, in whom it occurs, and its association with visual impairment, 
is important in the clinical management of diabetic maculopathy. This may be of 
particular relevance due to emerging evidence for intravitreal pharmacotherapies, 
such as anti-VEGF for the treatment of diabetic macular oedema (DMO).(37, 140, 
141)  
In type 1 diabetes, the role of peripheral ischaemia and consequent 
proliferative diabetic retinopathy, has been long established. Proliferative diabetic 
retinopathy occurs in approximately 50% of patients with Type 1 as compared to 15% 
in those with Type 2 diabetes.(4) Similarly, in adolescents, the prevalence and 
severity of all retinopathy has been reported to be higher in Type 1 compared to 
Type 2 diabetes, with a relatively high cumulative rate of progression to proliferative 
disease- 42% after 25 years.(142, 143) DMO, which affects 6.8% of all patients with 
diabetes, has also been reported to affect a greater proportion of those with Type 1 
diabetes (14% in Type 1, compared to 6% in Type 2).(144, 145) The prevalence and 
severity of macular ischaemia in Type 1 diabetes, however, is less clear.  
The distinction between Type 1 and Type 2 diabetes has become blurred in 
recent years with the increasing waistlines of the Western world. Although both 
syndromes share common metabolic pathways characterised by hyperglycaemia, 
their classification remains distinct and defined by their pathophysiology, such as the 
lack of insulin production in Type 1, and insulin resistance in Type 2. There is limited 
evidence regarding macular ischaemia in Type 1 diabetes. Although it has been 
reported to occur sooner after diagnosis in Type 2 compared to Type 1 disease, it is 
well known that the duration of disease in patients with Type 2 diabetes can be 
difficult to pinpoint, and patients can be diagnosed many years after the onset of 
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disease. In Type 1 diabetes, it is not known whether there is similar, greater, or a 
reduced propensity for macular ischaemia, compared to its counterpart- peripheral 
ischaemia.  
Increasing our understanding of how quickly DMI progresses, in whom it 
occurs, and its association with visual impairment, is important in the clinical 
management of diabetic maculopathy. The ongoing controversy regarding the 
potential adverse effects of anti-VEGF therapies on macular ischaemia, is largely 
based on case reports, and non-comparative cases series - in patients receiving 
treatment for DME,(33, 146, 147) as an adjunctive treatment with pars plana 
vitrectomy in diabetic retinopathy,(148) and in eyes treated for exudative age-related 
macular degeneration (AMD).(149, 150) These studies report that in the presence of 
macular ischaemia, there is an adverse effect on outcomes, or a limit to the benefits 
of treatments, however, the deleterious effects of these intravitreal treatments on 
DMI is far from clear. Firstly, larger prospective studies, such as the RESTORE, 
RISE/RIDE, and the DRCR net studies, did not address the potential effects of anti-
VEGF therapy on ischaemia.(37, 140, 141) Secondly, the BOLT study, the only prospective 
study which examined macular perfusion, found no clear associations between 
intravitreal injections of bevacizumab and DMI at 4 months.(39) A recent analysis of 
eyes with retinal vein occlusions, suggests that VEGF blockade with ranibizumab 
prevents worsening of “retinal nonperfusion”.(151) 
It is not known if, or how quickly DMI progresses. Addressing the 
shortcomings in our knowledge of “DMI progression” is likely to be of critical 
importance for a number of reasons. Firstly, the identification of those patients who 
are likely to progress may have considerable implications in those in a working age 
group. Secondly, it would aid in discerning between DMI progression, due to the 
natural history of the disease itself, from the effects of treatments received, and may 
prevent the unnecessary exclusion of patients, or untimely cessation of therapy. 
Diabetic retinopathy encompasses a group of predominantly vascular 
anomalies which if left untreated, ultimately results in visual loss. The overall global 
prevalence of any diabetic retinopathy is 34.6%, with up to 28 million persons 
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worldwide with vision-threatening diabetic retinopathy.(152) Broadly, the spectrum 
of disease has been classified according the behaviour of the retinal vasculature- (1) 
hyperperfusion (leakage and oedema), which results in the development of lesions 
such as macular oedema, peripheral hard exudates and microaneurysms, and (2) 
hypoperfusion (ischaemia), which results in enlargement of the foveal avascular zone 
(FAZ) in the macula, and capillary non perfusion and retinal neovascularisation in the 
retinal periphery.  
It is not known what causes the differential regional distribution of these 
vascular lesions (i.e. peripheral compared central retina), why they occur in some 
patients but not others, and how they might affect visual function. Epidemiological 
studies have suggested that age may be a key component to the different patterns of 
diabetic retinopathy observed; i.e. the predominance of macular oedema in older 
patients with type 2, and proliferative retinopathy in younger patients with type 1 
diabetes.(153, 154) Several possible mechanisms have been suggested, including, the 
loss of autoregulation in retinal arterioles and microvascular degeneration in older 
persons causing capillary leakage and consequent macular oedema, and in the 
younger age group, an intact posterior hyaloid acting as a scaffold for the formation 
of aberrant neovascularisation.(155, 156) However, the pathobiology of diabetic 
retinopathy remains unclear, and is unlikely that age alone is solely responsible.  
The advent of ultra widefield fluorescein angiography (uwFA) has provided for 
the first time, the opportunity to visualize both the central and peripheral retina in a 
single examination. Although widefield imaging of the retina has been in 
development over the past eighty years, older systems encountered obstacles which 
precluded its wide application in patients with diabetic retinopathy; such as the 
requirement of a contact lens, and clear ocular media for the acquisition of good 
peripheral images.(157, 158) In recent times, the Optos camera (Optos PLC, 
Dunfermline, UK) has incorporated both a scanning laser ophthalmoscope (which 
permits imaging through moderate media opacities), and an optical systemic with an 
ellipsoid mirror which allows reliable imaging of the peripheral retina up to the ora 
serrata.(159) This provides visualization of up to 200 degrees, compared to the 75 
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degrees achieved by piecing together the early treatment diabetic retinopathy study 
(ETDRS) 7-standard fields, taken using the traditional 50 degree-view digital fundus 
camera. As such, the logical next step was to investigate the applicability fluorescein 
angiography, superior to colour photography in detecting vascular lesions, to ultra 
widefield imaging. Several studies have already demonstrated, in diabetic eyes, a 
greater detection (compared to conventional fluorescein angiography) of peripheral 
lesions such as areas of capillary non perfusion, leakage, and.(160-164) Therefore, 
the development of uwFA offers the opportunity to examine, in the diabetic eye, the 
relationships between both peripheral and central vascular lesions, and may provide 
new insights into the pathophysiology behind the differential patterns of distribution 
of diabetic retinopathy lesions observed in patients.  
Although the visual importance of macular ischemia was established by a 
number of seminal fluorescein angiographic studies in the 1970s, many clinical 
questions remain unclear.(165-167) In particular, the appearance or consequences of 
macular ischemia on OCT imaging remains ill defined – a significant shortcoming 
given the widespread adoption of OCT for monitoring of treatment in clinical trials of 
diabetic retinopathy. A number of preliminary studies have suggested severe macular 
ischemia is associated with thinning and disorganization of retinal layers on OCT.(28, 
168, 169) In the bulk of OCT studies in diabetic retinopathy, however, the effects of 
macular ischemia are masked by coexisting macular oedema. It is perhaps not 
surprising then, that only modest correlations have been observed to date, between 
OCT-derived retinal thickness and visual acuity in these studies.(28, 170) Fortunately 
however, recent advances in OCT imaging offer the opportunity to more precisely 
characterize diabetic macular ischemia morphology using OCT. In particular, analysis 
of OCT image sets has become more sophisticated in recent years, with a move from 
simple measurements of retinal thickness to more detailed quantitative subanalysis 
of individual retinal layers and specific disease features.(171) In addition, the 
formulation of “enhanced depth imaging” scanning protocols now allows high-
resolution visualization of choroidal anatomy using the current generation of 
commercial OCT systems.(46)  
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In this chapter, the relationships between macular ischaemia, retinopathy 
severity, presence of concurrent macular oedema, age of patients, and visual 
function, in an effort to determine its prevalence and clinical significance in this 
cohort of patients. The impact of macular ischaemia, both in the central macula and 
paramacular areas, on visual function in patients with both type 1 and type 2 
diabetes mellitus are examined. Furthermore, in-depth, longitudinal qualitative and 
quantitative analyses of the rate of progression for macular ischaemia was 
performed.  The clinical features at the baseline FA which may predict progression 
are examined in an effort to identify parameters of interest for both clinical practice 
and future clinical trials using qualitative and quantitative analyses of capillary non-
perfusion and leakage, both in the central and peripheral retina. Finally, the 
relationships between these parameters and OCT-derived measurements of retinal 
thickness and visual acuity were analysed, in an effort to elucidate its clinical 
significance. 
 
2.2 Aim: 
To investigate the prevalence, natural history, and relationships of diabetic 
retinopathy, and its impact on retinal structure and function through the analysis of 
clinical retinal images in order to identify imaging biomarkers for diabetic eye 
disease.  
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2.3 Materials and Methods: 
Institutional Review Board (IRB)/Ethics Committee approval for data collection and 
analysis at the UCL Institute of Ophthalmology and Moorfields Eye Hospital, London 
was in place. 
Technical acknowledgements: I would like to thank Srinvas Sadda, Doheny Eye 
Institute, University of Southern California, Los Angeles, United States, for the 
provision of custom written software OCTOR and GRADOR for the analysis of clinical 
images used in this chapter, and also Gerald Liew, Center for Vision Research, 
Westmead Millenium Institute, University of Sydney, Sydney, Australia, for the 
provision of a validated, semi-automated software for the grading of retinal vessel 
calibre.  
2.3.1 Inclusion Criteria and Data Collection   
Clinical and imaging data were collected retrospectively from patients attending a 
single consultant-led medical retinal clinic, with a focus on diabetic eye disease, at 
Moorfields Eye Hospital, London, United Kingdom. All data were collected over a six-
month time period (December 1st 2010 to June 30th 2011).  
Patient demographic data, visual acuities, and retinopathy/maculopathy 
grades, were obtained from standardized electronic reports in the United Kingdom 
National Screening Committee (UK NSC) - Diabetic Eye Screening Programme. Patient 
age at time of attendance, and presence of ocular co-morbidity, were obtained from 
electronic patient records. Patients attending the clinic with a diagnosis of Type 2 
diabetes mellitus were included (patients with Type 1 diabetes mellitus are being 
analysed in a separate study). Patients with ocular comorbidities, including retinal 
arterial or venous occlusion, epiretinal membrane, neovascular age-related macular 
degeneration (AMD), inherited macular disease, or macular scarring of any etiology, 
were excluded.  
In most cases, FA and OCT images were obtained on the date of attendance in 
the clinic; however, patients were also included in the study if angiography had been 
performed within six months of the study attendance date. In patients with bilateral 
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disease of symmetrical severity, a single eye was selected using permuted-block 
randomization for inclusion in the study. In patients with bilateral asymmetrical 
disease, the eye with the greatest degree of ischemic maculopathy was selected. For 
inclusion in the study, all angiographic image sets had to be of sufficient quality to 
allow visualization of FAZ capillaries to allow grading of DMI severity.  
For the purpose for DMI progression analysis, FAs were graded according to 
ETDRS protocols (see below) and eyes with ETDRS DMI grades “mild”, “moderate” or 
“severe”, and at least two macular centred FA images, separated by a minimum 
interval of 6 months were identified. Patients with a definite presence of DMI – i.e. 
those with “mild”, “moderate” or “severe” ETDRS DMI grades were included, in order 
to assess the rate of progression and associations of this clinical entity.  
 
2.3.2 Fluorescein Angiography  
Grading methods for macular ischaemia: All angiographic images were acquired with 
a digital retinal camera system (Topcon TRC 50IX, Topcon Medical Systems Inc., 
Paramus, NJ). One early to mid-phase image (at 20-40 seconds), centred on the 
macula, was chosen for analysis (at later phases, fluorescence abnormalities 
commonly impair visualization of the retinal capillary network) (Figure 2.1). The FA 
images were chosen for optimal focus and intensity levels, which allowed 
visualisation of macular capillaries. No image manipulation was performed prior to 
grading. Macular ischaemia was dual-graded by two masked assessors using 
protocols and standard photographs from ETDRS Report No. 11 in which severity is 
determined by FAZ size, capillary loss or dilatation, and retinal arteriolar 
abnormalities.(21) According to these criteria, DMI was classified as none, 
questionable, mild, moderate, or severe. In the case of disagreement between 
graders, open adjudication was used to resolve the final grading decision. 
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Figure 2.1. Papillomacular and temporal ischaemia 
 (a) An example of an early phase Fundus Fluorescein Angiography (FA) image centred at the macula 
demonstrating papillomacular capillary dropout, non-contiguous with the foveal avascular zone (FAZ). 
(b) Annotated image of 1a with papillomacular ischaemia highlighted in red and the enlarged FAZ 
highlighted in yellow. (c) An example of an early phase FA image demonstrating temporal capillary 
dropout non-contiguous with the FAZ. (d) Annotated image of 1c with temporal ischaemia highlighted 
in green and the enlarged FAZ highlighted in yellow. 
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Figure 2.2. Definition of the papillomacular and temporal areas for 
ischaemia quantification. 
a) Tubulin beta III immunostaining of the retinal nerve fibre layer in postmortem human eye tissue. 
After fixation in 4% paraformaldehyde for 24 hours, the retina was dissected and whole mounted for 
immunohistochemistry. The dotted green line delineates the boundary for temporal ischaemia, 
located one disc diameter temporal to the central fovea. Solid blue lines represent one disc diameter. 
Solid white scale bars equal to 0.5mm. (b) The dotted red line delineates the boundary for the 
papillomacular area where increased density of nerve fibres/axons originating from the FAZ are 
located. Solid white scale bars equal to 0.5mm. (c) Overlay of equivalent papillomacular boundary 
onto FA depicting areas of capillary dropout. (Immunohistochemistry images from figures 2a, and 2b 
were kindly provided by Dr Michael Powner) 
 
Grading methods for temporal and papillomacular ischaemia: The presence of 
additional areas of capillary non-perfusion, non-contiguous with the FAZ, was also 
noted at the time of grading, “Papillomacular ischaemia” was defined by its location 
within the nasal quadrant of the ETDRS grid and/or the area of retina bordered by the 
temporal edge of the optic disc and the nasal edge of the FAZ, along the 
papillomacular nerve fibre raphe (Figure 2.2). “Temporal ischaemia” was defined as 
the area located one disc diameter temporal to the central fovea and within the 
superior and inferior temporal vascular arcades. 
 
2.3.3 Optical Coherence Tomography 
Grading Methods: Spectral domain OCT images were obtained using the Spectralis 
imaging system (Heidelberg Engineering, Germany). All OCT image sets contained a 
minimum of 13 B-scans distributed in a horizontal raster pattern overlying the area 
covered by the nine subfields of the Early Treatment Diabetic Retinopathy Study 
(ETDRS) grid. Custom image analysis software (OCTOR, Doheny Image Reading 
Center, Los Angeles) was used for quantitative analysis of OCT image sets. OCTOR has 
been described and validated in previous reports.(172, 173)  
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2.3.4 Ultra Widefield Imaging 
All uwFA images were acquired with the Optos C200 MA ultra widefield retinal 
imaging system (Optos PLC, Scotland, United Kingdom), which allows imaging of up to 
200 degrees (82%) of the retina in a single image. All patients received a standard 
infusion of 5 millilitres of 20% sodium fluorescein through the antecubital vein. One 
early to mid-phase image (at 20-40 seconds), and a second late-phase image (at 5-7 
minutes) centred on the optic disc, was chosen for analysis. The early to mid-phase 
was graded for peripheral and macular ischaemia, and late-phase image for 
peripheral leakage. All uwFA images were exported as .tiff files and analysed on 
commercially available software Adobe Photoshop CS4 extended (Photoshop, Adobe 
Systems, San Jose, CA). No image manipulation was performed prior to grading. 
 
2.3.5 Image analysis 
Quantification of the foveal avascular zone and other areas of capillary non-
perfusion: Quantitative analysis of all images was performed using a validated image 
viewer and grading software package (“GRADOR”, Doheny Image Reading Center, Los 
Angeles) that facilitates planimetric measurements. Using this software, the areas of 
the FAZ, and other areas of capillary non-perfusion, were assessed in square 
millimetres (mm2). After manual delineation of each area, measurements were 
calculated using a scale factor based on the camera’s angle of view. Temporal and 
papillomacular ischaemia were calculated in a similar fashion.  
Quantification of uwFA-derived areas of peripheral ischaemia and leakage: An 
ischemic index was calculated from the early to mid-phase FA using previously 
described methodology.(174-176) Briefly, areas of capillary nonperfusion, outside the 
temporal vascular arcades were expressed as a percentage of the total image area in 
pixels (Figure 2.3). 
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In addition, for this study, the “total area” was defined as an area in which 
retinal vasculature was in sharp focus, thereby allowing accurate visualisation of 
smaller retinal capillaries. Due to the spherical curvature of the eye, ultra widefield 
images commonly exhibit “blurred” areas in the far periphery when the central 
portion of the image is in focus. In excluding these “blurred” areas from “total area” 
measurements, the resultant image is smaller than the 200 degree scanning angle 
that can be achieved by the ellipsoidal mirror within the Optos imaging system. 
However, it avoids underestimating the peripheral ischemic index by the inclusion of 
parts of retina where capillary non perfusion cannot be visualised. 
A peripheral “leakage” index was adapted from the ischemic index, similarly 
calculated; where areas of FA leakage outside the temporal vascular arcades were 
quantified in pixels and expressed as a percentage of the total area (Figure 2.3). 
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Figure 2.3. Early and late-phase ultra widefield fluorescein angiogram 
image.  
A patient with diabetic retinopathy comprising of both peripheral and macular capillary non perfusion. 
(A, left) An early-phase uwFA image, acquired at 20 seconds. (A, right) 10X magnified early-phase ultra 
uwFA image, centred on the foveal avascular zone. (B, left) Annotated solid blue line delineates the 
boundary of the retina where capillaries are in sharp focus. This area was taken to be the “total retinal 
area”, which was the denominator as the peripheral ischemic index. Annotated solid green lines 
delineates areas of capillary non perfusion in the retinal periphery. The peripheral ischemic index was 
calculated as the percentage of the “total area of capillary non perfusion” over the “total retinal area”. 
(B, right) Annotated solid red line delineates the boundary of the foveal avascular zone area. (C, left) A 
late-phase uwFA image, acquired at 6 minutes. (C, right) 10X magnified uwFA image, centred on the 
foveal avascular zone. (D, left) Annotated solid blue line delineates the boundary of the retina where 
peripheral vasculature was in sharp focus. This area was also taken to be the “total retinal area” for 
the purpose for calculating the peripheral leakage index. Annotated solid green lines delineates areas 
of “vascular leakage” in the retinal periphery. The peripheral leakage index was similarly calculated as 
the percentage of the “total area of vascular leakage” over the “total retinal area”. (D, right) 
Annotated solid red arrowheads points to diffuse leakage from the perifoveal capillaries. uwFAs were 
graded for the presence of macular capillary leakage and classified as “none”, “focal leakage”, and 
“diffuse leakage”. 
 
Quantification of uwFA-derived areas of macular ischaemia and leakage: Boundaries 
for the FAZ were manually delineated, and area measurements were calculated, and 
analysed in pixels, but subsequently converted into square millimeters (mm2) for the 
purpose of clinical interpretation, using a scale factor based on the assumption that 
the disc area was 2.7mm2.(177) 
uwFAs were graded for the presence of macular capillary leakage- i.e. oedema in late-
phase angiograms. The uwFA macular oedema grades were classified as “none”, 
“focal leakage”, and “diffuse leakage”.  
Definitions (Table 2): The FAZ area, as measured using early to mid-phase 
uwFA was divided into “large” (>0.32mm2) and “small” (<0.32mm2) categories. As 
established in our previous study, a “large” FAZ area corresponds to an Early 
Treatment Diabetic Retinopathy Study (ETDRS)-defined diabetic macular ischaemia 
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grade of “moderate” to “severe”.(178) A low peripheral ischaemia/leakage index was 
defined as less than 50%, and a high peripheral ischaemia/leakage index more than 
50% of the total area. 
Quantification of retinal vessel calibres: Retinal arteriolar and venular calibres 
were measured from late phase FFA images (1-2 mins) when the retinal arterioles 
and venules were clearly outlined with fluorescein dye. FFA images had to have 
sufficient peripapillary vasculature visible to facilitate grading with a validated semi-
automated software which calculated the calibres of arterioles and venules coursing 
through a region 0.5 to 1 disc diameter from the disc margin.(179, 180) These values 
were then combined using formulas to derive the central retinal artery and venule 
calibre equivalent for that eye.(181) Arteriole to venule ratio (AVR) was calculated as 
the ratio of mean arteriolar to venular calibres (Figure 2.4).  
Segmentation protocol for OCT-derived retinal spaces: Boundaries were 
manually segmented in accordance with standardized OCT grading protocols.(182) 
The retinal space was defined as the space lying between the inner aspect of the 
internal limiting membrane and the outer border of the photoreceptor outer 
segments.(183, 184)  
Segmentation protocol for choroidal spaces: The choroid was defined as the 
space between the outer border of the retinal pigment epithelium and 
choroidoscleral junction. The choroid was further subdivided into Haller’s large vessel 
and Sattler’s medium vessel layers (Figure 2.5). Haller’s large vessel layer was defined 
as the outer choroid consisting large hypo-intense spaces representing large vascular 
luminal spaces. Sattler’s medium vessel layer consisted of small to medium size hypo-
intense spaces, surrounded by hyperintense stroma (increase scattering by high 
density of melanocytes) giving a mottled appearance on scans.(57) This layer also 
included the choriocapillaris, which at 10 µm, is not easily distinguished from the 
Sattler’s medium vessel layer on OCT images. The detailed choroidal segmentation 
protocol is illustrated in Figure 2.5. This protocol was used in the training of graders 
and was used prior to all grading sessions. 
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The mean retinal and choroidal thicknesses (µm) and volumes (mm3) were 
then calculated for the ETDRS areas 1-9 or the “total macular circle” (TMC), and 
ETDRS area 9 which corresponds to the foveal central subfield (FCS).  
Assessment of repeatability of segmentation: A subset of OCT images (n=20) 
were segmented three times by a single grader– once before training, and twice after 
training. This OCT image set was also segmented twice by the experienced grader 
(S.F.) to assess repeatability. The time-interval between each episode of 
segmentation was greater than two weeks for both graders. 
 
54 
 
 
 
55 
 
 
Figure 2.4. Arteriolar narrowing in persons with different severity grades of 
diabetic macular ischaemia.  
The left panel contains representative images from an eye with no diabetic macular ischaemia, and the 
right panel representative images from an eye with severe diabetic macular ischaemia. (A) contains 
colour fundus photographs; (B) early venous phase fundus fluorescein angiograms; the (C) magnified 
fundus fluorescein angiograms centred at the foveal avascular zone; in (D), macular centered 
magnified fundus fluorescein angiograms contain annotations of the foveal avascular zone and 
perifoveal capillaries; the (C) contains examples of how cross-sectional calibre of arterioles (red) and 
venules (blue) is measured. The boundaries foveal avascular zone is more irregular and its area 
enlarged in severe diabetic macular ischaemia (D, right panel) compared to no diabetic macular 
ischaemia (D, left panel). In E, the eye with no diabetic macular ischaemia shows a wider arteriolar 
calibre (left panel, mean arteriolar calibre 163.5 μm), while the eye with severe diabetic macular 
ischaemia shows arteriolar narrowing (right panel, mean arteriolar calibre 126.4μm). 
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Figure 2.5. Choroidal segmentation on OCT-derived images 
An example of a foveal centred B-scan, acquired using the enhanced depth optical coherence 
tomographic protocol. Annotations illustrate the instructions from the choroidal segmentation 
protocol, and demonstrate identification and segmentation of choroidal layers by examining changes 
in light reflectance at the different tissue interfaces. (a) Black arrows indicate the outer border of the 
retinal pigment epithelium (RPE) and white arrowheads the outer choroidal border (OCB) which 
represents the choroidoscleral interface. (b) Segmentation lines on the outer border of the RPE (red) 
and OCB (green) demarcating the total choroidal area / volume. (c) Black arrowheads indicate the 
junction between Sattler’s medium and Haller’s large vessel layers. Black stars indicate difficulty areas 
where the interface between both Sattler’s and Haller’s layers is ambiguous. Segmentation of these 
areas may be aided by clues from adjacent B-scans. (d) Segmentation line on the Sattler’s and Haller’s 
vessel layer interface (yellow). 
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2.3.5 Statistical analysis 
Patient demographic and imaging data were analysed with frequency and descriptive 
statistics. Normality of the variables was examined using histograms. As anticipated, 
distribution of visual acuity and FAZ measurements were negatively skewed and 
traditional regression analyses could not be applied to the data set. No simple 
transformation of data redressed the skewness. 
The Mann-Whitney U test was used to compare continuous variables, 
whereas the χ² test was used for categorical variables. Spearman’s rank correlation 
was used to test for associations between variables. Snellen visual acuities were 
converted to LogMAR (logarithm of the minimum angle of resolution) visual acuity 
for the purposes of statistical analysis. 
Multivariable quantile regression analysis was used to test for associations 
between logMAR visual acuity and each of - age, gender, retinopathy grade, diabetic 
macular oedema, FAZ measurements, and non-contiguous areas of ischaemia. 
Quantile regression is a statistical approach to model different sample percentiles or 
“quantiles” of an outcome variable with respect to predictor variables. It was used to 
assess for associations in this dataset due to the skewed distribution of parameters 
measured. An advantage of using this form of regression analysis, was that it allowed 
us to examine the more complex relationships between variables (such as the VA) 
which may have unequal variation for different ranges of another variable (ie FAZ), 
without converting continuous data into dichotomous or categorical fields, which 
loses information. This approach has been described in more detail elsewhere.(25) 
Briefly, the interpretation of quantile regression is similar to linear regression, but 
where linear regression models the mean of the outcome variable, quantile 
regression models selected percentiles, for example the 0.50 quantile (the median, or 
50th percentile). In this study, we analysed the 0.10, 0.25, 0.50, 0.75, and 0.90 
quantiles. We developed models for each DMI ischaemia grade, and further adjusted 
for potential confounders such as age (continuous variable), gender, retinopathy 
grade, and the presence of diabetic macular oedema (categorical variables). P values 
< 0.05 were considered statistically significant. Statistical analysis was performed 
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using the statistical software R 2.15.0 (http://cran.r-project.org, accessed May 24th, 
2012), with the addition of the “quantreg” package. 
The coefficient of repeatability (CR) of retinal and choroidal thickness 
measurements was calculated using the within-grader standard deviation (Sw) 
derived from the intra grader mean square of differences. The CR, as defined by 
Bland and Altman(185), was calculated as 1.96 times the standard deviation of the 
differences between two measurements: CR = 1.96 x √(2S2w) or 2.77Sw. To allow 
comparison with other studies, we also expressed the CR as a percentage of the 
mean measurement for all retinal and choroidal layers (CR / Mean), with a lower the 
CR / Mean percentage representing, greater repeatability within graders. The 
intraclass correlation coefficient (ICC) was used as a measure of relative reliability of 
measures within graders. 
Reproducibility or inter observer variability was assessed using Bland-Altman 
plots, using the mean thickness and volume measurements, segmented by each 
grader.(186) The mean difference and confidence intervals were calculated. 
Agreement between graders was also examined using Bland-Altman analysis, with 
the 95% limits of agreement (µm) (LoA) between graders calculated, after confirming 
that the measurement differences were normally distributed using histograms. 
 Statistical analyses were performed using statistical software R 2.15.0 (http://cran.r-
project.org, accessed May 24th, 2012), with the addition of the “quantreg” package; 
SPSS software version 16 (SPSS, Inc, Chicago, IL); and MedCalc software version 
10.3.2 (MedCalc Software, Mariakerke, Belgium).  
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2.4 Results: 
2.4.1 Diabetic macular ischaemia in type 2 diabetes 
 
2.4.1.1 Baseline Characteristics 
Electronic records of 2051 appointments were screened, and 1298 unique 
attendances identified. 821 patients attended for assessment of diabetic eye disease, 
of which, 767 patients had Type 2 diabetes. The male to female ratio was 5:4, and 
mean age was 64.2 years (SD: 12.6). Of the patients with Type 2 diabetes, 488 met 
the inclusion criteria for fluorescein angiography. In these cases, an attempt was 
made to grade both eyes for severity of DMI: in 401 patients, FA images were of 
sufficient quality to allow DMI grading in both eyes; in a further 52 patients, DMI 
grading was possible in a single eye only. In 35 patients, FA images were of 
insufficient quality to permit grading of DMI in either eye. Forty-five patients were 
then excluded due to the presence of ocular co-morbidities. In total, 408 eyes from 
408 patients were included in the analysis (Table 2.1). For this assessment of DMI 
severity, substantial inter-grader agreement was demonstrated, with a weighted 
kappa of 0.704. (SE: 0.087, 95% CI: 0.535 to 0.874). 
 
2.4.1.2 Symmetry of Disease: 
Within the 401 patients where both eyes were gradable, 62.1% had bilaterally 
symmetrical macular ischaemia. The difference in grade between the asymmetrical 
eyes was as follows: no more than one grade in 26.7% of patients, two grades in 8%, 
three grades in 3%, and four grades in 0.2%. Where there was symmetrical disease, 
one eye was randomized for analysis. In asymmetrical disease (37.9%), the eye with 
the most severe DMI grade was selected.  
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2.4.1.3 Prevalence of Diabetic Macular Ischaemia: 
Overall prevalence and severity of diabetic macular ischaemia by ETDRS-DMI grade: 
In the 408 eyes analysed, 39.7% had none, 18.4% questionable, 25.2% mild, 11% 
moderate, and 5.6% had severe ETDRS-DMI grades.  
 
Table 2.1: Patient demographics and clinical characteristics of patients 
(type 2 diabetes) with and without diabetic macular ischaemia. 
  
No DMI 
(n=162) 
DMI 
(n=246) 
p value 
Age, years, Mean (SD) 
 62 (11.4) 64 (12.2) 0.07 
Gender, n, female/male 
 72 / 90 105 / 141 0.63 
Eye, n, right/left 
 84 / 78 126 / 120 0.94 
FAZ area, mm2, median 
(IQR) 
 
0.19 (0.13 to 
0.25) 
0.29 (0.20 
to 0.42) 
< 0.001 
Retinopathy Grades  
 
DMI:No DMI (n=408) 
 
No Diabetic Retinopathy 
(n=44) 
(%) 24 (54.5) 20 (45.5) 0.83 
Mild-Moderate NPDR 
(n=139) 
(%) 
75 (54.0) 64 (46.0) 0.85 
Severe NPDR 
(n=67) 
(%) 
27 (40.3) 40 (59.7) 1.48 
 
PDR 
(n=158) 
(%) 
36 (22.8) 122 (77.2) 3.39 
 
Maculopathy Grades 
 
 
No DME / CSME 
(n=113) 
(%) 
55 (48.7) 58 (51.3) 1.05 
DME (Non CSME) 
(n=120) 
(%) 
53 (44.2) 67 (55.8) 1.44 
 
CSME 
(n=175) 
(%) 
54 (30.6) 121 (69.4) 2.24 
 
DMI = Diabetic Macular Ischaemia; NPDR = Non-Proliferative Diabetic Retinopathy; PDR= 
Proliferative Diabetic Retinopathy; DME = Diabetic Macular Oedema; CSME = Clinically 
Significant Macular Oedema; SD = Standard Deviation; IQR = Interquartile range 
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Prevalence of DMI (by ETDRS grade) within different severity grades of 
retinopathy and maculopathy (Table 2.1): In eyes with proliferative diabetic 
retinopathy (PDR) (both treated and untreated), concurrent DMI was seen in 77.2% 
of cases (in 22.8% of cases, DMI was not present). The occurrence of DMI was similar 
across all other grades of non-proliferative diabetic retinopathy (NPDR), and in 
patients without diabetic retinopathy (i.e., R0 in the NSC grading system). In eyes with 
clinically significant macular oedema (CSME), concurrent DMI was seen in 69.4% of 
cases (in 30.6% of cases, therefore, no DMI was observed). In eyes with DME, but 
without CSME, concurrent DMI was seen in 55.8% of cases (in 44.2% of cases, DMI 
was not present). An increase in the proportion of eyes with DMI in relation to eyes 
with no DMI, expressed as the “DMI : No DMI” ratio, was seen in patients with severe 
NPDR and PDR, and across all maculopathy grades. Table 2 shows the distribution of 
eyes between different grades of retinopathy and maculopathy in the presence or 
absence of DMI. 
 
Increasing FAZ area with ETDRS-DMI severity grades (Figure 2.6): As expected, 
the median FAZ area increased with grade of ETDRS-DMI severity, and ranged from 
0.19 mm2 (interquartile range (IQR): 0.13 to 0.25) in eyes with ETDRS-DMI grade: 
none, to 0.78 mm2 (IQR: 0.60 to 1.32) in eyes with ETDRS-DMI grade: severe. (Figure 
2.6) Highly significant differences in median FAZ area were seen across all subgroups 
of DMI, with the exception of “questionable” versus “mild” DMI. Median FAZ area 
was significantly correlated with ETDRS DMI severity grade (r=0.477, p<0.001). (Table 
2.2) 
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Figure 2.6. Distribution of diabetic macular ischaemia grades 
Box-plots of FAZ Area (mm2) in different Early Diabetic Treatment Retinopathy Study (EDTRS) grades of 
Diabetic Macula Ischaemia (DMI) – None, Questionable, Mild, Moderate, and Severe. The top of the 
box represents the 75th percentile, the bottom of the box represents the 25th percentile, and the line 
in the middle represents the 50th percentile. The whiskers represent the highest and lowest values 
that are not outliers or extreme values. Outliers and extreme values are represented by circles beyond 
the whiskers. 
 
Prevalence of temporal and/or papillomacular ischaemia: Temporal ischaemia 
was seen in 112 eyes (27.5%), while papillomacular ischaemia was seen in 34 eyes 
(8%). Both temporal and papillomacular ischaemia were most prevalent in higher 
ETDRS-DMI grades. This was most notable for temporal ischaemia, which was present 
in 87% of eyes in the severe subgroup, as compared to 6.2% of eyes in without DMI. 
Papillomacular ischaemia was also more frequently seen in the ETDRS-DMI severe 
subgroup (34.8% of eyes with severe vs. 10.7% of eyes with mild ETDRS-DMI grade). 
 
2.4.1.4 Visual Significance of Macular Ischaemia: 
Relationship between visual acuity and ETDRS-DMI severity Grade (Table 2.2): 
Median logMAR visual acuity (VA) was 0.2 (IQR: 0 to 0.3) (Snellen 20/32) in eyes with 
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none, 0.2 (IQR: 0 to 0.5) (Snellen 20/32) in eyes with questionable, 0.2 (IQR: 0.2 to 
0.5) (Snellen 20/32) in eyes with mild, 0.5 (IQR: 0.2 to 0.6) (Snellen 20/63) in eyes 
with moderate, and 0.6 (IQR: 0.3 to 0.8). (Snellen 20/80) in eyes with severe ETDRS-
DMI grades. Significant differences in VA were observed between moderate and 
severe ETDRS-DMI versus all other grades (Table 2.3). Overall, VA showed a weak but 
highly significant correlation to ETDRS grading of DMI severity (rho=0.22, p<0.001). 
 
Table 2.2: Comparing Median FAZ Area (mm2) between all Diabetic Macula 
Ischaemia subgroups. 
DMI 
Subgroups 
 p-values None Questionable Mild Moderate Severe 
None         
Questionable   <0.001**     
Mild   <0.001** 0.18     
Moderate   <0.001** <0.001** 0.002**   
Severe   <0.001** <0.001** <0.001** <0.001**   
 
DMI= Diabetic Macular Ischaemia; p values significant at 5% level are indicated with (*), 
and (**) at 1% level. 
 
Relationship between FAZ size and visual acuity (Table 2.3): Overall, we found 
no evidence any correlation between VA and FAZ area (mm2) (rho=0.061, p=0.219). 
However, when the data were stratified by severity of ischaemia, quantile regression 
models revealed a statistically significant association between VA and FAZ area (mm2) 
in all quantiles for eyes with moderate and severe ETDRS-DMI grades (Table 2.4, 
Figure 2.7). Severe DMI showed the strongest association with quantile regression 
coefficient, β = 0.406; SE 0.101, (p<0.001), at the 50th percentile. In moderate DMI, 
the greatest association was also observed at the 50th percentile, β = 0.299; SE 0.108, 
(p<0.006). The effects of FAZ area on VA on moderate and severe ETDRS-DMI grades 
for different quantiles are summarized in Table 2.5 and Figure 2.7A and B. No 
relationships were observed between VA and FAZ area for milder grades of 
ischaemia.   
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Table 2.3: Comparing Median Visual Acuities (LogMar) between all Diabetic 
Macula Ischaemia subgroups. 
 
DMI Grade  None Questionable Mild Moderate Severe 
 P value for VA 
None       
Questionable  0.651     
Mild  0.143 0.527    
Moderate  <0.001** 0.02* 0.03*   
Severe  <0.001** <0.001** <0.001** 0.04*  
 
DMI= Diabetic Macular Ischaemia; p values significant at 5% level are indicated with (*), 
and (**) at 1% level. 
  
Relationship of temporal and papillomacular ischaemia with visual acuity 
(Table 2.4): We investigated whether papillomacular and temporal ischaemia had a 
significant impact on VA after adjustment for FAZ area. A higher than expected 
association was observed in papillomacular ischaemia at the 25th, 50th, 75th and 90th 
quantile regression lines (Table 2.5, Figure 2.7). Thus, papillomacular ischaemia has 
an impact on VA independent of FAZ size. This effect was maintained after adjusting 
for potential confounders such as DME (Table 2.6). No relationship was observed 
with temporal ischaemia.  
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Table 2.4: Association between Visual Acuity and Foveal Avascular Zone 
area (mm2) stratified by EDTRS Diabetic Macular Ischaemia severity grades 
for five different Quantiles. 
 
  
 
10th Quantile 25th Quantile 50th Quantile 75th Quantile 90th Quantile 
Adjusting for age, (continuous variable) gender, retinopathy grade, and the presence of macular 
oedema (categorical variable) 
DMI Grade β SE p    β SE p β SE p    β SE p    β SE p    
                
Questionable 
(n=75) 
0.0
41 
0.0
64 
0.53
0 
0.0
01 
0.1
23 
0.9
94 
<0.0
01 
0.0
30 
0.99
2 
0.0
97 
0.1
42 
0.49
7 
0.4
06 
0.1
86 
0.03
0 
Mild 
(n=103) 
0.0
19 
0.0
63 
0.75
7 
0.1
99 
0.1
23 
0.1
07 
0.01
3 
0.0
44 
0.76
3 
0.1
10 
0.0
81 
0.17
7 
0.2
46 
0.1
22 
0.04
4 
Moderate 
(n=45) 
0.2
24 
0.0
83 
0.00
7** 
0.1
99 
0.0
93 
0.0
34* 
0.29
9 
0.1
08 
0.00
6** 
0.2
57 
0.0
99 
0.00
9** 
0.2
89 
0.1
17 
0.01
4** 
Severe 
(n=24) 
0.3
26 
0.0
83 
<0.0
01** 
0.3
03 
0.1
42 
0.0
34* 
0.40
6 
0.1
01 
<0.0
01** 
0.3
59 
0.1
18 
0.00
2** 
0.2
99 
0.1
28 
0.02
0* 
 
Coefficient (β) and standard error (SE) are reported for 10%, 25%, 50%, 75%, and 90%. Coefficients that are significant at 5% 
level are bold, and those at the 1% level are bold and underlined. p values significant at 5% level are indicated with (*), and (**) 
at 1% level. Standard errors are obtained using 1000 bootstrap replications. 
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Table 2.5: Association between Visual Acuity and area of Papillomacular or 
Temporal ischaemia (mm2) for five different Quantiles after adjusting for 
Foveal Avascular Zone area (mm2) as a co-variate. 
 
 
10th Quantile 25th Quantile 50th Quantile 75th Quantile 90th Quantile 
Adjusting for gender, retinopathy grade, the presence of macular oedema (categorical variables) and  
age, FAZ area (mm2) (continuous variables) 
Area of 
ischaemia 
β SE p β SE p β SE p    β SE p β SE p 
                
Papillomacular 
(n=34) 
0.3
02 
0.5
86 
0.6
12 
1.0
36 
0.5
00 
0.0
50* 
1.1
23 
0.3
55 
0.00
5** 
1.1
93 
0.38
1 
0.00
5** 
0.3
83 
0.54
7 
0.00
2** 
Temporal 
(n=112) 
0.0
60 
0.0
17 
0.0
01 
0.0
51 
0.0
15 
0.0
02 
0.0
56 
0.0
26 
0.03
9* 
0.0
75 
0.04
01 
0.07
9 
0.0
75 
0.04
54 
0.11
0 
 
Coefficient (β) and standard error (SE) are reported for 10%, 25%, 50%, 75%, and 90%. Coefficients that are significant at 5% 
level are bold, and those at the 1% level are bold and underlined. p values significant at 5% level are indicated with (*), and (**) 
at 1% level. Standard errors are obtained using 1000 bootstrap replications. 
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Table 2.6: Multivariable median regression between Visual Acuity and Area 
of Papillomacular ischaemia (mm2) adjusting for Foveal Avascular Zone 
area (mm2) and other clinical co-variates. 
 
 
Median 
Regression 
coefficient 
Standard Error p-value 
    
Papillomacular ischaemia 1.123 0.341 0.004** 
Foveal Avascular Zone Area 0.178 0.259 0.501 
Gender 0.17 0.162 0.291 
Age 0.01 0.012 0.401 
Diabetic Macular Oedema    
      No DME 0.193 0.271 0.485 
      Clinically Significant DME 0.310 0.485 0.530 
      Treated clinically significant 
DME 
0.106 0.252 0.679 
 
The median regression coefficient is reported with standard errors obtained using 1000 
bootstrap replications. Coefficients that are significant at 5% level are bold, and those at 
the 1% level are bold and underlined. p values significant at 5% level are indicated with 
(*), and (**) at 1% level.  
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Figure 2.7. Relationship between visual acuity and ischaemia 
(a) Line plot of quantile regression coefficients (vertical dotted line represents the median 
regression coefficient) of Visual Acuity with Foveal Avascular Zone area (mm2) in the 
moderate (dotted line) and severe (solid line) subgroups of diabetic macular ischaemia (DMI), 
after adjustment for age, gender, retinopathy grade and the presence of diabetic macular 
oedema. (b) Line plot of quantile regression coefficients (vertical dotted line represents the 
median regression coefficient) of Visual Acuity with Papillomacular and Temporal ischaemia 
area (mm2), after adjustment for age, gender, retinopathy grade, the presence of diabetic 
macular oedema and Foveal Avascular Zone area (mm2). 
 
2.4.2 Predictive factors for diabetic macular ischaemia in type 2 
diabetes 
2.4.2.1 Patient Characteristics: 
A total of 79 patients were identified, and of these, 61 patients had both eyes, which 
met the criteria. From the remaining 18 patients, one eye was chosen from each 
patient using random block permutation, and included in the analysis. Clinical and 
imaging data from two time points were collected and analysed (Figure 2.8).  
There were 24 females and 55 males with a median age of 63 (interquartile range 
[IQR], 56.5 to 70). At baseline, 44 eyes had both treated, or untreated  
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Figure 2.8. Progression of diabetic macular ischaemia 
(a)(i) An example of an early phase Fundus Fluorescein Angiography (FA) image centered at the macula 
demonstrating foveal avascular zone (FAZ). (a)(ii) Annotated solid green lines delineates the boundary 
of the FAZ and the perifoveal capillaries. (a)(iii) The FAZ boundary (solid green lines) from (a)(ii), with 
FA image removed. (b)(i) FA image of the same patient after a 2 year time interval. (b)(ii) Annotated 
solid red lines delineates the boundary of the FAZ and the perifoveal capillaries. (b)(iii) The FAZ 
boundary (solid red lines) from (b)(ii), with FA image removed. (c)(i) Merged FAs from (a) and (b) with 
green filters over the baseline FA, and red filters over the FA at 2 years. (c)(ii) A white vessel (solid 
white arrowheads) represents vasculature that is present at both time points. Green vessels (empty 
arrowheads) represent vasculature present at the baseline FA, but not at 2 years. Red vessels (solid 
black arrowheads) represent vasculature present at 2 years but not at the baseline FA. (c)(iii) An 
overlay of annotated FAZ boundaries from the baseline FA (solid green line), and FA at 2 years (solid 
red line). 
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proliferative diabetic retinopathy (DR), 38 eyes had none, or non-proliferative DR. 49 
eyes had clinically significant macular oedema (CSME), 18 with non-CSME, and 12 
with no macular oedema. In all eyes, the median FAZ area was 0.31 mm2 (IQR, 0.22 to 
0.43) at baseline, and 0.39 mm2 (IQR, 0.29 to 0.63) at the final FA. The median VA 
was 0.3 logarithm of the minimum angle of resolution (LogMar) (IQR, 0.2 to 0.5) both 
at the baseline, and final FA. The median time interval between FAs was 27 months 
(IQR, 16.5 to 53.5, Range, 7 to 126). 
 
2.4.2.2 Progression of ETDRS-DMI grades: 
At the baseline FA, within 79 eyes analysed, there were 42 eyes (53.2%) with “mild”, 
24 (30.4%) “moderate”, and 13 (16.5%) “severe” ETDRS-DMI grades. At the final FA, 
there were 39 eyes (49.4%) with “mild”, 25 (31.6%) “moderate”, and 15 (19.0%) 
“severe” ETDRS-DMI grades. 58 eyes (73.4%) had no change or an improvement of 
ETDRS-DMI grade between baseline and final FA, of which 31 had baseline ETDRS-
DMI grades of “mild”, 15 “moderate”, and 12 “severe”. In 9 eyes (11.4%), there was 
an improvement in the ETDRS-DMI grade, from “moderate” to “mild” in 8 eyes, and 
from “severe” to “moderate” in one eye. A total of 12 eyes (15.2%) showed 
progression in ETDRS-DMI grade, 9 from “mild” to “moderate”, 1 from “moderate” to 
“severe”, and 2 from “mild” to “severe”. Analysis of the baseline ETDRS-DMI 
subgroups reveal progression in 11/42 eyes (26.2%) in “mild”, 1/30 (3.3%) in 
“moderate”, and 0/7 (0%) in the “severe” grades (Table 2.7).  
 The median FAZ area was observed to increase from baseline to the final FA, across 
all ETDRS-DMI grades - with 0.28 mm2 (IQR, 0.19 to 0.35) to 0.31 mm2 (IQR, 0.25 to 
0.45) in “mild”, 0.37 mm2 (IQR, 0.28 to 0.47) to 0.41 mm2 (IQR, 0.34 to 0.66) in 
“moderate”, and 0.73 mm2 (IQR, 0.64 to 1.03) to 1.23 mm2 (IQR, 0.67 to 1.43) in the 
“severe” grades (Figure 2.9). This was significantly different within each ETDRS-DMI 
grade (p<0.001); progression observed across all severity grades. 
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Table 2.7: Foveal avascular zone area (FAZ) (mm2) at the baseline and final 
fluorescein angiogram and progression rate over time. 
 
FAZ area  
(Baseline) 
(mm2) 
FAZ area  
(Final) 
(mm2) 
Differenc
e in FAZ 
area  
(Final - 
Baseline) 
(mm2) 
p 
valu
e 
Time 
interval 
between 
FA 
(months) 
Change in 
FAZ area 
per year 
(mm2 / 
year) 
Change in 
FAZ area as 
a 
percentage 
of baseline 
FAZ area 
per year (% 
/ year) 
Median (Interquartile range)  
All eyes 
0.31 (0.22 
to 0.43) 
0.39 (0.29 
to 0.63) 
0.06 (0.01 
to 0.16) 
< 
0.001
** 
27.0 (16.5 
to 53.5) 
0.023 (0.001 
to 0.060) 
7.42 
ETDRS-DMI grade 
(Baseline) 
       
Mild  
(n = 42) 
0.28 (0.19 
to 0.35) 
0.31 (0.26 
to 0.45) 
0.05 ( 0 to 
0.11) 
< 
0.001
** 
27.5 (18.0 
to 49.5) 
0.021 (0.001 
to 0.060) 
7.50 
Moderate  
(n = 24) 
0.37 (0.28 
to 0.43) 
0.39 (0.33 
to 0.63) 
0.05 (0 to 
0.14) 
< 
0.001
** 
31.0 (18.5 
to 60.8) 
0.019 (0.001 
to 0.056) 
5.13 
Severe  
(n = 13) 
0.70 (0.38 
to 0.95) 
0.82 (0.55 
to 1.23) 
0.18 (0.08 
to 0.40) 
< 
0.001
** 
24.0 (18.0 
to 36.0) 
0.073 (0.048 
to 0.181) 
10.4 
FAZ area at 
baseline 
       
Small 
(<0.3mm
2)  
(n = 35) 
0.22 (0.16 
to 0.27) 
0.28 (0.21 
to 0.35) 
0.06 (0.02 
to 0.11) 
< 
0.001
** 
24.0 (14.0 
to 42.0) 
0.023 (0.007 
to 0.056) 
10.4 
Large 
(>0.3mm
2)  
(n = 44) 
0.41 (0.36 
to 0.59) 
0.55 (0.39 
to 0.86) 
0.06 (0 to 
0.20) 
< 
0.001
** 
34.0 (18.0 
to 59.8) 
0.024 (0 to 
0.065) 
5.85 
Diabetic 
Retinopathy 
       
None or 
NPDR  
(n = 35) 
0.29 (0.22 
to 0.35) 
0.34 (0.27 
to 0.61) 
0.06 (0.02 
to 0.18) 
< 
0.001
** 
24.0 (16.0 
to 35.5) 
0.040 (0.007 
to 0.068) 
13.8 
PDR (n = 
44) 
0.38 (0.27 
to 0.55) 
0.41 (0.31 
to 0.64) 
0.05 (0 to 
0.14) 
< 
0.001
** 
33.5 (16.8 
to 58.3) 
0.021 (0 to 
0.048) 
5.5 
Diabetic 
Maculopathy 
       
None or 
Non-
CSME (n 
= 30) 
0.31 (0.23 
to 0.41) 
0.37 (0.29 
to 0.61) 
0.06 (0.01 
to 0.17) 
< 
0.001
** 
28.0 (19.0 
to 56.0) 
0.022 (0.001 
to 0.061) 
7.10 
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CSME  
(n = 49) 
0.34 (0.22 
to 0.45) 
0.39 (0.30 
to 0.70) 
0.05 (0.01 
to 014) 
< 
0.001
** 
27.0 (15.0 
to 50.0) 
0.027 (0.001 
to 0.057) 
7.94 
Visual acuity 
(Baseline) 
(LogMar) 
       
Good (< 
0.3)  
(n = 48) 
0.31 (0.23 
to 0.40) 
0.38 (0.29 
to 0.56) 
0.05 (0.01 
to 0.12) 
< 
0.001
** 
28.0 (17.8 
to 63.8) 
0.019 (0.001 
to 0.042) 
6.13 
Poor (> 
0.3)  
(n = 31) 
0.32 (0.22 
to 0.80) 
0.48 (0.28 
to 0.80) 
0.10 (0.02 
to 0.21) 
< 
0.001
** 
27.0 (14.0 
to 47.0) 
0.046 (0.003 
to 0.141) 
14.4 
Visual Acuity 
progression  
(LogMar/year) 
       
No 
progressi
on 
(<0.05)  
(n = 56) 
0.32 (0.22 
to 0.40) 
0.39 (0.30 
to 0.55) 
0.04 (0 to 
0.12) 
< 
0.001
** 
34.0 (17.5 
to 59.8) 
0.018 (0 to 
0.042) 
5.62 
Progressi
on 
(>0.05)  
(n = 23) 
0.30 (0.22 
to 0.45) 
0.39 (0.28 
to 0.97) 
0.10 (0.05 
to 0.22) 
< 
0.001
** 
19.0 (15.5 
to 29.5) 
0.057 (0.026 
to 0.124) 
19.0 
 
The median and interquartile values of FAZ size, time interval (years), and FAZ progression rate are reported. The 
Wilcoxon Rank-Sum Test was used for statistical analysis of the difference in FAZ area between FA at baseline and final 
FA. p values significant at 5% level are indicated with (*), and (**) at 1% level. FA = Fluorescein Angiogram; ETDRS = 
Early Treatment Diabetic Retinopathy Study; DMI = Diabetic Macular Ischaemia; FAZ = Foveal avascular zone; NPDR = 
Non-Proliferative Diabetic Retinopathy; PDR= Proliferative Diabetic Retinopathy; DME = Diabetic Macular Oedema; CSME 
= Clinically Significant Macular Oedema  
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Figure 2.9. Change in foveal avascular zone stratified by diabetic macular 
ischaemia grade. 
Bar chart showing median foveal avascular zone (FAZ) area (mm2) and interquartile ranges for groups 
stratified by Early Treatment Diabetic Retinopathy – Diabetic Macular Ischaemia (ETDRS-DMI) grades 
“mild”, “moderate”, and “severe”. White and black bars denote FAZ area at baseline and final FAs 
respectively.  
 
2.4.2.2 Rate of FAZ area enlargement: 
The overall median enlargement rate of the FAZ area was 0.023 mm2/year (IQR, 
0.001 to 0.060) (Table 2.7). With a median baseline FAZ size of 0.31 mm2, this 
represents a FAZ area progression rate of 7.42% per year in all eyes. The enlargement 
rate was also examined in six categories, according to ETDRS-DMI grade, diabetic 
retinopathy and maculopathy grade, baseline visual acuity, and rate of visual acuity 
deterioration (LogMar/year).  
Enlargement of FAZ area was significantly higher in ETDRS-DMI grades: severe 
(0.073mm2 (10.4%)/year) verses mild (0.021mm2 (7.50%)/year) (p=0.02), or moderate 
(0.019mm2 (5.13%)/year) (p=0.03) (Figure 2.10), and in eyes which showed 
deterioration in visual acuity: (0.057mm2 (19.0%)/year), verses eyes which did not  
(0.018mm2 (5.62%)/year) (p=0.002). There was no significant difference in the FAZ 
enlargement rates in the sub categories - diabetic retinopathy (p=0.11) and 
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maculopathy grades (p=0.88), and baseline visual acuity (p=0.11) (Table 2.8). Though 
not statistically significant, eyes with poor baseline VA were observed to have more 
than twice the progression rate (0.046mm2 (14.4%)/year), compared to eyes with 
good baseline VA (0.019 mm2 (6.13%)/year) (p=0.11). There was no significant 
difference in time interval between baseline and final FA in all groups analysed 
(p>0.24) (Table 2.8). 
 
 
 
Figure 2.10. Foveal avascular zone growth rate by diabetic macular 
ischaemia grade. 
Bar chart showing median and interquartile ranges for FAZ foveal avascular zone (FAZ) area (mm2) 
enlargement or progression rate per year for groups stratified by Early Treatment Diabetic 
Retinopathy – Diabetic Macular Ischaemia (ETDRS-DMI) grades “mild”, “moderate”, and “severe”. 
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Table 2.8: Comparison of Foveal Avascular Zone area enlargement rates 
(mm2 / year) in different subgroups. 
Comparison of FAZ area enlargement rates per year (mm2 / year) p-value 
  
ETDRS-DMI Grade (Baseline)  
Mild vs Moderate 0.86 
Mild vs Severe 0.02* 
Moderate vs Severe 0.03* 
Diabetic Retinopathy (Baseline)  
None or NPDR vs PDR 0.11 
Diabetic Maculopathy (Baseline)  
None or non-CSME vs CSME 0.88 
Visual acuity  
At baseline (LogMar): Good < 0.3 vs Poor > 0.3 0.11 
Progression (LogMar/year): Progression > 0.05 vs No progression < 0.05 0.002** 
The Mann-Whitney U Test (continuous variables) and χ² test (categorical variables) was used the 
assess the differences in FAZ area progression rate (mm2 / year) between sub-categories. p values 
significant at 5% level are indicated with (*), and (**) at 1% level. FA = Fluorescein Angiogram; 
ETDRS = Early Treatment Diabetic Retinopathy Study; DMI = Diabetic Macular Ischaemia; FAZ = 
Foveal avascular zone; NPDR = Non-Proliferative Diabetic Retinopathy; PDR= Proliferative 
Diabetic Retinopathy; DME = Diabetic Macular Oedema; CSME = Clinically Significant Macular 
Oedema 
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2.4.2.3 Predictors of FAZ area enlargement: 
Multivariable logistic regression models were used to assess the relationship 
between FAZ enlargement rate (mm2/year) and its clinical co-variates, namely 
diabetic retinopathy and maculopathy grades, visual acuity, and the effects of 
treatment in the follow-up interval (Table 2.9). “DMI progression” was defined as a 
FAZ enlargement rate of greater than 0.03 mm2/year, which is approximately 
represents an increase of more than 10% of the median baseline FAZ area (in all eyes) 
per year. Model confounders such as age, gender, eye selected, time interval 
between baseline and final FA (continuous variable), diabetic retinopathy, and 
maculopathy grades (categorical variable) were adjusted for in the final regression 
model. 
Our multivariable logistic regression models for ETDRS-DMI grade and VA 
progression rates were good predictors for “DMI progression”, with areas under the 
curve of 0.74 and 0.79 via receiver operating characteristic curve assessment  
respectively, and a Hosmer-Lemeshow goodness-of-fit χ² test of 11.6 (p=0.17), and 
10.3 (p=0.24) respectively.  
ETDRS-DMI grade, as a categorical measure, was a significant independent 
risk factor for “DMI progression”. (OR=2.47, CI=1.21 to 5.05, p=0.02) This suggests 
that for every step increase in ETDRS-DMI severity grade, there is an approximately 
2:1 OR for “DMI progression”. We did not observe any association between DMI 
progression and the effects of retinal or macular laser treatments. At baseline, 40/79 
eyes (50.6%) were treatment-naive for pan-retinal photocoagulation (PRP), and 
49/79 (62.0%) for macula laser. 12 eyes had PRP laser, and 16 eyes macula laser 
treatment over the course of follow-up. There was no association of treatment 
effects with DMI progression, (OR=1.69, CI=0.51 to 5.57, p=0.39) and (OR=1.31, 
CI=0.40 to 4.26, p=0.65) respectively (Table 2.9). 
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Table 2.9: Multivariable logistic regression models of Foveal Avascular Zone 
area progression rate (mm2 / year) and other clinical co-variates.  
 
Baseline measurements Variable OR 95% CI p value 
     
ETDRS-DMI Grade Categorical 2.47 1.21 to 5.05 0.02* 
Diabetic Retinopathy Categorical 0.37 0.14 to 0.98 0.12 
Diabetic Maculopathy Categorical 1.02 0.37 to 2.82 0.12 
Visual acuity (LogMar) Continuous 3.43 0.50 to 23.5 0.10 
Treatment effects: PRP 
Categorical 
1.69 0.51 to 5.57 0.39 
Treatment effects: Macular laser 
Categorical 
1.31 0.40 to 4.26 0.65 
Multivariable logistic regression was used for statistical analysis of the relationship between FAZ 
area progression rate (mm2 / year) and clinical co-variates. Model confounders include age, 
gender, eye (right or left), time interval between baseline and final FA, and diabetic retinopathy 
and maculopathy grades. p values significant at 5% level are indicated with (*), and (**) at 1% 
level. FA = Fluorescein Angiogram; ETDRS = Early Treatment Diabetic Retinopathy Study; DMI = 
Diabetic Macular Ischaemia; NPDR = Non-Proliferative Diabetic Retinopathy; PDR= Proliferative 
Diabetic Retinopathy; DME = Diabetic Macular Oedema; CSME = Clinically Significant Macular 
Oedema; OR = Odds ratio; CI = Confidence interval. 
 
 
2.4.2.4 Predictors of VA deterioration: 
We also assessed whether DMI progression, was predictive of a deteriorating VA over 
time. Eyes which showed “DMI progression” - or an increase in FAZ area of more than 
10% per year, was associated with a loss of 0.05 LogMar or 1 line of Snellen VA per 
year (OR=4.60, CI=1.54 to 13.7, p=0.03), independent of age, gender, eye, or 
retinopathy and maculopathy grade. 
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2.4.3 Diabetic macular ischaemia in type 1 diabetes 
2.4.3.1 Patient Characteristics: 
Patient attendances over a period of 24 months were screened, and 105 patients 
with type 1 diabetes met the inclusion criteria. 12 patients were excluded due to the 
presence of ocular co-morbidities, and a further 9 had fluorescein angiogram images, 
which were of insufficient quality to permit grading of macular ischaemia. In total, 86 
eyes from 86 patients were included in the analysis. Patient demographics and 
clinical characteristics are listed in Table 2.10, and presented in two categories- eyes 
with and without diabetic macular ischaemia.  
 
2.4.3.2 Baseline Characteristics: 
The mean age of patients with macular ischaemia was significantly greater, 49.5 years 
(SD = 15.9), compared to those with no macular ischaemia, 41.6 years (SD = 14.6) 
(p=0.02). Eyes with macular ischaemia were also more likely to have had a vitrectomy 
(0/26 in eyes with “no macular ischaemia” compared to 6/54 [11.1%] in eyes “with 
macular ischaemia”, p<0.001). This was similarly observed with eyes that have had 
cataract surgery (Table 2.10).  
There were no eyes with retinopathy grade of “none”, 21 (24.4%) with mild to 
moderate nonproliferative diabetic retinopathy, 22 (25.6%) with severe 
nonproliferative diabetic retinopathy, and 43 (50.0%) who had either treated, or 
untreated proliferative diabetic retinopathy. The proportion of patients with macular 
ischaemia was highest in eyes with proliferative retinopathy, 35/43 eyes (81.4%), and  
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Table 2.10: Demographics and clinical characteristics of type 1 diabetes 
patients, with and without diabetic macular ischaemia. 
  
No Macular 
Ischaemia 
(n=26) 
Macular Ischaemia 
(n=60) 
p value 
Age, years, Mean (SD)  41.6 (14.6) 49.5 (15.9) 0.02* 
Gender, n, female/male  11 / 15 18 / 42 0.39 
Eye, n, right/left  10 / 16 37 / 23 0.08 
History of Diabetic 
Vitrectomy, n, yes / no  0 / 26 6 / 54 0.23 
History of Cataract Surgery, n, 
yes / no  1 / 25 6 / 54 0.37 
FAZ area, mm2, median (IQR)  0.15 (0.10 to 0.19) 0.32 (0.25 to 0.44) < 0.001** 
Visual Acuity (LogMar), 
median (IQR) 
 0 (-0.1 to 0.2) 0.2 (0 to 0.5) 0.007** 
Retinopathy Grades  
 
 
No Diabetic Retinopathy 
(n=0) 
(%)   
0.03* 
Mild-Moderate NPDR 
(n=21) (24.4%) 
(%) 
9 (42.9) 12 (57.1) 
Severe NPDR 
(n=22) (25.6%) 
(%) 
9 (40.9) 13 (59.1) 
PDR, treated and untreated 
(n=43) (50.0%) 
(%) 
8 (18.6) 35 (81.4) 
 
Maculopathy Grades 
 
No DME / CSME 
(n=44) 
(%) 
12 (27.3) 32 (72.7) 
0.24 
DME (Non CSME) 
(n=23) 
(%) 
10 (43.5) 13 (56.5) 
 
CSME, both treated and 
untreated 
(n=19) 
(%) 
4 (21.1) 15 (78.9) 
Paramacular ischaemia  
 
 
  
Papillomacular ischaemia 
(n=22) 
(%) 
3 (13.6) 19 (86.4) 0.0001** 
Temporal ischaemia 
(n=45) 
(%) 
8 (17.8) 37 (82.2) 0.0001** 
 
FAZ= Foveal Avascular Zone; NPDR = Non-Proliferative Diabetic Retinopathy; PDR= Proliferative 
Diabetic Retinopathy; DME = Diabetic Macular Oedema; CSME = Clinically Significant Macular 
Oedema; SD = Standard Deviation; IQR = Interquartile range. p values significant at 5% level are 
indicated with (*), and (**) at 1% level. 
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was significantly different between all three groups (p=0.03) (Table 2.10). There was 
no difference in proportion of eyes with macular ischaemia, between diabetic 
maculopathy grades (p=0.24). 
 
2.4.3.3 Prevalence of Diabetic Macular Ischaemia in type 1 diabetes: 
In the 86 eyes analysed, 26 eyes (30.2%) had none, 13 (15.1%) questionable, 28 
(32.6%) mild, 10 (11.6%) moderate, and 9 (10.5%) had severe macular ischaemia 
grades.  
Foveal avascular zone areas increased with severity of macular ischaemia: The 
median foveal avascular zone area was observed to increase with grades of macular 
ischaemia severity. Median foveal avascular zone areas were 0.15mm2 (interquartile 
range [IQR], 0.10 to 0.19) in “none”, 0.27mm2 (IQR, 0.18 to 0.30) in “questionable”, 
0.30mm2 (IQR, 0.23 to 0.37) in “mild”, 0.40mm2 (IQR, 0.32 to 0.50) in “moderate”, 
and 0.82mm2 (IQR: 0.48 to 1.15) in “severe” macular ischaemia grades. Highly 
significant differences between median foveal avascular zone areas were seen across 
all grades of macular ischaemia (p<0.001). 
Prevalence of temporal and papillomacular ischaemia: The area of temporal 
and PM areas of ischaemia were quantified as previously described. Temporal 
ischaemia was present in 45/86 eyes (52.3%), and papillomacular ischaemia in 22/86 
(25.6%). The median area of temporal ischaemia was 0.60mm2 (IQR, 0.17 to 1.69), 
and 0.033 mm2 (IQR, 0.016 to 0.069) in papillomacular ischaemia. Both temporal and 
papillomacular ischaemia showed modest correlations to foveal avascular zone area 
measurements (ρ=0.38, p<0.001, and ρ=0.27, p=0.013 respectively), and were more 
prevalent in establish ischaemia (i.e. ETDRS defined macular ischaemia grades mild, 
moderate and severe). Temporal ischaemia was present in 31/47 eyes (66.0%), in the 
“mild to severe” macular ischaemia grades, compared to 14/47 eyes (35.9%) in “none 
or “questionable”. This was similarly observed in papillomacular ischaemia, which 
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was present in 16/39 eyes (34.0%), in the “mild to severe” macular ischaemia grades, 
compared to 6/39 eyes (15.4%) in “none or “questionable”. 
 
2.4.3.4 Clinical significance of macular ischaemia in type 1 diabetes: 
Multivariable logistic regression models were also used to assess the relationships 
between age, visual acuity and macular ischaemia. Model confounders such as 
gender, eye selected, diabetic retinopathy and maculopathy grades (categorical 
variables), and visual acuity (continuous variable), were adjusted for in the final 
regression model. The presence of “macular ischaemia” was defined as ETDRS 
defined grades of questionable, mild, moderate, or severe. Our multivariable logistic 
regression models for age were good predictors for the presence of “macular 
ischaemia”, with areas under the curve of 0.87 (standard error [SE]=0.04, 95% 
confidence interval [CI]=0.78 to 0.93) via receiver operating characteristic curve 
assessment, and a Hosmer-Lemeshow goodness-of-fit χ² test of 7.78 (p=0.46).  
Relationship between age and macular ischaemia: The mean age difference 
between patients with and without macular ischaemia was 7.9 years, and of the 
patients with macular ischaemia, 51/60 (85.0%) were aged greater than 30 years, 
compared to 18/26 (69.2%) in those younger than 30 years. (χ²=4.32, p=0.04) (Figure 
2.11). Furthermore, univariate analysis showed that age, per decade increase, was 
significantly predictive of any grade of macular ischaemia (OR=1.42, 95% CI=1.05 to 
1.93, p=0.02). This association remained significant, and was strengthened in 
multivariate models with severity of concurrent diabetic retinopathy, and visual 
acuity (OR=2.30, 95% CI=1.27 to 4.16, p=0.006) (Table 2.11).  
Relationship between visual acuity, with paramacular and macular ischaemia: 
We observed a significant difference between the median LogMAR visual acuity in 
eyes with “no macular ischaemia”, 0 (IQR: -0.1 to 0.2) (Snellen 20/20), compared to 
eyes with “macular ischaemia” 0.2 (IQR: 0 to 0.5) (Snellen 20/32) (p=0.007) (Table 
2.11). In univariate analysis, a loss of visual acuity was associated with macular 
ischaemia (OR=1.35, 95% CI=1.07 to 1.70, p=0.01). Eyes with a visual acuity of greater 
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than 0.3 LogMar (6/12 Snellen), were also associated with macular ischaemia 
(b=2.06, SE=0.71, p=0.004) and diabetic maculopathy (b=0.83, SE=0.34, p=0.01) 
(Table 3). No associations were observed between visual acuity and foveal avascular 
zone area (ρ=0.062, p=0.57), temporal (ρ=0.030, p=0.84), or papillomacular 
ischaemia area (ρ=0.048, p=0.84).  
 
 
 
Figure 2.11. Proportion of eyes with diabetic macular ischaemia by age in 
type 1 diabetes 
Bar chart of the number of eyes with and without diabetic macular ischaemia (DMI), in patients aged 
greater, or less than 30 years. Chi-squared test showed a significantly higher proportion of eyes with 
“DMI”, in those greater than 30 years of age (χ²=4.32, p=0.04). 
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Table 2.11: Multivariable logistic regression models for the diagnosis of 
diabetic macular ischaemia in type 1 diabetes, per decade increase in age, 
and other clinical co-variates.  
 Variable OR 95% CI p value 
     
Age (per decade increase) Categorical 2.30 1.27 to 4.16 0.006** 
Visual acuity (LogMAR) Continuous 1.40 1.06 to 1.83 0.02* 
Diabetic Retinopathy Categorical 2.79 1.13 to 6.89 0.03* 
Diabetic Maculopathy Categorical 0.52 0.23 to 1.20 0.13 
Temporal ischaemia Categorical 3.26 0.84 to 12.6 0.09 
Papillomacular ischaemia Categorical 4.45 0.77 to 25.8 0.10 
Gender Categorical 1.64 0.45 to 5.98 0.46 
     
Multivariable logistic regression was used for statistical analysis of the relationship between eyes 
with a diagnosis of any grade of diabetic macular ischaemia and it’s clinical co-variates. The 
significance level for the overall model fit was p=0.006. p values significant at 5% level are 
indicated with (*), and (**) at 1% level. OR=Odds Ratio; 95% CI=95% Confidence Interval. 
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2.4.4 Retina vessel calibre measurements in diabetic macular ischaemia 
 
Of 53 patients examined, 18 (34%), 18 (34%) and 17 (32%) had none/mild, moderate 
and severe DMI respectively.  There were 23 (38%) females, 10 (19%) with previous 
PRP, 6 (11%) with NVE, 4 (7%) with NVD) and mean age was 62.3 years (range 27 to 
96 years).  
 Table 2.12 shows that persons with moderate or severe DMI had narrower 
mean retinal arteriolar calibre than persons with no DMI (140.6 µm 95% Confidence 
Interval (CI) 134.7, 146.4 vs 150.7 µm, 95% CI 142.5, 158, p=0.04) The association of 
narrower arterioles with moderate/severe DMI remained after multivariate 
adjustment for age, gender, previous panretinal photocoagulation and 
neovascularisation at the disc and elsewhere (adjusted mean retinal arteriolar calibre 
of 140.7 µm 95% CI 135.5, 146.0 vs 150.4 µm, 95% CI 142.9, 157.8, p=0.04) Increasing 
severity of DMI was also associated with narrower arterioles, with multivariate 
adjusted mean arteriolar calibres of 150.6, 142.1 and 139.1 µm in participants with 
none/mild, moderate and severe DMI respectively.(p trend=0.04)  Retinal venular 
calibre and arteriole to venule ratio (AVR) were not associated with DMI, with 
venular calibre 240.6 µm 95% CI 227.3, 254.0 and AVR 0.63 95% CI 0.60, 0.66 in 
persons with no DMI and venular calibre 233.0 µm 95% CI 223.4, 242.6 µm and AVR 
0.61 95% CI 0.58, 0.63 in persons with moderate/severe DMI, respectively.  
Additional adjustment for NSC diabetic retinopathy grade did not change these 
results. Excluding patients with PRP (n=10) from our analyses attenuated the 
statistical significance of the results but did not change the direction of 
effect.(adjusted arteriolar calibres of 153.3, 146.9 and 143.5 µm in participants with 
none/mild, moderate and severe DMI, respectively.(p trend 0.09)).        
 Increased FAZ (greatest dimension and area of ischaemia) were also 
associated with narrower arteriolar calibre (Table 2.13). Each standard deviation 
decrease in arteriolar calibre was associated with increases of 0.21 mm (95% CI 0.05, 
0.38) in diameter and 0.19 mm2  (95% CI 0.04, 0.33) in area (p=0.01 for both, Figures 
2.12 and 2.13). Figure 2.13 shows that in our sample, 77% of persons in the 
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narrowest quartiles of arteriolar calibre had DMI, compared to 38% in persons in the 
largest quartiles. Venular calibre and AVR were not associated with FAZ diameter or 
area.   
 
Table 2.12: Retinal vessel calibres by severity of diabetic macular 
ischaemia. 
 
Diabetic macular  
ischaemia 
severity 
 Mean arteriolar calibre, 
µm (95% CI) 
Mean venular calibre, 
µm (95% CI) 
Mean arteriole to venule 
ratio (AVR) 
 
 N  Unadjusted Multivariate   
Adjusted 
Unadjusted 
 
 
Multivariate  
Adjusted 
Unadjusted Multivariate  
Adjusted 
None 18 150.7 
(142.5, 
158.9) 
150.6 
(143.0, 
158.1) 
240.6 
(227.4, 
253.9) 
243.1 
(230.3, 
256.0) 
0.63 
(0.60, 
0.66) 
0.62 
(0.59, 0.66) 
Moderate 18 142.4 
(134.2, 
150.7) 
142.1 
(134.9, 
149.3) 
238.8 
(225.6, 
252.1) 
238.8 
(226.6, 
251.1) 
0.60 
(0.57, 
0.63) 
0.60 
(0.56, 0.63) 
Severe 17 138.6 
(130.1, 
147.1) 
139.1 
(131.1, 
147.1) 
226.8 
(213.2, 
240.5) 
224.2 
(210.6, 
237.7) 
0.61 
(0.58, 
0.65) 
0.62 
(0.59, 0.66) 
p-trend  0.04 0.04 0.23 0.12 0.25 0.64 
     
 
   
None 18 150.7 
(142.5, 
158.9) 
150.4 
(142.9, 
157.8) 
240.6 
(227.3, 
254.0) 
242.1 
(229.1, 
255.1) 
0.63 
(0.60, 
0.66) 
0.63 
(0.59, 0.66) 
Moderate/Severe 35 140.6 
(134.7, 
146.4) 
140.7 
(135.5, 
146.0) 
233.0 
(223.4, 
242.6) 
232.2 
(223.2, 
241.3) 
0.61 
(0.58, 
0.63) 
0.61 
(0.59, 0.63) 
Difference  10.1 
(0.1, 20.2) 
9.6 
(0.2, 19.1) 
7.6 
(-8.8, 24.0) 
9.9 
(-6.6, 26.3) 
0.03 
(-0.01, 
0.07) 
0.02 
(-0.03, 0.06) 
p-value  0.04 0.04 0.36 0.23 0.18 0.44 
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Table 2.13: Changes in retinal vessel calibre and size of foveal avascular 
zone. 
Size of foveal 
avascular 
zone 
Per SD decrease in 
arteriolar calibre 
Per SD decrease in venular 
calibre 
Per SD decrease in 
arteriole to venule ratio 
(AVR) 
 Unadjusted Multivariate 
adjusted 
Unadjusted Multivariate 
adjusted 
Unadjusted Multivariate 
adjusted 
Greatest 
linear 
dimension 
(mm) 
0.17 
(0.04, 0.31) 
0.21 
(0.05, 0.38) 
0.11 
(-0.03, 0.26) 
0.15 
(-0.001, 0.31) 
0.08 
(-0.06, 
0.22) 
0.04 
(-0.12, 0.19) 
       
p-value 0.01 0.01 0.11 0.06 0.28 0.62 
       
Area of 
ischaemia 
(mm2) 
0.15 
(0.03, 0.27) 
0.19 
(0.04, 0.33) 
0.09 
(-0.04, 0.21) 
0.12 
(-0.02, 0.26) 
0.08 
(-0.05, 
0.20) 
0.04 
(-0.09, 0.18) 
p-value 0.02 0.01 0.17 0.08 0.22 0.53 
 
 
 
 
Figure 2.12. Relationship between foveal avascular zone enlargement and 
visual acuity deterioration in type 1 diabetes. 
Bar chart showing median and interquartile ranges for FAZ foveal avascular zone (FAZ) area (mm2) 
enlargement or progression rate per year for groups stratified by visual acuity progression rate 
(LogMar / year) – < 0.3 and > 0.3. 
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Figure 2.13. Relationship between foveal avascular zone size and retinal 
arteriolar calibre. 
Scatterplots showing the relationship between the foveal avascular zone and arteriolar calibre in eyes 
with diabetic macular ischaemia. The greatest linear diameter of the foveal avascular zone is plotted 
against arteriolar calibre in the top figure (Pearsons r=0.34, p=0.01), and in the bottom figure, foveal 
avascular zone area is plotted against arteriolar calibre (Pearsons r=0.32, p=0.02.) 
 
 
 
88 
 
 
 
Figure 2.14. Comparing DMI severity grade by retinal arteriolar calibre. 
Bar chart comparing the proportion of eyes with different severity grades of diabetic macular 
ischaemia (DMI) by arteriolar calibre quartiles. Bars represent the number of persons with none/mild 
(dark grey) compared to moderate/severe diabetic macular ischaemia (light grey). 
 
2.4.5 Repeatability and Reproducibility of OCT-derived measurements 
in diabetic retinopathy 
 
2.4.5.1 Patient Characteristics: 
51 eyes of 51 patients with a diagnosis of type 2 diabetes with a mean age of 
60.1 years were included in this study.  
 
2.4.5.2 Repeatability of Measurements: 
The repeatability of retinal and choroidal measurements was assessed in subset of 20 
eyes randomly selected from the study cohort. Each image set was manually 
segmented twice by each “trained” grader. (The junior grader received training prior 
to both episodes of segmentation) The CR (µm or mm3), CR expressed as a 
percentage of mean thickness or volume (CR/Mean), and reliability (ICC) for all 
indices measured in the TMC and FCS are presented in Tables 2.14, 2.15. 
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Repeatability of thickness and volume measurements (Tables 2.14, 2.15): 
Thickness measurements of the TMC showed better repeatability than those at the 
FCS (Figure 2.15). The CR of both retinal and choroidal thicknesses ranged from 19.2 
to 35.2 µm in the TMC, and 26.9 to 49.0 µm in the FCS. TMC thickness measurements 
were also more reliable in retinal, total choroidal, and Sattler’s medium vessel layers. 
The lowest CR/Mean percentages (greatest repeatability) were observed in the TMC 
the retina and total choroidal thickness measurements. (6.7 and 11.8 respectively). 
Segmentation for choroidal sublayers, Haller’s large vessel and Sattler’s medium 
vessel layers showed less repeatability, with higher CR / Mean percentages. 
Repeatability of volume measurements were similar to that of thickness 
measurements, as observed in the CR / Mean percentages.  
The reliability of both thickness and volume measurements, as expressed by 
the intraclass correlation coefficient (ICC), showed good reliability (ICC > 0.8) across 
all layers, apart from measurements in Haller’s large vessel layer at the FCS 
(thickness: ICC 0.78, Volume: ICC 0.76). 
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Table 2.14: Repeatability and Reliability of Retinal and Choriodal Thickness 
Measurements in Patients with Type 2 Diabetes 
Thickness 
Measurements 
(µm) 
(Graders 1 & 2) 
CR  
(µm) 
CR / Mean 
(%) 
ICC 95% CI 
 
 
 
  Retina 
 
 
  
 TMC 19.2 6.7 0.98 0.95 to 0.99 
 FCS 49.0 18.1 0.98 0.95 to 0.99 
Choroid 
 
 
  
 TMC 26.9 11.8 0.97 0.94 to 0.99 
 FCS 48.3 19.6 0.93 0.83 to 0.97 
Haller's Layer 
 
 
  
 TMC 35.2 29.6 0.86 0.68 to 0.94 
 FCS 38.2 29.7 0.78 0.53 to 0.91 
Sattler's Layer 
 
 
  
 TMC 29.2 26.0 0.89 0.73 to 0.95 
 FCS 39.0 32.2 0.88 0.73 to 0.95 
  
 
  
TMC = Total macular circle (ETDRS areas 1-9), FCS = Foveal centre subfield (ETDRS area 9), Haller’s layer = 
Haller’s large vessel layer of the choroid, Sattler’s layer = Sattler’s medium vessel layer of the choroid, CR = 
Coefficient of repeatability, CR/Mean = The coefficient of repeatability, expressed as a percentage of the mean, 
ICC = Intraclass correlation coefficient, CI = confidence interval. 
  
 
  
 
 
Table 2.15. Repeatability and Reliability of Retinal and Choriodal Volume 
Measurements in Patients with Type 2 Diabetes 
Volume 
Measurements (mm3) 
(Graders 1 & 2) 
CR  
(mm3) 
CR / Mean 
(%) 
ICC 95% CI 
 
 
 
  Retina 
 
 
  
 TMC 0.64 8.1 0.97 0.94 to 0.99 
 FCS 0.04 18.7 0.98 0.95 to 0.99 
Choroid 
 
 
  
 TMC 0.83 13.1 0.97 0.92 to 0.99 
 FCS 0.04 20.6 0.92 0.80 to 0.97 
Haller's Layer 
 
 
  
 TMC 1.03 31.4 0.85 0.66 to 0.94 
 FCS 0.03 29.7 0.76 0.48 to 0.90 
Sattler's Layer 
 
 
  
 TMC 0.80 25.8 0.89 0.74 to 0.95 
 FCS 0.03 31.4 0.88 0.71 to 0.95 
  
 
  
TMC = Total macular circle (ETDRS areas 1-9), FCS = Foveal centre subfield (ETDRS area 9), Haller’s layer = 
Haller’s large vessel layer of the choroid, Sattler’s layer = Sattler’s medium vessel layer of the choroid, CR = 
Coefficient of repeatability, CR/Mean = The coefficient of repeatability, expressed as a percentage of the mean, 
ICC = Intraclass correlation coefficient, CI = confidence interval. 
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2.4.5.3 Reproducibility of Measurements: 
Reproducibility of retinal and choroidal measurements (Tables 2.16, 2.17): The 
reproducibility of thickness and volume measurements between both trained graders 
are displayed in Table 2.16 (thickness) and Table 2.17 (volume) for all retinal and 
choroidal layers. Bland-Altman plots were used to illustrate agreement between 
graders (Figures 2.15, 2.16, 2.17, and 2.18). No significant changes were observed 
with interobserver variability for the range of retinal and choroidal measurements. 
 To examine whether the 95% limits of agreements were significantly different 
between observers, the variance of the interobserver measurement differences were 
calculated and the F statistic (variance ratio) presented (Table 2.18). The variance 
ratio between graders was not statistically significant in all layers. However, the data 
showed a trend towards a higher variance ratio in the choroidal sub-layers quantified 
at the FCS. TMC measurements showed similar variance ratios in all layers.  
Factors which may affect agreement were also analysed. A univariate generalised 
linear model was fitted to the data, with the difference in thickness measurements 
between graders as the dependent variable, and retinopathy grade, maculopathy 
grade, age, gender, and visual acuity as co-variates. Visual acuity (VA) was the only 
factor which showed significant association with retinal and choroidal thickness 
measurement difference between graders (Table 2.18). There was no significant 
association in the choroidal sublayers. Scatter plot analysis of VA and LoA did not 
reveal any association between these two factors (Figure 2.19). 
The effect of training on reproducibility of measurements (Table 2.19): As expected, 
the mean intergrader differences were reduced after training. This was most 
apparent in measurements of the choroid and its sublayers. 
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Figure 2.15. Reproducibility of OCT-derived retinal thickness  
Bland-Altman plot illustrating the reproducibility of retinal thickness measurements. Mean difference 
between graders, 8.5 µm; 95% confidence intervals, -19.4 to 36.5 µm. The variance ratio (F statistic) of 
intergrader differences showed no significant difference between graders. (p=0.91 (TMC), p=0.94 
(FCS)) 
 
Figure 2.16. Reproducibility of OCT-derived choroidal thickness  
Bland-Altman plot illustrating the reproducibility of total choroidal thickness measurements. Mean 
difference between graders, 8.0 µm; 95% confidence intervals, -33.5 to 49.4 µm. The variance ratio (F 
statistic) of intergrader differences showed no significant difference between graders. (p=0.94 (TMC), 
p=0.68 (FCS)) 
93 
 
 
 
Figure 2.17. Reproducibility of OCT-derived Haller’s layer measurements 
Bland-Altman plot illustrating the reproducibility of Haller’s large vessel layer thickness measurements. 
Mean difference between graders, -4.1 µm; 95% confidence intervals, -42.6 to 34.5 µm. The variance 
ratio (F statistic) of intergrader differences showed no significant difference between graders. (p=0.98 
(TMC), p=0.49 (FCS) 
 
Figure 2.18. Reproducibility of OCT-derived Sattler’s layer thickness  
Bland-Altman plot illustrating the reproducibility of Sattler’s medium vessel layer thickness 
measurements. Mean difference between graders, 13.7 µm; 95% confidence intervals, -17.4 to 44.8 
µm. The variance ratio (F statistic) of intergrader differences showed no significant difference between 
graders. (p=0.88 (TMC), p=0.45 (FCS)) 
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Table 2.16. Reproducibility of Retinal and Choroidal Thickness 
Measurements in Patients with Type 2 Diabetes. 
Layers Measured 
(Thickness) 
Interobserver 
Mean Difference 
(µm) 
95% CI  
(µm) 
95% Limits of Agreement  
(µm) 
    Retina 
   
 TMC 8.52 4.51 to 12.5 27.9 
 FCS 2.80 -4.26 to 9.87 48.8 
Choroid 
    TMC 7.99 2.04 to 13.9 41.5 
 FCS 9.56 1.85 to 17.3 53.1 
Haller's Layer 
    TMC -4.05 -9.96 to 1.86 38.6 
 FCS -2.12 -10.9 to 6.63 56.5 
Sattler's Layer 
    TMC 13.7 8.95 to 18.5 31.1 
 FCS 14.0 7.16 to 20.8 44.0 
    TMC = Total macular circle, FCS = Foveal centre, Haller’s layer = Haller’s large vessel layer of the choroid, Sattler’s layer = 
Sattler’s medium vessel layer of the choroid, ICC = Intraclass correlation coefficient, CI = confidence interval. 
    
 
 
Table 2.17. Reproducibility of Retinal and Choroidal Volume Measurements 
in Patients with Type 2 Diabetes. 
Layers Measured (Volume) 
(mm3) 
Interobserver 
Mean Difference 
(mm3) 
95% CI  
(mm3) 
95% Limits of Agreement  
(mm3) 
    Retina 
   
 TMC 0.36 0.18 to 0.54 1.26 
 FCS 0.00 -0.0035 to 0.0071 0.04 
Choroid 
   
 TMC 0.31 0.10 to 0.52 0.43 
 FCS 0.01 0.0013 to 0.014 0.04 
Haller's Layer 
   
 TMC -0.06 -0.24 to 0.13 1.21 
 FCS -0.11 -0.14 to -0.09 0.17 
Sattler's Layer 
   
 TMC 0.42 0.28 to 0.56 0.92 
 FCS 0.01 0.0057 to 0.017 0.03 
    TMC = Total macular circle, FCS = Foveal centre, Haller’s layer = Haller’s large vessel layer of the choroid, Sattler’s layer = 
Sattler’s medium vessel layer of the choroid, ICC = Intraclass correlation coefficient, CI = confidence interval. 
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Table 2.18. The Variance Ratio (F Statistic) of Intergrader Differences in 
Retinal and Choroidal Measurements 
Layers Measured 
(Graders 1 & 2) 
F Test p Value F Test p Value 
 
Thickness  
measurements 
Volume  
measurements 
 
 
 
  Retina 
 
 
  
 TMC 1.18 0.56 1.03 0.91 
 FCS 1.00 1.00 1.02 0.94 
Choroid 
 
 
   TMC 1.14 0.64 1.02 0.94 
 FCS 1.15 0.62 1.12 0.68 
Haller's Layer 
 
 
   TMC 1.22 0.50 1.01 0.98 
 FCS 1.32 0.36 1.23 0.49 
Sattler's Layer 
 
 
   TMC 1.26 0.44 1.05 0.88 
 FCS 1.32 0.35 1.26 0.45 
  
 
  
TMC = Total macular circle (ETDRS areas 1-9), FCS = Foveal centre subfield (ETDRS area 9), Haller’s layer = Haller’s large 
vessel layer of the choroid, Sattler’s layer = Sattler’s medium vessel layer of the choroid, F test = variance ratio 
  
 
  
 
 
Figure 2.19. Reproducibility of OCT-derived choroidal thickness 
measurements 
Bland-Altman plot illustrating the reproducibility of total choroidal thickness measurements. Mean 
difference between graders, 8.0 µm; 95% confidence intervals, -33.5 to 49.4 µm. The variance ratio (F 
statistic) of intergrader differences showed no significant difference between graders. (p=0.94 (TMC), 
p=0.68 (FCS))
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Table 2.19. The Effect of Manual SegmentationTraining on the 
Reproducibility of Retinal and Choroidal Thickness Measurements. 
 
 
 
 
 
 
 
 
 
 
  
 
Before Training After Training 
Layers 
Measured 
(Thickness) 
Intergrade
r Mean 
Difference 
(µm) 
95% CI 
(µm) 
95% 
Limits of 
Agreement 
(µm) 
Intergrade
r Mean 
Difference 
(µm) 
95% CI 
(µm) 
95% Limits 
of 
Agreement 
(µm) 
Retina 
   
   
 TM
C 
-5.98 -9.13 to -
2.83 
8.63 4.07 -2.64 to 
10.8 
18.4 
 FCS -4.44 -9.25 to 
0.37 
13.2 -8.96 -32.7 to 
14.8 
65.0 
Choroid 
   
   
 TM
C 
23.7 11.3 to 
36.1 
34.0 12.3 0.29 to 
24.2 
32.8 
 FCS 33.1 9.09 to 
57.13 
65.8 21.3 0.34 to 
42.2 
57.4 
Haller's 
Layer 
   
   
 TM
C 
-14.3 -32.4 to 
3.82 
49.6 -4.74 -19.0 to 
9.48 
39.0 
 FCS -6.74 -38.1 to 
24.6 
85.9 5.90 -17.9 to 
29.7 
65.3 
Sattler's 
Layer 
   
   
 TM
C 
37.1 24.0 to 
50.1 
35.7 16.7 5.31 to 
28.2 
31.3 
 FCS 39.1 23.6 to 
54.7 
42.5 14.7 3.20 to 
26.3 
31.6 
    
   
TMC = Total macular circle, FCS = Foveal centre subfield, Haller’s layer = Haller’s large vessel layer of 
the choroid, Sattler’s layer = Sattler’s medium vessel layer of the choroid, CI = confidence interval. 
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2.4.6 Analysis of diabetic macular ischaemia using OCT-derived 
measurements in diabetic retinopathy 
 
2.4.6.1 Baseline Characteristics: 
One hundred consecutive patients with Type 2 diabetes mellitus were included in this 
study. The retinal nerve fibre layer, inner and outer retinal thickness measurements 
were analysed. (Figure 2.20) Of these, 60 patients underwent “enhanced depth 
imaging” (EDI).(46) In these cases, analysis of the choroid was also performed.  
 
 
Figure 2.20. Segmentation of retinal and choroidal layers  
(a) and (b) are examples of a fluorescein angiograph in an eye with diabetic macular ischaemia. Green 
horizontal lines represent, optical coherence tomography B-scans (c-f), acquired using the enhanced 
depth optical coherence tomographic protocol. (c) The retinal nerve fibre layer area (green) was 
segmented in 13 B-scans acquired over the macular. (d) Similarly, measurements of the inner retina 
(red), outer retina (green), (e) total choroid (blue), (f) Sattler’s medium vessel layer (yellow), and 
Haller’s large vessel layer (blue) were taken. 
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Twelve patients did not have FA images of sufficient quality to permit grading 
of macular ischaemia in either eye. These patients were excluded from analysis. From 
each patient, we selected the eye with the greatest macular ischaemia severity, using 
permutated block randomization where macular ischaemia severity was symmetrical 
(n=32). This was to ensure inclusion of patients with a greater diabetic macular 
ischaemia severity within our patient cohort. 
For the 100 eyes that were analysed, the male to female ratio was 1:3, and 
mean patient age was 62 years (standard deviation (SD): 12). The proportions of eyes 
with ETDRS defined grades of retinopathy and maculopathy are presented in Table 
2.20. In the 88 eyes graded for macular ischaemia, 34 eyes (38.6%) had none, 12 
(13.6%) questionable, 23 (26.1%) mild, 6 (6.8%) moderate, and 13 (14.8%) severe 
ETDRS-defined diabetic macular ischaemia grades (Table 2.20). 
 
2.4.6.2 The Effects of Ischaemia on Retinal Morphology: 
Coexistence of diabetic macular oedema with macular ischaemia (Table 2.21): DME, 
defined as a foveal retinal thickness of greater than 275µm, was present in 49/100 
eyes (49%). The proportions of DME, within different diabetic macular ischaemia 
grades, are presented in Table 2.20. The proportion of eyes with any grade of 
macular ischaemia was comparable in both DME subgroups (55.6% “with DME” 
verses 44.4% “without DME”). There were no significance differences in age or 
gender, between both macular ischaemia or DME subgroups. 
Outer retinal thickness measurements in diabetic macular ischaemia (Table 2.22): In 
the analysis of all eyes, a trend towards a negative correlation was observed between 
FAZ area and retinal thickness measurements (r=-0.19, p=0.07). However, we 
observed that outer retina measurements significantly thicker at the FCS in eyes 
“with macular ischaemia” (167.4 ± 18.5 µm) compared to eyes with “no macular 
ischaemia” (150.4 ± 31.4 µm) (p=0.04). When eyes with DME were excluded, the 
outer retina was significantly thinner in eyes “with macular ischaemia” (223.1 ± 31.2 
µm) compared to eyes with “no macular ischaemia” (244.9 ± 37.2 µm) (p=0.007). 
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Inner retinal measurements were not significantly different between groups. 
Correlation of retinal nerve fibre layer thickness with area of the foveal avascular 
zone (Table 2.22): We analysed the RNFL thickness measurements in two groups – 
“all eyes” with FAZ measurements (n=88), and in eyes “without DME” (n=39). 
 
Table 2.20. Baseline demographic and clinical characteristics of patients in 
OCT-derived measurement in diabetic macular ischaemia study. 
Clinical Features   
   
Age n (SD) 62 (12) 
Gender M:F 1.3 
Diabetic retinopathy grade (n=100)   
No DR n  5 
NPDR n  54 
PDR n  41 
Diabetic maculopathy grade (n=100)   
None n  32 
DME n  30 
CSME n  38 
ETDRS-DMI grade 
(n=88) 
  
None n (%) 34 (38.6) 
Questionable n (%) 12 (13.6) 
Mild n (%) 23 (26.1) 
Moderate n (%) 6 (6.8) 
Severe n (%) 13 (14.8) 
   
ETDRS = Early treatment diabetic retinopathy study; DMI = Diabetic Macular Ischaemia; NPDR = 
Non-Proliferative Diabetic Retinopathy; PDR= Proliferative Diabetic Retinopathy; DME = 
Diabetic Macular Oedema; CSME = Clinically Significant Macular Oedema; SD = Standard 
Deviation 
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Table 2.21. Prevalance of diabetic macular oedema in different grades of 
ETDRS defined grades of diabetic macular ischaemia. 
ETDRS-DMI grades  
DME 
(n=49) 
No DME 
(n=39) 
    
None 
(n=34) (38.6%) 
n (%) 19 (55.9%) 15 (44.1%) 
Questionable 
(n=12) (13.6%) 
n (%) 4 (33.3%) 8 (66.7%) 
Mild 
(n=23) (26.1%) 
n (%) 13 (56.5%) 10 (43.5%) 
Moderate 
(n=6) (6.8%) 
n (%) 4 (66.7%) 2 (33.3%) 
Severe 
(n=13) (14.8%) 
n (%) 9 (69.2%) 4 (30.8%) 
All grades 
(n=54) (61.4%) 
n (%) 
30 (55.6%) 24 (44.4%) 
    
ETDRS = Early treatment diabetic retinopathy study; DMI = Diabetic macular ischaemia; 
DME = Diabetic macular oedema. 
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Table 2.22. Mean thickness values of the total, inner and outer retina, nerve fibre layer, choroid, and Haller’s large vessel layer. 
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In “all eyes”, the FAZ area showed weak correlation to RNFL thickness at the TMC (r=-
0.231, p=0.03), but not at the FCS (r=-0.02, p=0.88), temporal (outer: r=-0.10, 
p=0.482) (inner: r=-0.11, p=0.43), or papillomacular quadrants (outer: r=-0.21, 
p=0.482) (inner: r=-0.25, p=0.14). 
In eyes “without DME”, the FAZ area showed significant negative correlation 
with RNFL thickness over the papillomacular quadrant, particularly in the outer 
quadrant (outer: r=-0.62, p<0.001) (inner: r=-0.38, p=0.04). This was not observed at 
the TMC (r=-0.12, p=0.44), FCS (r=-0.02, p=0.884), or temporal quadrants (outer: r=-
0.12, p=0.54) (inner: r=-0.27, p=0.16).  
 
2.4.6.3 The Effects of Ischaemia on Choroidal Morphology: 
Haller’s large vessel layer thickness in diabetic macular ischaemia (Table 2.22): 
Haller’s large vessel layer was significantly thicker in eyes “with macular ischaemia”, 
compared to eyes with “no macular ischaemia”, both at the FCS (144.3 ± 51.0 versus 
103.5 ± 39.4 µm µm) (p=0.01) respectively and TMC (138.2 ± 42.6 µm versus 104.2 ± 
30.9 µm) (p=0.01). There was no significant difference in total choroidal thickness 
between at the FCS (p=0.11), or TMC (p=0.07). There was also no significant 
difference in Haller’s layer or choroidal thickness between eyes with, and without 
DME.  
Correlation of Haller’s large vessel layer thickness to FAZ area: In eyes 
“without DME”, Haller’s layer over the TMC, was correlated to the size of FAZ area 
(r=0.43, p=0.04). This was not observed in “all eyes” (r=0.22, p=0.16), or eyes “with 
DME” (r=0.11, p=0.64). Interestingly, there was no correlation between Haller’s layer 
thickness and retinal thickness measurements. (r=0.16, p=0.31) 
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2.4.6.4 Relationships between Visual Acuity and Optical Coherence 
Tomography-Derived Parameters: 
Significant correlations were observed between VA, and the FAZ area (r=0.36, 
p=0.02), papillomacular ischaemia area (r=0.613, p=0.01), but not with the temporal 
ischaemia area (r=0.22, p=0.29). These relationships are consistent with findings from 
our previous study.(187)  
Retinal thickness and visual acuity: In eyes with both macular ischaemia and 
oedema, we observed a positive correlation between VA and total retinal thickness, 
(r=0.52, p=0.001) and outer retinal thickness measurements (r=0.33, p=0.04) at the 
FCS. Interestingly, in eyes with macular ischaemia but without oedema, we observed 
the converse, where VA was negatively correlated to total retinal thickness, (r=-0.37, 
p=0.004) and outer retinal thickness measurements (r=-0.44, p=0.001) at the FCS. 
There were no significant associations in the analysis of “all eyes”, or between VA and 
inner retinal thicknesses measurements. 
Retinal nerve fibre layer and visual acuity: In eyes with macular ischaemia but 
without oedema, we observed a negative correlation between VA and RNFL thickness 
over the papillomacular area, (r=-0.37, p=0.004) which was lost in the analysis of “all 
eyes” (r=0.20, p=0.18), and eyes with both macular ischaemia and oedema (r=0.335, 
p=0.08). There were no associations between VA and RNFL thickness measurements 
the analysis of “all eyes”. 
Subfoveal choroidal thickness and visual acuity: VA was moderately correlated 
to choroidal thickness measurements at the FCS in macular ischaemia grades “mild” 
to “severe” (n=42) (r=0.47, p=0.03). This correlation was further strengthened in eyes 
with macular ischaemia grades “moderate” to “severe” (n=19) (r=0.74, p=0.009). 
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2.4.7 Relationship of peripheral retinal and central macular ischaemia 
 
2.4.7.1 Baseline Characteristics: 
Ultra widefield FA images from 47 patients were assessed. The median age of all 
patients was 55 years (interquartile range [IQR]=15.0), 21 patients (44.7%) were 
female, and 12 (25.5%) were diagnosed with Type 1, and 35 (74.5%) Type 2 diabetes. 
In all patients, the median FAZ area was 0.35mm2 (IQR=0.28mm2), median peripheral 
ischemic index was 31.9% (IQR=38.3%), and median peripheral leakage index was 
17.7% (IQR=29.7%). There were no differences with age, gender, and diabetes type, 
in all 3 categories- “FAZ area”, “peripheral ischaemia index”, and “peripheral leakage 
index” (Table 2.23).  
 
Table 2.23. Peripheral ischaemia and leakage index in all patients and in 
those with a small compared to a large foveal avascular zone area. 
  
All 
(n=47) 
Small FAZ 
(n=20) 
Large FAZ 
(n=27) 
p-value 
Percentage of PRP laser Treated area / Total area visualised, %, (IQR)  
            74.5 (12.4) 74.2 (7.4) 77.6 (19.9) 0.57 
Percentage of Peripheral ischaemia to total area visualised, (IQR)  
          All eyes  14.6 (40.4) 8.9 (12.7) 33.7 (44.0) 0.004** 
          PRP laser naive  
          (n=20) 
 38.8 (38.8) 13.2 (32.3) 45.6 (45.2) 0.04* 
          PRP laser treated 
          (n=27) 
 9.2 (10.1) 8.9 (9.3) 9.2 (9.2) 0.97 
Percentage of Peripheral FA leakage to total area visualised, (IQR)  
          All eyes  11.4 (18.9) 7.1 (19.4) 14.8 (20.4) 0.08 
          PRP laser naive  
          (n=20) 
 12.9 (18.0) 6.5 (8.4) 20.6 (22.5) 0.01* 
          PRP laser treated 
          (n=27) 
 9.1 (21.7) 7.3 (24.1) 9.3 (8.3) 0.90 
      
 
IQR = Interquartile range 
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In our cohort, a large proportion of patients, 35/47 (74.5%), were graded with 
proliferative diabetic retinopathy. Of these, there were a significantly greater 
proportion of eyes with of proliferative diabetic retinopathy in the group with a high 
(> 50%) peripheral leakage index. 27/47 patients (57.4%) were naive to pan-retinal 
photocoagulation (PRP) laser treatment in our cohort. No significant differences were 
observed between PRP treatment naive and treated patients across all three 
categories.  
Regarding the presence of macular oedema, 26/47 patients (55.3%) had a UK 
NSC grade of diabetic macular oedema, compared to 32/47 patients (68.0%), with a 
uwFA macular oedema grade- defined as central capillary leakage observed on late-
phase uwFA images. Of these, 9 patients had “focal leakage” and 23 patients had 
“diffuse leakage”. No significant differences were observed in either the UK NSC 
maculopathy grades or uwFA macular oedema grades across all three categories 
(Table 2.23).  
 
2.4.7.2 The Relationship between Peripheral Ischaemia and Peripheral 
Leakage: 
An association between peripheral ischaemia and peripheral leakage index in laser 
naive eyes (Table 2.23): In all eyes, no association was observed between the 
peripheral ischaemia or leakage index (r=0.20, p=0.19). However, in eyes that were 
laser naive, a significant association was observed (r=0.56, p=0.004).  
 
2.4.7.3 The Relationship between Peripheral and Macular Ischaemia: 
A high peripheral ischemic index is associated with a large FAZ (Table 2.24): In all 
eyes, the median FAZ area was significantly larger in eyes with a high peripheral 
ischaemia index (0.56mm2 [IQR=0.86]), compared to eyes with a low peripheral 
ischaemia index (0.32mm2 [IQR=0.28]) (p=0.02) (Figure 2.21). A similar trend was 
observed when only eyes that were PRP laser treatment naive (n=27) were analysed, 
(0.55mm2 [IQR=0.55]) versus 0.27mm2 [IQR=0.05]), though this did not reach 
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statistical significance (p=0.06). In addition, a moderate correlation was observed 
between the peripheral ischaemia index and FAZ area, both in all eyes (r=0.49, 
p=0.0001) and in eyes that were laser naive (r=0.55, p=0.003) (Figure 2.22).  
A high peripheral leakage index was associated with a large FAZ in laser naive 
eyes (Table 2.24): When all eyes were included, no difference was observed in the 
size of the FAZ between eyes with a low or high peripheral leakage index. However, 
in eyes that were laser naive, there was a moderate correlation between the FAZ 
area, and the peripheral leakage index (r=0.44, p=0.02) (Figure 2.22). 
 
2.4.7.4 The Effects of Peripheral Ischaemia on Retinal Thickness 
Measurements: 
No relationship between peripheral ischaemia or leakage was observed with macular 
oedema (Table 2.24): In all eyes, no significant difference was observed with NSC 
maculopathy or uwFA macular oedema grades, for either the peripheral ischaemia or 
leakage indices. Similarly, there were no differences in OCT-derived retinal thickness 
measurements of the foveal central subfield (FCS), in eyes with a high or low, 
ischemic or leakage indices. 
The retina is thinner in the presence of macular but not peripheral ischaemia 
(Table 2.24): The median FCS retinal thickness measurement in eyes with a large FAZ 
was 217µm (IQR=81.8), compared to 272µm (IQR=36.0) (p=0.02) in eyes with a small 
FAZ. In the presence of a high peripheral ischaemia index, a thinner retina was also 
observed at the FCS (226µm [IQR=94.5] compared to 267µm [IQR=75.0]), however, 
this was not statistically significant (p=0.08). There was no difference in the retinal 
thickness measurements between eyes with a high or low peripheral leakage index.   
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Table 2.24. Comparison between patients with a small or large foveal 
avascular zone area, and low (<20%) or high (>20%) peripheral ischaemia 
and leakage indexes. 
 FAZ area (mm2) 
Peripheral ischaemia index 
(%) 
Peripheral leakage index 
(%) 
 
Small 
(<0.32
mm2) 
(n=20) 
Large 
(>0.32
mm2) 
(n=27) 
p-
value 
Low 
(<50%) 
(n=33) 
High 
(>50%) 
(n=14) 
p-
valu
e 
Low 
(<50%) 
(n=35) 
High 
(>50%) 
(n=12) 
p-
valu
e 
Age, Median 
(IQR) 
51 
(26.8) 
57 
(12.5) 
0.09 
56 
(15.0) 
51 (9.3) 0.40 55 (14.0) 
55 
(27.8) 
0.17 
Female 
Gender, n 
(%) 
7 
(35.0) 
14 
(51.9) 
0.39 
15 
(45.5) 
6 (42.9) 0.88 13 (37.1) 
8 
(66.7) 
0.08 
Affected eye 
– right, n (%) 
10 
(50.0) 
17 
(63.0) 
0.56 
19 
(57.6) 
8 (57.1) 0.77 20 (57.1) 
7 
(58.3) 
0.87 
Diabetes, n 
(%) 
         
          Type 1 
7 
(35.0) 
5 
(18.5) 
0.29 
9 
(27.3) 
3 (21.4) 
0.94 
8 (22.9) 
4 
(33.3) 
0.31 
          Type 2 
13 
(65.0) 
22 
(81.5) 
24 
(72.7) 
11 (78.6) 27 (77.1) 
8 
(66.7) 
UK NSC 
Retinopathy 
grade, n (%) 
         
          Non-
proliferative 
3 
(15.0) 
9 
(33.3) 
0.28 
10 
(30.3) 
2 (14.3) 
0.43 
10 (28.6) 
2 
(16.7) 
0.04* 
          
Proliferative 
17 
(85.0) 
18 
(66.7) 
23 
(69.7) 
12 (85.7) 25 (71.4) 
10 
(83.3) 
UK NSC 
Maculopathy 
grade, n (%) 
         
          No 
DME 
12 
(60.0) 
14 
(51.9) 
0.80 
18 
(54.5) 
8 (57.1) 
0.88 
19 (54.3) 
7 
(58.3) 
0.60 
          DME 
8 
(40.0) 
13 
(48.1) 
15 
(45.5) 
6 (42.9) 16 (45.7) 
5 
(41.7) 
uwFA 
Macular 
oedema 
grade, n (%) 
         
          None 
11 
(55.0) 
13 
(48.1) 
0.87 
16 
(48.5) 
8 (57.1) 
0.82 
19 (54.3) 
5 
(41.7) 
0.94 
          Focal 
& Diffuse 
9 
(45.0) 
14 
(51.9) 
17 
(51.5) 
6 (42.9) 16 (45.7) 
7 
(58.3) 
PRP laser          
          Naive 
8 
(40.0) 
19 
(70.3) 
0.07 
17 
(51.5) 
10 (71.4) 
0.35 
25 (71.4) 
2 
(16.7) 
0.16 
          
Treated 
12 
(60.0) 
8 
(29.7) 
16 
(48.5) 
4 (28.6) 10 (28.6) 
10 
(83.3) 
Retinal 
thickness, 
Median μm 
(IQR) 
272 
(36.0) 
217 
(81.8) 
0.02* 
267 
(75.0) 
226 
(94.5) 
0.08 
258 
(76.3) 
276 
(68.0) 
0.24 
Median FAZ 
area, mm2, 
(IQR) 
0.24 
(0.08) 
0.55 
(0.54) 
0.0001
** 
0.32 
(0.28) 
0.56 
(0.86) 
0.02* 
0.40 
(0.41) 
0.28 
(0.21) 
0.12 
Visual acuity, Median 
LogMAR, (IQR) 
   
    
          Test 
eye 
0 
(0.20) 
0.2 
(0.35) 
0.02* 
0.2 
(0.30) 
0.2 (0.60) 0.21 0.2 (0.50) 
0.2 
(0.23) 
0.53 
          
Contralateral 
eye 
0 
(0.30) 
0.3 
(0.60) 
0.02* 
0.2 
(0.50) 
0.2 (0.80) 0.43 0.2 (0.75) 
0.3 
(0.35) 
0.97 
  
 
       
UK NSC = United Kingdom National Screening Committee; uwFA = ultra widefield fluorescein angiogram; IQR 
= Interquartile range; DME = Diabetic Macular Oedema; FAZ = Foveal Avascular Zone; Log MAR = Logarithm 
of the Minimum Angle of Resolution. p values significant at 5% level are indicated with (*), and (**) at 1% level. 
OR=Odds Ratio; 95% CI=95% Confidence Interval. 
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Figure 2.21. Comparison of the Peripheral Ischemic and Leakage Indices  
Comparison between indices were made according to foveal avascular zone size categories; small 
(<0.32mm2) and large (>0.32mm2); in all eyes, and in eyes which are laser-naive. Box-plots of the (A), 
(C) peripheral ischemic index (%), and (B, D) peripheral leakage index (%)  in eyes with a small or 
large foveal avascular zone size. Analysis was performed in (A, B) all eyes, and those which were 
(C, D) laser-naive. The top of the box represents the 75th percentile, the bottom of the box 
represents the 25th percentile, and the line in the middle represents the 50th percentile. The 
whiskers represent the highest and lowest values that are not outliers or extreme values. Outliers 
and extreme values are represented by circles beyond the whiskers. A significant difference was 
observed in all categories, except that between (B) the peripheral leakage index and foveal 
avascular zone in all eyes. 
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2.4.7.5 Clinical Significance of Peripheral Ischaemia and Leakage in Diabetes: 
A poor visual acuity was associated with macular but not peripheral ischaemia: A 
significant correlation was found between visual acuity and FAZ area (r=0.53, 
p=0.0002), but not the peripheral ischaemia index (r=0.25, p=0.09), or the peripheral 
leakage index (r=0.09, p=0.57). 
When visual acuity evaluated in a step-wise multivariable regression model, 
including clinical factors (age, gender, eye analysed, PRP laser treatment), and other 
ocular parameters measured (FAZ area, OCT-derived central retinal thickness, 
peripheral ischaemia and leakage index), the variables that remained independently 
associated were, age (Zero order correlation coefficient [r]=0.33, p=0.03), FAZ area 
(r=0.45, p=0.02), and OCT-derived central retinal thickness measurements (r=0.38, 
p=0.01), (R2-adjusted=0.36) (Figure 2.22). 
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Figure 2.22. Relationship between peripheral ischaemia, leakage and FAZ 
area  
Scatter plots showing the relationships between (A), (C) peripheral ischemic index (%), and (B), (D) 
peripheral leakage index (%) with the foveal avascular zone area. Analysis was performed in (A, B) all 
eyes, and those which were (C, D) laser-naive. A significant relationship was observed in all categories, 
except for (First row, right) the association between the peripheral leakage index and foveal avascular 
zone in all eyes. 
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2.5 Discussion: 
2.5.1 The impact of DMI on vision, and retinal and choroidal thickness 
measurements  
In this chapter, we were interested in examining the impact of ischaemia, both in the 
central macula and paramacular areas, on visual function. We examined in detail the 
prevalence, symmetry, and relationship of diabetic macular ischaemia to the severity 
of co-existing retinopathy, retinal morphology and visual acuity. DMI and retinal 
thickness and volumes were manually quantified using custom software, and 
demonstrated statistically significant correlations between visual acuity, size of FAZ 
and retinal thickness and volume in type 2 diabetic eyes. 
There is a paucity of information regarding the prevalence of DMI due to the 
rarity of recent large clinical trials using standard fluorescein angiography with the 
purpose of identifying macular ischaemia. The Early Treatment Diabetic Retinopathy 
Study (EDTRS), which only included a few cases of severe macular ischaemia (2.3% of 
eyes at baseline), was limited by attrition (36%), remains as the only large 
prospective study to grade specifically for DMI.(24) They observed at baseline that 
53.4% of eyes had some form of DMI, and 7.2% of eyes with moderate to severe DMI. 
A more recent, but smaller observational case series of 63 patients, also using the 
EDTRS grading system for DMI, observed a similar proportion of eyes (50%) with 
evidence of FAZ damage.(188) In this current study, the prevalence of eyes with any 
grade of DMI in this was higher (60.3%), and even more so in eyes with moderate to 
severe DMI (16.6%). This was probably reflective of the study centre as a tertiary 
referral hospital, and the type of patients who required fluorescein angiography. 
However, this allowed for more detailed subgroup analysis of larger numbers of 
patients with a more severe disease phenotype, and comparisons of their retinal 
morphology and visual function 
A high incidence of symmetry was observed in patients with bilateral DMI, 
with the majority of patients (88.8%) having no greater than one EDTRS DMI grade 
difference between either eye. To the authors’ knowledge, bilaterality or symmetry 
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of DMI has not been previously described elsewhere. Consistent with previous 
studies, we observed increasing severity of DMI, as measured by the FAZ size, in 
more advanced grades of retinopathy.(40, 42, 43, 137) Some studies report that the 
relationship between FAZ size and DR severity occurs from the earlier stages of 
NPDR(40, 137) and others only in more advance disease(189, 190). This discrepancy 
is most likely due to the large inter subject variability of the FAZ; ranging between 
0.05 and up to 1.05 mm2 in non-diseased subjects.(40, 137, 189, 191, 192) In this 
study, the mean FAZ area of eyes without DMI, fell on the higher side of previously 
reported normal ranges, consistent with the hypothesis that the FAZ may be affected 
in early disease. A study which used adaptive optics study scanning laser 
ophthalmoscopy to assess the FAZ, observed an altered retinal parafoveal capillary 
network in eyes even before the onset of diabetic retinopathy, suggesting that foveal 
capillary perfusion may be altered in diabetics without clinically visible disease.(193) 
 In this study, we chose two areas of non-contiguous capillary perfusion 
where ischaemia may have a functional significance, and described standardized 
quantification of those areas. First, temporal ischaemia (TI) – an area that has been 
observed clinically to be a risk factor for, or a driver of macular oedema, and has 
been previously associated with angle neovascularisation in proliferative diabetic 
retinopathy.(194) Second, papillomacular ischaemia (MPI)- an area where the 
capillary network overlies and supplies the nerve fibres of the papillomacular bundle, 
originating from the central macula. We hypothesized that ischaemia in these areas 
may have an impact on visual acuity. Eyes with the presence of concurrent TI or MPI 
had significantly larger FAZ areas which suggest that these areas of ischaemia tend to 
occur in more severe DMI phenotypes. Similarly, retinal thickness and volume 
measurements over EDTRS areas 4&8, which correspond to the MPI area, were 
significantly higher in eyes with a greater severity of DMI. We observed significant 
correlations between the area TI and MPI and visual acuity. There are several 
potential explanations for why this is so. It may simply reflect the severity of diabetic 
eye disease as a whole, where eyes with larger areas of retinal ischaemia have poor 
visual acuity, or it could be due to the location in which these capillary network sub-
serves. Increased areas of retinal ischaemia in proliferative diabetic retinopathy are 
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associated poor visual acuity. However, we observed in this study, that the area of 
temporal ischaemia is independent of FAZ size, which is a surrogate marker for DMI 
severity. This suggests that the location of ischaemia may be an independent effect 
on visual function. Interestingly, although retinal capillary network supplies in the 
inner two-thirds of the retina, 7-40% of normal eyes have an addition supply from the 
choroidal circulation via the cilioretinal artery(195, 196), which supplies a large 
proportion of the papillomacular bundle. This incidence has been found to lie 
between 13.9-38% in diabetic eyes, and may explained the lower numbers of MPI 
compared to TI observed in our current study.(197, 198) Data from a recent study 
which analysed retinal blood flow using the Retinal Functional Imager, found that 
eyes which exhibit cilioretinal-retinal vascular anastomosis were associated with 
increased arterial and venous retinal blood flow velocities and the increased 
occurrence diabetic macular oedema. It is possible that the cilioretinal artery confers 
a protective effect from ischaemia. 
Although previous studies have demonstrated the correlation of macular 
ischaemia with impaired visual acuity(41), this relationship is not always 
straightforward. Morphological changes do not always correspond with functional 
change, and visual acuity has been shown to be preserved in the presence of 
advanced macular ischaemia.(42, 43) Visual acuity, though a crude measure of 
macular function, remains as the most common parameter used in most studies of 
diabetic macular disease. More recently, microperimetry has been used to provide 
more detailed functional assessment of the macular. Most studies that address the 
relationship of diabetic macular disease and visual function, do so in the field of 
diabetic macular oedema, assessing ischaemia only as a secondary outcome 
measure. (199-202) A recent structure-functional correlative study, using the Nidek 
MP-1 Microperimetry showed correlation of reduced sensitivity with diabetic 
macular oedema, but no effects on areas of capillary nonperfusion.(203) However, 
this was a small pilot study of fifteen patients in eyes with non-proliferative diabetic 
retinopathy, and did not include more severe grades of DMI. Another study on 
twenty-five patients, which examined the functional outcome of an enlarged FAZ on 
multifocal electroretinogram, showed correlation between ischaemia areas and a 
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prolonged implicit time but not in amplitude.(204) In this present study, a low but 
significant correlation (r=0.26) was observed between FAZ area and visual acuity 
across all patients which strengthened in the severe DMI group (r=0.6). This 
correlation was lost in subgroup analysis of all other grades of ischaemia. We also 
observed that visual acuities were significantly different between eyes with no 
ischaemia, and the moderate and severe DMI subgroups (p<0.02), but not with 
questionable or mild disease. This suggests that functional impairment secondary to 
ischaemia may only occur in severe disease. It is possible that a threshold of 
structural damage has to be reached before vision is affected.  Similarly, with OCT 
measurements of retinal thickness and volume, we found that there was no 
correlation to vision in eyes with none to mild DMI, and a stronger than expected 
correlation in eyes with moderate to severe DMI. (r=0.75)  
Increases in retinal thickness may be due to macular oedema, ischaemia or 
both. It is often difficult to determine the degree to which each accounts for 
decreased visual function. Across all patients, we found a correlation of retinal 
thickness and visual acuity (r=0.32), which strengthened (r=0.52) when patients with 
macular oedema were excluded. Though the numbers in this group were small 
(n=15), it suggests that ischaemia plays an important role in visual function even in 
the mixed diabetic macular disease where ischaemia and oedema co-exist. Previous 
studies on diabetic macular oedema, have reported a range of correlations with 
visual function (r = 0.13 to 0.89), with most showing modest correlations to 
acuity.(38, 205-209) This wide range of correlations, likely reflects the multiple 
factors which govern vision that are often not addressed; such as compromised 
retinal microcirculation, choroidal circulation and duration of disease. These studies 
on DMO also show consistently, that the location of disease at the foveal point 
thickness or the EDTRS central subfield has better correlation with visual acuity than 
the whole macular grid. We found that there was little difference in both the central 
field in the whole macular grid, for both thickness and volume measurements in DMI. 
Ischaemia in the wider macular area, unlike oedema, may a distal effect on visual 
acuity which is mostly dependent on the foveal function(210).  
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We have observed that both inner and outer retinal thickness increases with 
DMI severity. However, the inner retina did show thinning, only when taken as a ratio 
to the outer retinal thickness, to increasing FAZ size. Only in the outer retinal 
thickness was correlated to visual acuity. This is consistent to earlier studies in which 
the retinal circulation is compromised, such as retinal vein occlusion, where atrophic 
changes in the inner retina have been reported.(211, 212) Inner retinal thinning was 
first observed, in the era of time-domain OCT, to be a finding of DMI.(38, 205) More 
recent OCT studies have concurred(168, 213, 214), and showed specifically a 
correlation of ganglion cell layer loss with FFA areas of capillary dropout(168). None 
of these studies examined the association with VA. We found only one study which 
examines the relationship of retinal layers and vision where photoreceptor outer 
segment length was found to correlate to VA in patients with diabetic macular 
oedema.(206) Interestingly, it was also in the outer retina that the association was 
observed. 
There is a scarcity of studies that examine the relationship of DMI and visual 
acuity. The main advantages of our study are its large sample size, and the utilization 
of manual OCTOR and GRADOR grading which allows quantification of any 
morphological spaces of interest. There are several limitations to this study. First, the 
retrospective cross-sectional nature of the work carries an inherent limitation of 
biased selection of patients with a more severe disease requiring FFAs, and does not 
account for confounders of visual acuity, such as cataracts that were not recorded in 
the electronic case notes. It also does not examine the way ischaemia and visual 
acuity changes over time. Second, the number of eyes which had concurrent SD-OCT 
and FFA were small, as the study was carried out in a single site where patients 
tended to undergo Topcon OCT scans. These were not included in this study as the 
amount of speckle noise in the images did not allow repeatable manual segmentation 
of retinal layers. Finally, visual acuity data was collected as best corrected Snellen 
acuity in a clinical setting and converted to LogMar for analysis. Ideally, visual acuity 
should be assessed using ETDRS charts with protocol refraction. The limitations of 
visual acuity assessment using Snellen charts are well documented.(215) 
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The presence of macular ischaemia has been reported to impart a poor 
prognosis after laser(21) or anti-vascular endothelial growth factor (anti-VEGF) 
therapy(33) for diabetic macular oedema. However, the grade of ischaemia in which 
this occurs and the extent in which it affects treatment outcomes is unknown. Even in 
the age of emerging anti-VEGF treatments, there is a lack of evidence from FFA based 
evaluation of the retinal microcirculation in clinical trials.(216, 217) Moreover, 
patients with DMI are often excluded from these studies.(218) The BOLT study is the 
only prospective randomised trial where detailed evaluation of macular ischaemia 
was before and after laser or anti-VEGF treatment.(39, 219) No statistically significant 
worsening of macular perfusion was evident at 4, and 12 months. However, as the 
authors note, patients with severe DMI were not included in the study, and the 
numbers of patient were too small to detect clinically significant adverse events. 
Prospective FFA-based evaluation of the effects of anti-VEGF trials on retinal 
perfusion need to be undertaken. However, before this is done, the natural history of 
DMI needs to be elucidated with prospective longitudinal studies, which examine the 
impact of ischaemia on visual function, using reliable and reproducible structure-
function correlative indices. This has not been undertaken so far, probably due to the 
invasive nature of fluorescein angiography and the lack of reproducible functional 
assessment. Recent rapid advancement of adaptive optics and eye-tracking 
technology may negate the need for FFAs and allow accurate mapping of macular 
function over time. The results from such a study would help determine whether a 
window of opportunity exists, before the onset of diabetic retinal neuropathy, where 
vascular rescue can occur. This threshold will define the critical therapeutic window 
for delivery of emerging vascular stem cell treatments. 
In summary, diabetic macular ischaemia is present in more than half the 
diabetic population that attend for assessment of eye disease. It occurs even in early 
retinal disease, and is symmetrical in a majority of cases. Visual function only tends to 
be affected in moderate to severe ischaemia, and is associated with the presence and 
size of non-contiguous capillary dropout in area overlying the papillomacular bundle 
and temporal to the macula. Retinal thickness as a whole increases with severity, but 
there is a negative association of the ratio of inner and outer retinal thickness to size 
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of FAZ. Changes in the outer but not inner retinal morphology has an impact on visual 
acuity. 
 
2.5.2 Diabetic macular ischaemia progression    
A recent paradigm shift in the treatment of diabetic macular oedema - from laser 
photocoagulation to anti-VEGF pharmacotherapy, has highlighted the importance of 
a better understanding the natural history of DMI. “Mixed diabetic maculopathy” is 
often observed in clinical practice, with few patients exhibiting features of either DMI 
or DME exclusively. In a recent cross-sectional analysis, we observed concurrent DMI 
(of any severity grade) in up to 70% of cases with clinically significant macular 
oedema (CSME).(187) In the current study, we performed longitudinal quantitative 
analyses of FA images obtained in a cohort of patients with Type 2 diabetes mellitus, 
and an ETDRS-DMI grade of mild, moderate, or severe. Using this approach, we 
estimate the rate of FAZ enlargement, and evaluate baseline parameters that may be 
predictive of DMI progression. 
 In our analysis of EDTRS-defined DMI grade progression - 15% of eyes showed 
an advancement of at least one severity grade per year. In contrast, the EDTRS 
demonstrated no change in the distribution of DMI grades over a period of 5-year 
study period.(24) This may be due to only a few cases of severe macular ischaemia 
being included in the EDTRS. In our cohort, longitudinal quantification of the FAZ 
area, detected a significant FAZ enlargement across all EDTRS-DMI severity grades. 
(median time interval = 27 months) A possible explanation for the discrepancy 
between ETDRS-DMI grade progression, and FAZ enlargement observed, is that 
qualitative grading alone may not be sufficiently sensitive for the detection of DMI 
progression. FAZ enlargement rates were found to be greater in more severe grades 
of ischaemia, ranging from an increase of approximately 5% (of baseline FAZ area per 
year) in “mild”, to 7% in “moderate”, and 10% in “severe” EDTRS-DMI grades. 
Although the increases in FAZ area with advancing stages of diabetic retinopathy is 
well known, its progression over time has never been assessed.(40, 42, 43, 137, 189, 
193) In addition, to assessing the FAZ enlargement rates in different EDTRS-DMI 
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grades, we also evaluated the effects of baseline diabetic retinopathy and 
maculopathy severity, FAZ size, and visual acuity. FAZ enlargement rates were found 
to be more than three-fold higher in eyes that showed a deterioration of VA over the 
same time-interval, (19%) compared to those which did not. (5.6%) Although 
previous studies examining the impact of FAZ size on visual acuity have been 
contradictory,(43, 137, 190) we demonstrate in this study, a clear association 
between worsening VA and FAZ enlargement rates. 
In this report, we also investigated a number of clinical parameters we 
hypothesized to be of significance to “DMI progression” – defined as a FAZ 
enlargement rate of greater than 10% baseline FAZ area per year. Moreover, in this 
process, we developed stratified regression models for baseline FAZ size in order to 
identify “clinical thresholds” for “DMI progression”. A strong association, 
independent of age, gender, retinopathy and maculopathy severity, was observed 
between DMI progression and baseline FAZ area at a threshold of 0.6 mm2. These 
results have important clinical implications as it provides a practical method that at 
risk of DMI may identify progression. In practice, this translates to – eyes with a FAZ 
area, greater than a third of the optic nerve head, has an approximately 6:1 OR of 
DMI progression. Similarly, we observed a 2:1 OR for DMI progression for every step 
increase in ETDRS-DMI grade, suggesting that eyes with larger FAZ areas and greater 
severity of DMI have an increased risk of progression. VA deterioration over time was 
also an independent predictor of DMI progression. In agreement our previous 
analyses showing a strong relationship between VA and moderate to severe grades of 
DMI, we observed a 5:1 OR of DMI progression, in eyes which showed a VA 
deterioration of greater than 0.05 LogMar units per year. (<1 line Snellen acuity)  
Surprisingly, we did not observe any association between the severity of 
diabetic retinopathy or maculopathy grades, with DMI progression. Previous studies, 
have shown that DMI is a risk factor for DME and PDR – i.e. the EDTRS, which 
reported a 1-year risk of development of PDR at 18.2% without DMI, and 41.3% with 
severe DMI.(24, 43, 220), (35) We speculate that it may be possible that DMI 
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progression precedes the worsening of retinopathy or maculopathy, though this 
needs be addressed in larger prospective cohorts. 
Our study has a number of strengths, combining longitudinal analysis with 
standardized qualitative and quantitative assessment of FA images, in an area with a 
relative paucity of data. For example, the median time interval between FAs analysed 
was greater than 2 years, allowing for changes in the FAZ area (clinically observed to 
progress slowly) to be detected. Our use of FA grading software equipped with 
standard planimetric tools allowed quantification FAZ area, enabling detection of 
small changes over time. We combined these measurements with multivariate 
statistical modelling, accounting for known confounders of FAZ measurements, such 
as age, severity of diabetic retinopathy, and macular oedema, often overlooked in 
other studies.  
Our study also has a number of limitations. Firstly, the retrospective nature of 
the work results in an inherently biased selection of patients. However, we 
purposefully identified patients with a diagnosis of established DMI, in order to 
assess our main outcome measure – rate of FAZ enlargement. However, future 
prospective studies will be required to validate the thresholds (i.e. baseline FAZ size) 
established in this study. A further limitation is our reliance on Snellen visual acuities, 
the limitations of which have been well documented.(221, 222) In prospective clinical 
trials, VA is now typically assessed using ETDRS vision charts with protocol refraction.  
The results of this study provide insight into the natural history of DMI, 
demonstrating a FAZ enlargement rate of 5 to 10% of baseline FAZ area per year, in 
eyes with established DMI. We identified prognostic determinants - baseline FAZ size, 
and a deteriorating VA, which may serve as robust independent predictors of DMI 
progression in patients with Type 2 diabetes mellitus.  
 
2.5.3 Diabetic macular ischaemia in type 1 diabetes 
The prevalence of established ischaemia (i.e., ETDRS defined grades: mild, moderate, 
and severe), in our cohort of patients with Type 1 diabetes, was 54.7% - higher, than 
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previously reported in the literature (Table 2.24). A likely explanation, is that our 
patients comprised of those referred from a national screening program for diabetic 
eye diseases, and were attending a dedicated tertiary-referral medical retinal clinic 
with the intention to diagnose or treat.(223) These patients may be more typical of 
those seen in clinical practice, than those recruited for many clinical trials (for 
example, in ETDRS, patients with active proliferative and severe non-proliferative 
retinopathy were excluded). Similarly, more recent clinical trials, such as the 
RISE/RIDE and RESTORE studies, specifically excluded patients with macular 
ischaemia.(37, 140) The prevalence of macular ischaemia in Type 1 diabetes (54.7%) 
was also higher than previously observed in a similar cohort of patients with Type 2 
diabetes (41.3%). In fact, a higher prevalence was observed in all ischaemia types 
quantified in Type 1 compared to Type 2 diabetes, namely, established (54.7% versus 
41.3%), advanced (22.2% versus 16.6%), temporal (52.3% versus 27.5%), and 
papillomacular ischaemia (25.6% versus 8.3%) (Table 2.24). A possible explanation for 
the increased prevalence in both macular and paramacular ischaemia in Type 1 
compared to Type 2 diabetes, may be that central macular capillary nonperfusion 
mirrors peripheral capillary nonperfusion. In our multivariable regression model, we 
observed an association between a diagnosis of macular ischaemia and severity of 
peripheral retinopathy (Table 2.11). Interestingly, a recent study using wide-field 
angiography has observed an association between peripheral ischaemia and macular 
oedema.(224) From these findings, we suggest that peripheral and macular ischaemia 
may also be associated in Type 1 diabetes.  
The effect of age, on the development and progression of diabetic 
retinopathy and macular oedema, has been thoroughly investigated in large 
epidemiological studies. However, the impact of age on diabetic eye disease appears 
to be dependent upon the population studied, and the type of retinopathy examined. 
In Type 2 diabetes, the United Kingdom Prospective Diabetes Study showed that an 
older age was associated with progression in eyes with established diabetic 
retinopathy. However, studies in different populations have observed the converse; 
that an older age was protective of any diabetic retinopathy.(225, 226) The Wisconsin 
Epidemiologic Study of Diabetic Retinopathy, which followed a cohort of persons 
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with Type 1 diabetes over 25 years, did not observe any effects of either age at 
baseline assessment, or age of diagnosis, on the progression of retinopathy.(143) In 
this study, we hypothesized that age, through its effect on microvascular 
degeneration and pericyte loss leads to capillary dropout, and increases the risk of 
developing ischaemia.(227-229) We observed that patients with macular ischaemia 
were older (mean age 49.5 years), compared to those without ischaemia (mean age 
41.6 years) (p=0.02). In fact, age itself, per decade increase, was an independent risk 
factor for macular ischaemia (OR=2.30, 95% CI=1.27 to 4.16, p=0.006). A possible 
explanation for this is that older patients in our study, may have had longer duration 
of disease. Interestingly, our previous study of macular ischaemia in Type 2 diabetes 
found no significant age differences in patients with (mean age 64.0 years) or without 
ischaemia (mean age 62 years) (p=0.07).(187)  
In addition to assessing the prevalence of macular ischaemia and its 
relationship to age, we also evaluated its visual significance. We observed that eyes 
with any grade of macular ischaemia had significantly worse vision, unlike in our 
related study of patients with Type 2 diabetes, where an association was only 
observed with advanced macular ischaemia (ETDRS grades moderate and 
severe).(187) In addition, unlike in Type 2 diabetes, no associations were observed 
between visual acuity and papillomacular ischaemia despite its higher prevalence. 
(25.6% in Type 1 compared to 8.3% in Type 2 diabetes) (Table 2.25). One possibility is 
that a high proportion of patients with papillomacular ischaemia, also  
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Table 2.25: Comparison of the prevalence of diabetic macular ischaemia 
between Type 1 and Type 2 diabetes. 
 
Type of ischaemia 
ETDRS 
Grades 
 
Type 1 
Diabetes 
(n=86) 
Type 2 
Diabetes 
(n=408) 
Established macular 
ischaemia 
Mild, 
Moderate, 
Severe 
n (%) 47 (54.7) 171 (41.3) 
Advanced macular ischaemia 
Moderate, 
Severe 
n (%) 19 (22.1) 68 (16.6) 
Temporal macular ischaemia NA n (%) 45 (52.3) 112 (27.5) 
Papillomacular ischaemia NA n (%) 22 (25.6) 34 (8.3) 
ETDRS = Early Treatment Diabetic Retinopathy Study 
 
 
had concurrent macular ischaemia (86.4%) (Table 2.10), thereby confounding its 
effects on visual acuity. However, it may be that in Type 1 diabetes, the location and 
severity of macular ischaemia impacts less upon visual function than in Type 2 
diabetes. 
The strengths of this study, include the number of eyes with diabetic macular 
ischaemia analysed (n=60, Table 2.10), a relatively large number for an area where 
there is relative paucity of data, the use of standardized protocols for qualitative 
grading of ischaemia, and the use of validated software for quantification of areas of 
capillary dropout. The limitations to the study include an inherent selection bias due 
to its inclusion of patients attending a tertiary referral clinic, with an intention to 
treat, and to its retrospective cross-sectional design. However, the data presented is 
likely to represent a majority of patients in ophthalmic clinical practice, compared to 
the clinical trial scenario, where patients with more severe grade of diabetic macular 
ischaemia are more likely to be excluded. Furthermore, the prevalence reported 
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more likely reflects patients referred with symptoms or signs of sight-threatening 
retinopathy, compared to that of a FA-based population survey, and therefore may 
better reflect a potential future treatment cohort. Secondly, data concerning 
systemic parameters such as blood pressure, HbA1c, and disease duration were not 
collected, and are likely to play a role in diabetic macular ischaemia.(9, 139)  
In summary, there is a high prevalence of diabetic macular ischaemia (54.7%) 
in patients with Type 1 diabetes attending a tertiary referral medical retinal clinic. 
These patients were older, and macular ischaemia of any grade was visually 
significant. Although no treatment currently exists for diabetic macular ischaemia, 
this condition often co-exists with, and if severe, may influence the treatment of 
diabetic macular oedema. A greater understanding of diabetic macular ischaemia, 
including whom it affects, and its impact on visual acuity, would enable the clinician 
to better manage diabetic macular disease in patients with Type 1 diabetes.  
 
2.5.4 The relationship of diabetic macular ischaemia to retinal vessel 
calibre 
A narrower retinal arteriolar calibre measured on FFA is associated with DMI. The 
mean arteriolar calibre was 10.1 µm narrower in moderate/severe DMI compared to 
none/mild DMI. A narrower arteriolar calibre was also associated with more severe 
DMI grades, larger FAZ diameter and area. These associations persisted 
independently, after adjustment for markers of peripheral ischaemia such as NVD, 
NVE, prior laser therapy, and NSC diabetic retinopathy grading score. Venular calibre 
and AVR were not associated with DMI. These data suggest that retinal arteriolar 
calibre may be a quantitative marker of presence and severity of DMI. 
 The major epidemiological studies on diabetic retinopathy did not perform 
FFA on participants and hence there are few studies with which to compare our 
results. However, a narrower arteriolar calibre is associated with lower limb 
amputation, (230) and peripheral neuropathy, (231) and therefore may be a marker 
for ischemic diabetic complications. In the absence of diabetes, narrower arterioles 
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are also associated with small vessel lacunar stroke and reduced myocardial 
perfusion, and elevated markers of endothelial dysfunction.(232-234) These suggest 
that retinal arteriolar narrowing may be an ischaemic biomarker marker in both the 
retinal and systemic microcirculation.  
 The presence of narrower arterioles, by reducing available blood flow, may 
contribute to a propensity to DMI. Alternatively, arteriolar narrowing in DMI may 
occur in response to reduced metabolic needs. These results provide support for 
both hypotheses and future longitudinal studies may clarify the question of cause or 
effect.    
 It was unexpected that venular calibre was not associated with DMI. Other 
reports have observed that wider retinal venules are strongly associated with 
increasing retinopathy severity, incidence, and progression.(235-237) However, these 
well established associations of venular widening were made in peripheral ischaemia, 
and our study which examined central DMI did not detect any associations. This may 
be due to the pathogenesis of  venular widening, which is dependent upon vascular 
endothelial growth factors,(VEGF) which may not be raised to the same extent in DMI 
as in peripheral ischaemia.(238-240) This study suggests that arteriolar and venular 
calibre may be differentially related to ischaemia that is located in a central or 
peripheral location. 
Strengths of this study include measurement of DMI and vessel calibers from 
the same series of FFAs, use of validated methods of grading both variables, and 
multivariable adjustment for retinopathy severity and peripheral ischemia (i.e. PRP, 
NVE, NVD). Limitations include firstly, the lack of adjustment for blood pressure as 
this data is not routinely collected from our eye clinic. Nonetheless, as high blood 
pressure is related to more severe diabetic retinopathy, our adjustment for 
retinopathy severity may be considered a partial and indirect adjustment for blood 
pressure. Further, in the event that the association attenuated with adjustment for 
blood pressure, this in itself would not change our primary finding that narrower 
arterioles may indicate the presence of DMI. Secondly, we measured vessel calibers 
from FFAs, rather than color fundus photographs as reported in most epidemiological 
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and clinical work. We do not believe this would result in significant bias as others 
have shown high correlation and only very slight differences in caliber measurements 
from FFA and color photographs.(241) Nevertheless, we will conduct future studies 
to measure retinal caliber from color photographs in eyes with DMI to determine if 
retinal calibre from color photographs can be a marker of DMI without the need for 
FFA. Finally, the number of patients actually analysed (53) is a small sample of the 
original population of type 2 diabetic patients (408). We do not believe this would 
bias our findings as we included all the participants with severe and moderate DMI, 
and a random subsample of controls with none/mild DMI. Poor quality images which 
could not be graded occurred in similar proportions in these 2 groups, suggesting that 
this was unlikely to bias our results. Further, including more of the original sample in 
our study would only increase the number of controls without DMI, and would not 
change our findings. 
 In summary, we report that narrower retinal arterioles are associated with 
the presence and severity of DMI. Narrower arterioles are also associated with larger 
FAZ diameter and area. These associations were independent of markers of 
peripheral ischaemia and suggest measurement of retinal arteriolar calibre may be 
useful to further characterize and understand underlying vascular changes in eyes 
with DMI.                 
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2.5.5 The relationship of peripheral and central retinal ischaemia 
In the current study, our objective was to better understand the relationships 
between peripheral and central vascular complications of diabetic retinopathy, and 
how these lesions affect visual function. We performed both qualitative and 
quantitative analyses of uwFA images obtained in a cohort of patients with diabetes 
mellitus. Using this approach, we examined the relationships between peripheral 
capillary non perfusion, peripheral leakage, FAZ size, OCT-derived central macular 
thickness measurements, and evaluated the visual significance of these parameters. 
 Retinal capillary non perfusion in diabetes first demonstrated using Indian ink 
preparations by Norman Ashton in 1953, in series of post mortem retinae from 
diabetic patients.(242) There, he described a loss of the peripheral capillary bed, 
predominantly on the side of retinal artery, with narrowing and “corkscrew coiling” in 
the corresponding pre-capillary arterioles. Subsequently, more recent histological 
evidence for macular capillary non perfusion was demonstrated by Bresnick et al in 
1976, who observed acellularity in perifoveal capillaries.(167) In the early 1990s, 
these findings were visualized in vivo with fluorescein angiography using a 30 degree-
field camera, and classified by the Early Treatment Diabetic Retinopathy Study 
(ETDRS).(21) The ETDRS approach to the assessment of macular ischaemia consisted 
of grading of two vascular structures; (1) capillaries and (2) arterioles, using reference 
photographs. Capillary abnormalities included the loss of perfusion, broadening, or 
an increase in the size of foveal avascular zone (FAZ). Arteriolar abnormalities, were 
graded according to descriptions such as “pruning”, “staining” and “focal narrowing”. 
Interestingly, and perhaps due to the limitations portended by retinal photography at 
the time, the ETDRS standard photographs for arteriolar abnormalities were taken 
only from areas outside the perifovea. In this study, we were able to visualize with 
good resolution, not only both the capillary and arteriolar features of diabetic 
macular ischaemia, but also the presence of these features in peripheral, as well as in 
the central macula locations within a single uwFA image. This allowed, for the first 
time, simultaneous analysis of both capillary and arteriolar abnormalities in both 
peripheral and central retina.  
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In our analyses, we observed that a relationship exists between capillary non 
perfusion in the peripheral retina and central macula. Eyes with a high peripheral 
ischaemia index (>50% peripheral capillary non perfusion of total retinal area 
visualized) had a larger FAZ compared to those with a low peripheral ischaemia index, 
and there was a modest correlation between peripheral and central ischaemia, both 
in all eyes examined (r=0.49), and in those that were treatment naïve (r=0.55). A 
similar trend was also observed with the peripheral leakage index, but only in eyes, 
which had not received laser photocoagulation therapy, probably representing the 
regression of neovascular tufts in treated eyes. Figure 2.23 is an example of a 
previously laser-treated eye, with leaking neovascular tufts in the mid-peripheral 
retina. This is in agreement with our previous work, where we observed that a 
majority of eyes with proliferative diabetic retinopathy (a surrogate marker for 
peripheral ischaemia) had some evidence of macular ischaemia (77.2%).(178) It is 
well known that peripheral retinal ischaemia is a primary risk factor for developing 
proliferative diabetic retinopathy, and for the majority of patients, it probably 
represents the “ischemic state” of the eyes as a whole. However, it is important to 
note that there are patients who do not follow this pattern. Figure 2.24 is an example 
of such a patient, who has extensive peripheral ischaemia, but a relatively preserved 
foveal avascular zone and good visual acuity. How and why this occurs is not known. 
However, with the emergence of uwFA imaging, we now possess the ability to detect 
this occurrence in patients with diabetes, and future observations in this cohort may 
lend insight into the pathophysiology governing patterns of ischaemia in the diabetic 
retina. 
128 
 
 
 
Figure 2.23 An example of an early and late-phase ultra widefield 
fluorescein angiogram (uwFA) image of a laser-treated diabetic patient, 
demonstrating peripheral neovascularisation, and leakage.  
In eyes that had already received previous laser treatment, the peripheral ischemic and leakage 
indices were calculated only as a percentage of non-lasered areas of the peripheral retina. (top left) An 
early-phase uwFA image, acquired at 20 seconds. (top right) Annotated solid blue line delineates the 
boundary of the non-lasered retina where capillaries are in sharp focus. This area was taken to be the 
“total retinal area”, which was the denominator as the peripheral ischemic index. Annotated solid 
green lines delineates areas of capillary non perfusion in the non-lasered retinal periphery. Annotated 
solid red line delineates the boundary of the foveal avascular zone area. (bottom left) A late-phase 
uwFA image, acquired at 6 minutes. (bottom right) Annotated solid blue line delineates the boundary 
of the non-lasered retina where capillaries are in sharp focus. Again, this area was taken to be the 
“total retinal area”, which was the denominator as the peripheral leakage index. Annotated solid 
green lines delineates areas of vascular leakage in the non-lasered retinal periphery. 
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Figure 2.24. An example of an early and late-phase ultra widefield 
fluorescein angiogram (uwFA) image diabetic patient with severe 
peripheral capillary non perfusion but only mild macular ischemia.  
In this study, the majority of eyes with mild macular ischemia (i.e. a small foveal avascular zone 
measuring <0.32mm2) had a peripheral ischemia index of less than 50%. However, we observed two 
outliers with extensive peripheral capillary non perfusion, but a relatively intact foveal avascular zone. 
The visual acuity of this representative eye was 0.2 LogMAR units. (Top left) An early-phase uwFA 
image, acquired at 20 seconds. (Top right) 10X magnified early-phase uwFA image, centred on the 
foveal avascular zone. (Bottom left) A late-phase uwFA image, acquired at 6 minutes. (Bottom right) 
10X magnified uwFA image, centred on the foveal avascular zone.  
 
In this study, we also examined the relationships between OCT-derived retinal 
thickness measurements with peripheral and central retina ischemic indices. We 
observed that patients with a large FAZ had a significantly thinner retina compared to 
those with a small FAZ (272 ± 36.0μm versus 217 ± 81.8μm respectively). Conversely, 
retinal thickness measurements were not different between patients with a high 
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compared to low peripheral ischaemia index (258 ± 76.3μm versus 276 ± 68.0μm). It 
appears that thinning of the central macular, i.e. retinal neurodegeneration, occurs 
with macular but not peripheral ischaemia. This loss of retinal tissue in central 
ischaemia is in agreement with our previous work, where we observed a reduction of 
visual function in those with moderate to severe diabetic macular ischaemia 
(corresponding to the definition of a “large FAZ”= 0.32mm2 in this study).(178, 243) 
Recent uwFA studies utilizing have reported an association between 
peripheral ischaemia and diabetic macular oedema.(244, 245) This is unsurprising as 
epidemiological studies have long observed that diabetic retinopathy severity is the 
major ocular factor associated with diabetic macular oedema. In our study however, 
although a thicker retina was observed in eyes with a high peripheral leakage index, 
this did not reach statistically significance (p=0.28). In eyes with a high peripheral 
ischemic index, the opposite was observed (a thinner retina), but again, this was not 
statistically significant (p=0.08). A possible explanation for this discrepancy may be 
the difference in study populations between studies. In this study, a large proportion 
of our patients (27/47 [57.4%]) had concurrent diabetic macular ischaemia; 
compared to previous uwFA studies which may have examined population of patients 
with macular oedema, but minimal or no macular ischaemia.  
In light of the relationships observed in this study, we hypothesize that the 
pattern distribution of ischaemia and vascular leakage in diabetic eyes, may be 
suggestive of how any functional loss may be reversible or amenable to treatment. In 
Figure 2.25, the relationships observed in this study are represented 
diagrammatically, with solid arrows representing statistically significant relationships, 
and dashed arrows trends. From our observations, we suggest two patterns of 
diabetic retinopathy phenotypes exist; which we have represented as either a 
“therapeutic triangle” or a “degenerative triangle”. For example, in the “degenerative 
triangle” a patient may present with central vision loss, macular ischaemia, and 
retinal thinning. Conversely, in the “therapeutic triangle” a pattern of visual loss and 
macular ischaemia may occur with retina thickening. If it is confirmed in future 
prospective studies, that these patterns of capillary non perfusion and leakage are 
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indeed indicative of the treatability of the disease, they may be useful in forming 
algorithms to identify a window of opportunity for treatment where irreversible 
visual loss has not occurred, or be used to prognosticate a patients’ response to 
treatment.  
 
 
 
Figure 2.25. Flowchart of the relationships of the two parameters quantified 
in this study- capillary non perfusion, and vascular leakage, in the 
peripheral retina, and central macula.  
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The strengths of this study include, combining a previously validated 
technique for quantifying macular ischaemia in order to calculate the peripheral 
ischaemia and leakage indices, and its novel application to examine different patterns 
disease in the peripheral and central retina. The limitations of this study are inherent 
to its retrospective, cross-sectional design, and analysis of uwFA images sets from a 
small number of patients. However, uwFA imaging is a relatively new imaging 
modality, therefore, though the data we present is exploratory in nature, there are 
no existing prospective data which examines the relationships between the macular 
and retinal periphery, and our observations may serve to guide larger prospective 
studies. 
The results of this study, obtained from uwFA images, provide an insight into 
the relationships between diabetic vascular complications in the retinal periphery 
and central macular. Although a relationship exists between ischaemia in the center 
and periphery, it was only macular ischaemia that was associated with a reduced 
visual function that was further accompanied by retinal thinning. uwFA enables the 
clinician, for the first time, to observe simultaneously, different patterns capillary 
leakage and non perfusion. These patterns may be of clinical significance and warrant 
future evaluation in prospective studies.  
 
  
133 
 
 
2.6 Chapter summary: 
 
In this chapter, DMI was examined in large clinical population of patients with 
diabetes, attending a tertiary eye referral hospital. DMI was observed to be more 
prevalent than previously thought but only impacted on visual function when present 
in moderate to severe severity. Furthermore, a papillomacular location had a greater 
impact on visual acuity. A relationship between peripheral and central ischaemia was 
also observed. However, it was only central macular ischaemia that was associated 
with reduced visual function.The progression rate was calculated at about 7% per 
year, and progression of DMI itself was predictive of visual loss. DMI was more 
prevalent in type 1 diabetes, and associated with narrower retinal arterioles, 
neurodegeneration (thinner retinal nerve fibre layer and outer retinal layers), and 
thicker Haller’s large vessel layer of choroid. No effective treatment currently exists 
for patients with visual loss attributable to DMI – such a patient group may be an 
appropriate first target for the development of cellular therapies in diabetic 
retinopathy.  Increasing our understanding of DMI is crucial in developing therapeutic 
strategies for this disease entity. 
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3. Clinical imaging in inflammatory eye disease 
3.1 Introduction: 
Uveitis comprises of a group of diseases characterized by intraocular inflammation, 
and is an important cause of blindness worldwide.(246) The annual incidence of 
uveitis is between 17 and 52 per 100,000 of the population, with up to 35% of 
patients reported to suffer significant visual impairment or legal blindness.(247-250) 
One of the greatest challenges in caring for patients with sight-threatening uveitis is 
the lack of objective markers of disease activity. This applies in context of routine 
clinical practice, where patients receive direct treatment for ocular inflammation, or 
in clinical trials where these markers are important in order to establish efficacy of 
new therapies and ensure standardization of care.(251)  
Panuveitis is a subtype of uveitis and represents a generalized inflammation 
of the entirety of the uveal tract as well as the retina and vitreous. This occurs to 
15%-25% of patients with uveitis.(252-254)  There are numerous causes of panuveitis 
and can be broadly classified into infectious or autoimmune categories. It is 
noteworthy that in clinical practice, despite advances ophthalmic imaging capabilities 
and the availability of laboratory-based diagnostic tests, it is common that a 
definitive cause of panuveitis is not established. In this chapter, relatively common 
uveitic conditions such as idiopathic panuveitis, sarcoid- and tuberculosis (TB)- 
associated uveitis, and punctate inner choroidopathy (PIC) are covered, with respect 
to the imaging modalities used to detect, diagnose, and monitor these conditions in 
the vitreous, retina and choroid. 
In this chapter, enhanced depth imaging (EDI) protocols were used to acquire 
OCT-derived images of the choroid in eyes with idiopathic, sarcoid and TB-associated 
granulomatous uveitis, and punctate inner choroidopathy. Quantitative analysis of 
these images was performed in an effort to identify parameters, which may 
potentially be applied in the clinical arena, for example to aid diagnosis and measure 
disease activity.  A further exploratory study was performed to obtain measurements 
of vitreous signal intensity from OCT image sets obtained in cohorts of patients with 
intermediate and posterior uveitis. These findings were correlated with standard 
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assessments of vitreous haze in an effort to develop an improved marker of 
inflammatory activity in patients with this disease. Objective quantification of ocular 
inflammation using these techniques, if validated for inflammatory eye disease, may 
in future be applied in the context of diabetic eye disease.  
 
3.1.1 Idiopathic panuveitis 
Idiopathic panuveitis represents this diagnosis of exclusion, and describes cases of 
panuveitis in which a diagnosis cannot be assigned, despite thorough clinical, imaging 
and laboratory investigation. For this reason, it has been under represented in clinical 
and laboratory research. Akin to an orphan disease, idiopathic panuveitis has not 
received attention due to its lack of a diagnostic label.  
Imaging modalities used for the assessment of panuveitis has traditionally 
been fluorescein angiography (FA); for evaluation of the neuroretina, retina vessels, 
and retinal pigment epithelium (RPE), and indocyanine green angiography (ICGA); for 
assessment of inflammatory lesions in the choroid and the choroidal vasculature. 
Although the patterns of fluorescence, leakage and staining observed on FA and ICGA 
provide useful information for diagnosis and monitoring of disease activity, they do 
not provide any information regarding ultra-structural changes. Optical coherence 
tomography (OCT), which provides excellent cross-sectional images of the retina and 
the RPE had limited use previously in patients with panuveitis, due to the presence of 
anterior synechiae, cataracts, or vitritis, (poor media clarity) precluding the 
acquisition of images. The advances of spectral-domain OCT however, and adaptation 
of its software for ‘‘enhanced depth imaging’’ (EDI) (46) has allowed in vivo 
evaluation of the choroid – which by definition, is implicated in “panuveitis”.  
The term “Idiopathic” panuveitis may be, in fact, a misnomer. Although the 
aetiology of this disease entity is unknown, as with many of the “white dot 
syndromes”, it is the absence of distinguishing features on more traditional modes of 
imaging, such as FA and ICGA that defines this disease. The ability of EDI OCT to 
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examine the choroid in detail may provide clues to better describe the disease 
process in these patients. 
 
3.1.2 Sarcoid and TB- associated panuveitis 
Granulomatous uveitis is a chronic inflammatory process that can involve both the 
anterior and posterior segments of the eye.(255) It is characterized by clinical 
features such as “mutton-fat” keratic precipitates in the cornea, cells within the 
anterior chamber and vitreous, retinal vasculitis, and focal or diffuse choroidal 
lesions.(256-259) Granulomatous disease may result from either an autoimmune 
process, most commonly sarcoidosis,(256, 257) or a systemic infection, usually 
tuberculosis (TB),(256, 260, 261) occurring either as an isolated ocular condition or as 
part of a wider systemic disease.(262)  
Sarcoid and TB-associated granulomatous uveitis can cause visual disability 
from inflammatory sequelae such as cystoid macula oedema, glaucoma, or 
chorioretinal ischaemia.(263) Fortunately, the majority of patients with sarcoid and 
TB-associated uveitis are responsive to immunosuppressive treatment and/or the 
appropriate antimicrobial therapy.(264) However, these treatments can have 
potential side effects, causing significant ocular and systemic morbidity linked to 
duration and dosage of treatment and even a possible increase in mortality rates 
with biologics such as TNFα.(265, 266) And so, the clinician faces the constant 
challenge of balancing the risk of uncontrolled inflammation on visual outcome with 
the potentially devastating side effects of immunosuppressive therapy. It is therefore 
important that the level of treatment for each individual patient is closely titrated 
against disease activity. In current practice, methods for assessing disease activity are 
largely reliant on clinical examination - grading the number of cells and intensity of 
flare in anterior chamber or vitreous by manual or automated means, or measuring 
the size of retinal or choroidal lesions.(267) Although fluorescein and indocyanine 
green angiography offers additional information regarding disease activity, it is an 
invasive procedure, and not suitable for the frequent testing required to closely 
titrate treatment to disease activity in the patient.(268)  
137 
 
 
In recent years, the rapid advancement of optical coherence tomography 
(OCT) technology has allowed non-invasive imaging of the choroid in addition to the 
retina in cross-section.(46, 269, 270) Several early studies have indicated how OCT-
derived choroidal images can be useful in uveitic disorders. For example, OCT has 
been used (1) to describe characteristic features of specific uveitis entities, including 
thinning of Haller’s large vessel layer of the choroid in idiopathic panuveitis and 
extra-macular choroidal changes in birdshot chorioretinopathy;(271, 272) to identify 
distinct stages of a disease process as illustrated by punctate inner 
choroidopathy;(273, 274) (3) objective measurement of vitreous inflammation(275), 
and (4) to monitor response to therapy, exemplified by a reduction of subfoveal 
choroidal thickening with corticosteroid therapy in Vogt-Koyanagi-Harada 
disease.(276) However, the full potential of OCT in uveitic diseases has yet to be 
realised.   
 
3.1.3 Punctate inner choroidopathy 
Punctate inner choroidopathy (PIC), a disease that typically affects young myopic 
women, is characterized by the development of multiple, small, yellow-white spots in 
the posterior pole of each eye.(277-279) These “PIC lesions” are thought to occur at 
the level of the inner choroid and retinal pigment epithelium (RPE), and develop in 
the absence of clinically apparent intraocular inflammation. After a few weeks, these 
acute PIC lesions resolve, leaving atrophic spots with variable pigmentation. In many 
patients, such resolution leads to improvement or resolution of visual symptoms. 
However, in about 40%, more severe visual loss subsequently occurs, primarily due to 
development of choroidal neovascularisation (CNV).(277-280)  
 In recent years, the advent of intravitreal anti-angiogenic therapies has 
greatly improved the treatment options for patients with PIC who develop CNV.(280-
285) Despite this, the underlying pathophysiology of the disorder remains little 
understood. For example, during the acute phase, patients often complain of 
photopsia and visual field defects out of proportion to lesion size and extent,(277, 
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286) thus suggesting the presence of more widespread disease than is clinically 
evident (in fact, widespread focal areas of choroidal hypofluorescence may be seen 
on indocyanine green (ICG) angiography).(287) Furthermore, in the continued 
absence of clinicopathologic correlative studies, the nature of the acute PIC lesions – 
and their role in CNV development – remains unclear (on fluorescein angiography 
(FA), these lesions show early hyperfluorescence with late staining).(279) Fortunately 
however, recent advances in optical coherence tomography (OCT) imaging offer 
some exciting opportunities to address these issues. 
 In patients with uveitic disease, OCT is most commonly used for the 
evaluation of cystoid macular oedema (CME),(288, 289) although its use for diagnosis 
and phenotyping has increased in recent years.(290) A recent case report described 
the evolution of an acute multifocal choroiditis without inflammation that was PIC-
like (291) Despite this, the OCT features of PIC have not been extensively evaluated. 
For the most part, the use of OCT in PIC studies has been restricted to assessment of 
treatment response in patients with CNV.(281, 283, 292) More recently, a small 
number of studies have attempted to evaluate PIC lesion characteristics in the 
absence of CNV.(293-295) Although these studies have utilized the latest generation 
of “spectral domain” OCT technology, the rarity of the disease means that their 
patient numbers are small (i.e., case reports or small case series). Furthermore, as a 
result of limitations with conventional OCT scanning, these studies have been unable 
to comprehensively evaluate disease features of the choroid. Given that PIC has long 
been regarded as a disease of the inner choroid – and hence the name – this 
represents a significant shortcoming. In 2008 however, Spaide et al., described a 
method by which OCT scanning protocols could be modified to permit direct 
visualization of the choroid (EDI-OCT).(46) Since this seminal work, EDI-OCT has been 
used to evaluate the choroid in a variety of conditions, with examples including high 
myopia and Vogt-Koyanagi-Harada (VKH) disease.(296, 297)  
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3.1.4 Novel methods for quantification of vitreous inflammation 
The current gold standard for assessing vitreous inflammation in patients with 
intermediate and posterior uveitis is the National Eye Institute (NEI) system for 
grading of vitreous haze.(298, 299) In this system, often referred to as the 
Nussenblatt scale, the patient’s eye is examined with an indirect ophthalmoscope 
and the appearance compared to a series of photographs representing various 
degrees of fundal vitreous haze. This assessment is recognised as a surrogate 
endpoint by the FDA and has been adopted as a primary outcome in almost all recent 
studies of uveitis. Despite this, the technique has a number of limitations, notably 
that it is: 1) subjective, with only moderate inter-observer agreement; 2) non-
continuous, leading to very large steps in disease activity between categories; 3) 
poorly discriminatory at lower levels of vitreous haze, with most cases of active 
uveitis being scored at 0.5+ or 1+; 4) limiting of sensitivity in a clinical trial context 
(where a two point change is required to be counted as significant).(300, 301) 
In recent years, ophthalmology has been revolutionized by the introduction of 
a new imaging modality, optical coherence tomography (OCT).(26) OCT provides 
high-resolution, cross-sectional images of ocular tissues in a non-invasive manner. 
From an early stage in its development, OCT has also been pioneering in its attempts 
to provide automated measurements of disease morphology and thus objective 
markers for clinical care.(302) Until recently, OCT imaging has focused in large part 
on the neurosensory retina, allowing qualitative assessment of disease features such 
as cystoid macular oedema (CME) and providing automated measurements of retinal 
thickness.(205, 303) Lately however, the use of OCT for direct visualization of 
vitreous inflammatory cells in patients with uveitis has been described.(304) In 
addition, quantitative assessment of OCT image sets has begun to evolve, from 
simple measurements of thickness or volume, to the assessment of more novel 
parameters such as optical density/signal intensity.(305-311) Taken together, these 
advances present an opportunity to derive objective, OCT-derived measurements of 
inflammation in patients with uveitis. 
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3.2 Aim:  
To investigate recent and novel imaging techniques for quantifying inflammation in 
the human vitreous, retina and choroid using OCT-derived images in patients with 
uveitis. The rationale for including patients with uveitis is to identify retinal 
inflammation imaging biomarkers that may be applied to diabetic retinopathy, where 
inflammation is hypothesized to play a role in the pathogenesis and prognosis of 
disease. 
 
  
141 
 
 
3.3 Materials and Methods: 
3.3.1 Inclusion criteria and data collection 
Clinical and imaging data were retrospectively collected from consecutive patients 
diagnosed with idiopathic panuveitis, sarcoid and TB-associated panuveitis, and 
punctate inner choroidopathy attending a specialist uveitis clinic over a period of six-
months. Patient notes were also checked 12 months later to confirm diagnoses. 
Approval for data collection and analysis was obtained from a UK National Health 
Service (NHS) research ethics committee and adhered to the tenets set forth in the 
Declaration of Helsinki. 
Patients included in this study had the following assessments: physical 
examination for features of systemic inflammatory or autoimmune disease; complete 
ophthalmic examination including best corrected visual acuity (BCVA), disease activity 
and duration, treatment, and presence of cystoid macular oedema (CMO) or 
epiretinal membrane (ERM); a standard laboratory work-up for panuveitis, including 
full blood count with differential analysis, angiotensin-converting enzyme, 
autoantibody screen, C-reactive protein, erythrocyte sedimentation rate, liver and 
kidney function tests, treponemal EIA, and quantiFERON TB-Gold test; chest X-ray, FA 
and ICGA. Patients with myopia or hypermetropia of greater than 6 diopters were 
excluded. The right eye was included in patients with bilateral disease.   
The First International Workshop on Ocular Sarcoidosis (FIWOS) 
recommended four levels of certainty for diagnosis in patients in whom other 
possible causes of uveitis had been excluded:(312) (1) biopsy-supported diagnosis 
with a compatible uveitis was labelled as definite ocular sarcoidosis; (2) if biopsy was 
not done but chest x-ray was positive showing bilateral hilar lymphadenopathy 
associated with a compatible uveitis, the condition was labelled as presumed ocular 
sarcoidosis; (3) if biopsy was not done and the chest x-ray did not show bihilar 
lymphadenopathy but there were three of the classic intraocular signs and two 
positive laboratory tests, the condition was labelled as probable ocular sarcoidosis; 
and (4) if lung biopsy was done and the result was negative but at least four classic 
intraocular signs and two positive laboratory investigations were present, the 
142 
 
 
condition was labelled as possible ocular sarcoidosis. Only patients with definite, 
presumed or probable sarcoidosis were included in this study. The combination of 
clinical signs and laboratory tests proposed by the FIWOS has been validated to be 
highly specific and sensitive for the diagnosis of ocular sarcoidosis.(313) 
With TB associated uveitis the large variations in clinical presentation and the 
lack of uniformity in diagnostic criteria makes diagnosis difficult.(314) Most patients 
have no evidence of Mycobacterium tuberculosis in their ocular biopsies.(315) 
Patients with clinical ocular signs suggestive of TB,(259) and positive microscopy or 
culture of Mycobacterium tuberculosis from any bodily fluid, in the absence of 
another identifiable cause for their uveitis were labelled as definite ocular TB. In the 
absence of confirmatory microbiology, when other identifiable causes of uveitis had 
been excluded, patients were labelled as presumed ocular TB only if they met all of 
the following 3 published criteria: (1) Ocular signs suggestive of TB(259); (2) Positive 
QuantiFERON-TB Gold test(316-320); (3) Positive response to anti-tuberculous 
therapy(321). 
In patients with granulomatous uveitis, disease activity was recorded from 
notes based on clinical examination and investigations including macula OCT, fundus 
fluorescein and indocyanine green angiography. Anterior chamber activity was 
graded by measuring the number of cells and intensity of flare. Posterior segment 
activity was based on the clinician’s impression of significant vitritis, vasculitis, 
chorioretinitis, papillitis. Cases of intermediate uveitis, posterior uveitis and 
panuveitis were recorded as ‘posterior uveitis’. Only cases of isolated anterior 
chamber activity with or without cystoid macula oedema were recorded as ‘anterior 
uveitis’. 
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3.3.2 Optical coherence tomography image acquisition and analysis 
 
3.3.2.1 Acquisition of EDI OCT-derived images 
Spectral domain OCT images were acquired on the Spectralis imaging system. 
(Heidelberg Engineering, Germany).  This system acquires 40,000 A-scans per second 
with an axial resolution, in tissue, of 7 m, and a transverse resolution of 14 µm. All 
images were acquired using a custom EDI scanning protocol (each image set 
consisted of 7 OCT B-scans obtained in a 20 x 15 degree horizontal raster pattern, and 
with each individual B-scan generated from 50 averaged scans). No image 
manipulation was performed prior to analysis.  
 For the assessment of vitreous inflammation, volume scans centered on the 
fovea were obtained. The EDI mode was not used in any case and the zero delay line, 
or the point of maximum sensitivity, was maintained on the vitreous side.(322) 
 
3.3.2.1 Analysis of EDI OCT-derived images 
For the generation of retinal and choroidal thickness maps, raw OCT data were 
exported from the Heidelberg Spectralis OCT system and imported into validated 
custom grading software (OCTOR) developed by Doheny Image Reading Center, Los 
Angeles, California.(173, 323) All OCT image sets contained a minimum of 13 B-scans 
distributed in a horizontal raster pattern overlying the area covered by the nine 
subfields of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid. For each 
OCT image set, the inner and outer boundaries of both the retina and the choroid 
were manually segmented. All boundaries were drawn in accordance with a standard 
OCT grading protocol by a grader masked to patient identity, underlying diagnosis 
and disease activity.(324) 
The retinal space was defined as the space lying between the inner aspect of 
the internal limiting membrane and the outer border of the photoreceptor outer 
segments. The choroid was defined as the space between the outer border of the 
retinal pigment epithelium and choroidoscleral junction. The choroid was further 
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subdivided into Haller’s large vessel and Sattler’s medium vessel layers. On OCT, the 
walls of blood vessels appear hyperreﬂective, and their lumens appear 
hyporeﬂective. Haller’s large vessel layer was defined as the outer choroid, consisting 
of large hypointense spaces representing large vascular luminal spaces (with luminal-
to-vessel wall ratio ≥50%).(325) Sattler’s medium vessel layer consisted of small- to 
medium-sized hypointense spaces, surrounded by hyperintense stroma (with a 
lumen-to-vessel wall ratio <50%), giving a mottled appearance on scans. This layer 
also included the choriocapillaris, which is not easily distinguishable with the current 
resolution of OCT images.(326, 327) The foveal central subfield (FCS) in micrometers 
(µm), corresponds to the Early Treatment Diabetic Retinopathy Study (ETDRS) central 
subfield (area 9), and the total macular circle (TMC), corresponds to ETDRS areas 1-9.  
In cases of PIC, the number of visible PIC lesions was then counted using 
macula-centered NIR fundal images (55° field of view). Only those lesions that were 
included in the 7 raster OCT scans covering the 20x5º scanned area were selected for 
analysis. OCT lesions that could be interpreted as CNV were classified as “definitely 
CNV” or ”questionably CNV” were correlated with previous clinical records, colour 
fundus photographs and fluorescein angiography images and were excluded from 
qualitative analysis. Location of definite CNV lesions was addressed with these clinical 
data as subfoveal, juxtafoveal and extrafoveal for subgroup analysis purposes. Each 
PIC lesion included in OCT image sets was then evaluated for the following changes in 
retinal morphology: 1) focal elevation of the RPE (with underlying hyporeflective 
space between RPE and Bruch´s membrane and increased penetration of light 
through the inner choroid), 2) focal atrophy of the outer retina/RPE, and 3) presence 
of sub-RPE deposits (with hyperreflective signal within the lesion). Choroidal 
morphology was then assessed, including: 1) presence of focal hyperreflective dots in 
the inner choroid, and 2) focal thinning of the choroid adjacent to PIC lesions. 
Examples of each retinal and choroidal morphologic feature are illustrated in Figure 
3.1 
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Figure 3.1. Qualitative analysis of punctate inner choroidopathy (PIC) 
lesions by optical coherence tomography (OCT).  
[A] Retinal pigment epithelium (RPE) elevation with sub-RPE hyporeflective signal. [B] Focal disruption 
of outer retinal layers and RPE atrophy, with window defect resulting in increased signal transmission 
from inner choroid. [C] Sub-RPE deposit with hyperreflective signal. [D] Multiple hyperreflective dots 
in the inner choroid. [E] Focal choroidal thinning localized beneath atrophic PIC lesion. 
 
In the qualitative Analysis of the Vitreous using OCT, the presence or absence 
of intravitreal cellular infiltrates was noted each OCT image set. These were defined 
as hyperreflective dots in the vitreous that were larger and of greater density than 
background speckle noise.(304) These were differentiated from the larger, non-
punctate, irregular condensations within the vitreous cavity, which appeared to 
reflect normal age-related vitreous syneretic changes. Examples of vitreous cells and 
flare, as seen on OCT, are presented for a variety of uveitic aetiologies in Figure 3.2.  
In the quantitative Analysis of the Vitreous using OCT: Raw OCT data were 
exported from the Heidelberg Spectralis OCT system and imported into validated 
custom grading software OCTOR.(328, 329) This software enables easy navigation of 
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spectral domain OCT volume scans and manual boundary annotation of each B-scan, 
or a subset of B-scans. Based on these boundaries, the intensity of all pixels in a 
morphologic compartment of interest (e.g., vitreous) can be summed, and mean OCT 
intensity values generated.(170, 330) Image contrast was not adjusted either before 
or after export from the OCT system. For each OCT image set, boundaries were 
manually segmented in accordance with standardized OCT grading protocols (Figures 
3.3 and 3.4).(330, 331) These boundaries consisted of: 1) “vitreous top”, the 
uppermost extent of the vitreous space as visualized on OCT, 2) internal limiting 
membrane (ILM), the inner boundary of the neurosensory retina, 3) retinal pigment 
epithelium (RPE)-inner, the inner boundary of the RPE, and 4) RPE-outer, the outer 
boundary of the RPE. The “vitreous” was defined as the space lying between the 
vitreous top and the ILM. The “RPE” was defined as the space lying between the 
inner and outer boundaries of the RPE.  
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Figure 3.2. Optical coherence tomography images of vitreous haze  
Visualization of age-related and inflammatory changes in the vitreous using spectral-domain optical 
coherence tomography (SD-OCT). A, An OCT B-scan obtained from a 74-year-old woman without 
uveitis demonstrating detachment of the posterior hyaloid face (arrows) and age-related vitreous 
condensation (arrowhead). B, An OCT B-scan obtained from a patient with birdshot chorioretinopathy 
demonstrating vitreous cells with minimal vitreous haze (clinical vitreous haze score .0.5, vitreous 
signal intensity/retinal pigment epithelium [VIT/RPE]-relative intensity 0.0783). C, An OCT B-scan 
obtained from a patient with sarcoid-related panuveitis demonstrating vitreous cells in combination 
with moderate vitreous haze (clinical vitreous haze score .1.0, VIT/RPErelative intensity 0.2222). D, An 
OCT B-scan obtained from a patient with idiopathic panuveitis demonstrating vitreous cells in 
combination with moderate to severe vitreous haze (clinical vitreous haze score .2.0, VIT/RPE-relative 
intensity 0.2701). E, An OCT B-scan obtained from a patient with idiopathic panuveitis demonstrating 
vitreous cells in combination with more severe vitreous haze (clinical vitreous haze score .3.0, VIT/RPE-
relative intensity 0.3818). 
 
After completion of grading, mean intensity values were calculated for the 
vitreous space (termed “VIT-Absolute Intensity”) and the RPE space (termed “RPE-
Absolute Intensity”) in the foveal central subfield (i.e., the 1 mm in diameter central 
subfield of the ETDRS grid). Intensity values for the vitreous and RPE spaces were 
then expressed as a ratio (termed “VIT/RPE-Relative Intensity”). To assess 
reproducibility, a second, experienced OCT grader, also in a masked fashion, also 
segmented the OCT image sets. 
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Figure 3.3. Quantitative assessment optical coherence tomography images 
of vitreous haze  
Quantitative assessment of the vitreous using spectral-domain optical coherence tomography (SD-
OCT) at initial presentation in a 57- year-old patient with idiopathic panuveitis (clinical vitreous haze 
score 2.). A, An OCT B-scan revealing widespread intravitreal cellular infiltrates and diffusely increased 
vitreous signal intensity. B, An OCT B-scan after manual segmentation of the vitreous compartment 
(boundaries: vitreous top to internal limiting membrane) and the retinal pigment epithelium (RPE) 
(boundaries: RPE-inner to RPE-outer), with a resulting vitreous signal intensity/retinal pigment 
epithelium (VIT/RPE)-relative intensity of 0.3550. ILM. internal limiting membrane. 
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Figure 3.4. Quantitative assessment of the vitreous using spectral-domain 
optical coherence after corticosteroid treatment. 
1 month after treatment with oral corticosteroids, this 57-year-old patient with idiopathic panuveitis 
had an OCT B-scan (A) revealing a significant reduction in both vitreous haze and inflammatory cells. 
(B) An OCT B-scan after manual segmentation of the vitreous compartment, with a resulting vitreous 
signal intensity/retinal pigment epithelium (VIT/RPE)-relative intensity of 0.1267. 
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3.3.2 Statistical analysis 
Non-parametric analyses were used as histograms reveal that the distribution of data 
was skewed to the left. The Chi-squared test was used to assess categorical variables 
and, Mann-Whitney U test and Spearman’s rank correlation coefficient were applied 
to continuous variables. Multivariable regression was then used to model the effects 
of clinical characteristics on mean OCT intensity values. Snellen BCVA was converted 
to logarithm of the minimum angle of resolution (LogMAR) equivalents for the 
purposes of statistical analysis. Reproducibility, or inter observer variability, was 
assessed using Bland-Altman plots, using the mean OCT intensity values obtained by 
each grader. The mean difference and confidence intervals were calculated. 
Agreement between graders was also examined using Bland-Altman analysis, with 
the 95% limits of agreement (LoA) between graders calculated after confirming that 
the measurement differences were normally distributed using histograms. 
 Due to multiple statistical comparisons, we applied a Sidak correction to 
adjust p values to a more stringent value of p≤0.004, to allow for an experimental 
wide type 1 error of 10%. Less stringent p<0.05 were also presented. Statistical 
analyses were performed using SPSS software version 16 (SPSS, Inc, Chicago, IL).  
 
3.4 Results: 
3.4.1 Idiopathic panuveitis  
3.4.1.1 Baseline characteristics 
Twenty-one eyes from 21 patients were analysed. The mean age was 47.7 years 
(range: 23-88), and male to female ratio was 1:2. The mean VA was 0.29 logMAR 
(range: -0.08 to 1.78) (6/12 Snellen). Seventeen patients (80.9%) had bilateral and 4 
unilateral (19.1%) disease. All patients had clinically inactive disease at the time of 
data acquisition. Patient demographics and clinical characteristics are summarized in 
Table 3.1.  
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3.4.1.2 Visual Significance of Clinical Parameters 
Poor visual acuity is associated with longer duration of disease: The mean disease 
duration of all eyes was 78.4 months with a wide range: 1 to 240 months. 
Approximately half or 10 eyes (47.6%) had disease duration of greater than 24 
months, and 11 eyes (52.4%) less than 24 months. The mean VA was significantly 
worse in patients with longer disease duration (>24 months) (p=0.05), and was 
negatively correlated with the duration of disease. (ρ=-0.49, p=0.03)  
Treatment modality has no effect on visual acuity: The majority of eyes 
(90.5%) were on some form of immunosuppressive treatment. Four eyes (19.1%) 
were on systemic steroids, 7 (33.3%) were on systemic steroids with a second-line 
immunosuppressive agent, 7 (33.3%) were on topical steroids, 1 (4.7%) had 
periocular steroids, and 2 (9.5%) were not on any treatment. There was no significant 
difference in VA between any of the treatment subgroups. (p>0.40)  
The presence of concurrent CMO and ERM is associated with poor visual 
acuity: The proportion of eyes with CMO and ERM were 14.3% and 28.6% 
respectively. VA in these eyes was significantly lower compared to the rest of the 
patients (p=0.007). 
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Table 3.1. Demographics and clinical characteristics of patients with 
idiopathic panuveitis. 
 
Patient Age Sex  Eye Type Duration 
(months
) 
Treatment CMO Activity ERM BCVA 
logMAR 
(Snellen) 1 53 M RE Bilateral 168 Systemic steroids No Inactive No 0.60 (6/24) 
2 75 F RE Bilateral 132 Systemic steroids No Inactive Yes 0.78 (6/36) 
3 50 F LE Unilateral 144 Topical steroids Yes Inactive No 1.30 (3/60) 
4 41 F RE Bilateral 108 Systemic steroids and 
mycophenolate mofetil 
Yes Inactive No 1.78 (1/60) 
5 48 M RE Bilateral 48 Topical steroids No Inactive No -0.08 (6/5) 
6 27 M RE Bilateral 100 Systemic steroids and 
mycophenolate mofetil 
No Inactive Yes 0.30 (6/12)  
7 33 F RE Unilateral 12 No treatment No Inactive No -0.08 (6/5) 
8 35 F RE Unilateral 5 No treatment No Inactive Yes 0 (6/6) 
9 55 M RE Bilateral 144 Periocular steroids No Inactive No 0 (6/6) 
10 74 F RE Bilateral 144 Topical steroids No Inactive Yes 0.30 (6/12) 
11 57 F RE Bilateral 132 Systemic steroids No Inactive No -0.08 (6/5) 
12 88 F RE Bilateral 120 Topical steroids No Inactive Yes 0.30 (6/12) 
13 79 F RE Bilateral 36 Systemic steroids and 
mycophenolate mofetil 
Yes Inactive No 0.48 (6/18) 
14 26 M RE Bilateral 36 Systemic steroids and 
mycophenolate mofetil 
No Inactive No 0.18 (6/9) 
15 39 F RE Bilateral 32 Systemic steroids and 
mycophenolate mofetil 
No Inactive No -0.08 (6/5) 
16 23 F RE Bilateral 24 Systemic steroids and 
mycophenolate mofetil 
No Inactive No 0 (6/6) 
17 37 M RE Bilateral 240 Systemic steroids No Inactive No 0.18 (6/9) 
18 39 M RE Bilateral 1 Topical steroids No Inactive No -0.08 (6/5) 
19 26 F RE Bilateral 1 Topical steroids No Inactive No 0.18 (6/9) 
20 43 F RE Unilateral 15 Topical steroids No Inactive Yes 0.18 (6/9) 
21 53 F RE Bilateral 5 Systemic steroids and 
azathioprine 
No Inactive No 0 (6/6) 
 (CMO: cystoid macular oedema, ERM: epiretinal membrane, BCVA: best corrected visual acuity) 
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3.4.1.3 Qualitative features of EDI OCT: 
As expected, there was a lack of distinctive features in the EDI OCT of this patient 
cohort. We did not observe any evidence of inflammatory masses in any of the 147 B-
scans from 21 eyes. In the 4 patients with unilateral disease, we also reviewed OCT 
images from the unaffected eye as a basis of comparison to the affected eyes, paying 
particular attention to the choroidal vasculature. We observed a qualitative 
difference in the vascular pattern of Haller’s large vessel layer (HLVL) in “affected” 
compared to “unaffected” eyes. There was a decrease in hypo reflective areas, 
corresponding to the vessel lumen, in “affected” eyes. A similar pattern was observed 
in 13/17 remaining eyes. (Figure 3.5) 
 
3.4.1.4 Clinical Significance of Retinal and Choroidal OCT parameters: 
Retinal and choroidal thickness measurements: The mean retinal thickness was 342.1 
μm ± 110.3 and ranged from 218 to 686 μm. The mean choroidal thickness was 233.7 
μm ± 73.3 and ranged from 103 to 319.8 μm. Its sublayers – Sattler’s medium vessel 
layer (SMVL) and HLVL were 66.1 μm ± 36.7 and 167.8 μm ± 53.7 respectively. A 
summary of thickness and volume measurements are listed in Table 3.2. 
Ratio of choroidal layers to retinal thickness measurements: There were no 
significant correlations between retinal and choroidal parameters with duration of 
disease, treatment modality, and VA. However, when thickness of the choroidal 
layers were expressed as a ratio of the retina (Table 3.2), the “choroid: retina ratio” 
(C:R) showed significant correlation to VA. (r=0.58, p=0.006) This correlation was 
maintained in HLVL to retinal thickness ratio (H:R) (r=0.56, p=0.009), but not in the 
SMVL to retinal thickness ratio (S:R). (r=0.352, p=0.12)  
Comparing eyes with and without CMO, the C:R and H:R ratio was significantly 
different between the two groups (p=0.01). There was no difference in the S:R ratio. 
(p=0.155) with age. This correlation was maintained in the C:R (r=-0.60, p=0.004) and 
S:R (r=-0.705, p<0.001) ratios, but not in the H:R ratio (r=-0.39, p=0.08). 
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Table 3.2. OCT-derived measurements of the retinal, choroidal layers and ratios for all patients with idiopathic panuveitis. 
Patient Retinal 
thickness 
(μm) 
Retinal 
volume 
(mm3) 
Choroidal 
thickness 
(μm) 
Choroidal 
volume 
(mm3) 
Sattler’s 
thickness 
(μm) 
Sattler’s 
volume 
(mm3) 
Haller’s 
thickness 
(μm) 
Haller’s 
volume 
(mm3) 
Sattler’s/ 
Choroid 
ratio 
Haller’s/ 
Choroid 
ratio 
Sattler’s/ 
Retina ratio 
Haller’s/ 
Retina 
ratio 
Chroid/ 
Retina 
ratio  
1 287.60 9.80 192.70 6.56 52.10 1.78 140.60 4.79 0.27 0.73 0.18 0.49 0.67 
2 279.10 10.18 103.00 3.76 34.20 1.25 68.90 2.51 0.33 0.67 0.12 0.25 0.37 
3 686.30 24.21 239.40 8.43 77.00 2.71 162.40 5.73 0.32 0.68 0.11 0.24 0.35 
4 595.60 16.89 310.00 8.80 106.30 3.01 204.10 5.78 0.34 0.66 0.18 0.34 0.52 
5 303.40 10.34 284.80 9.70 52.10 3.49 182.30 6.18 0.36 0.64 0.34 0.60 0.94 
6 471.40 16.07 256.00 8.72 105.90 3.61 150.20 5.11 0.41 0.59 0.22 0.32 0.54 
7 299.00 9.83 319.80 10.52 128.60 4.23 191.60 6.29 0.40 0.60 0.43 0.64 1.07 
8 328.80 10.44 310.60 9.86 159.40 5.05 151.60 4.81 0.51 0.49 0.48 0.46 0.94 
9 284.20 10.37 203.60 7.40 27.10 .99 176.50 6.42 0.13 0.87 0.10 0.62 0.72 
10 328.90 10.82 181.00 5.94 52.80 1.73 128.30 4.21 0.29 0.71 0.16 0.39 0.55 
11 218.90 7.22 171.40 6.04 37.00 1.30 134.40 4.73 0.22 0.78 0.17 0.61 0.78 
12 272.70 8.96 138.90 4.56 30.30 .99 108.60 3.57 0.22 0.78 0.11 0.40 0.51 
13 333.60 11.34 147.30 5.01 30.80 1.05 116.50 3.97 0.21 0.79 0.09 0.35 0.44 
14 340.80 13.73 357.60 14.40 87.60 3.52 270.10 10.84 0.24 0.76 0.26 0.79 1.05 
15 293.00 10.31 297.10 10.47 61.50 2.15 235.90 8.26 0.21 0.79 0.21 0.81 1.01 
16 329.10 11.21 259.40 8.79 66.00 2.24 193.70 6.58 0.25 0.75 0.20 0.59 0.79 
17 328.60 11.60 279.00 9.80 61.00 2.13 218.60 7.65 0.22 0.78 0.19 0.67 0.85 
18 296.10 13.93 144.20 6.77 33.10 1.56 111.10 5.22 0.23 0.77 0.11 0.38 0.49 
19 304.80 10.39 269.70 9.18 60.00 2.04 210.00 7.15 0.22 0.78 0.20 0.69 0.88 
20 312.80 10.65 294.30 10.03 33.70 1.15 260.80 8.87 0.11 0.89 0.11 0.83 0.94 
21 290.30 10.59 148.00 5.38 40.30 1.45 108.30 3.90 0.27 0.73 0.14 0.37 0.51 
Mean 
±SD 
342.1 
± 110.3 
11.8 
± 3.6 
233.7  
± 73.3 
8.1 
± 2.5 
66.1 
± 36.7 
2.25 
±1.1 
167.8  
± 53.7 
5.8 
± 1.9 
0.27±0.1 0.72 
± 0.1 
0.19 
± 0.1 
0.51 
± 0.1 
0.71 
± 0.2 
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3.4.2 Granulomatous panuveitis  
3.4.2.1 Baseline characteristics 
Over a six-month period, 36 patients with a diagnosis of granulomatous uveitis 
suspected to be secondary to sarcoidosis or tuberculosis were imaged according to 
the protocol above. Nine patients were excluded as diagnoses were later reclassified 
(1 syphilis, 1 Lyme disease, 7 idiopathic panuveitis). Patient demographics and clinical 
characteristics of the 27 patients included are listed in Table 3.3.  
 
Table 3.3. Baseline demographic and clinical characteristics of all patients, 
and in those with a diagnosis of sarcoid or tuberculosis. 
  All 
(n=27) 
Sarcoid 
(n=13) 
Tuberculosis 
(n=14) 
p-value 
 
Demographics 
  
Age, Median (IQR)  51 (25.5) 52 (18.0) 46 (22.0) 0.20 
Female Gender, n 
(%) 
 16 (59.3) 3 (23.1) 8 (57.1) 0.16 
Affected eye – right, 
n (%) 
 17 (63.0) 8 (61.5) 9 (64.3) 0.80 
Visual acuity - 
LogMAR,  
Median (IQR) 
 0.18 (0.30) 0.18 (0.26) 0.24 (0.30) 0.53 
Diagnosis type, n (%)      
          Presumed  11 (40.7) 4 (30.8) 7 (50.0) 0.08 
          Probable  4 (14.8) 4 (30.8) 0 (0.0) 
          Definitive  12 (44.4 5 (38.4) 7(50.0) 
Disease Activity      
          Active  10 (37.0) 5 (38.5) 5 (35.7) 0.80 
          Quiescent  17 (63.0) 8 (61.5) 9 (64.3) 
Uveitis      
          Anterior  5 (18.5) 3 (23.1) 2 (12.3) 0.93 
          Posterior  22 (81.5) 10 (76.9) 12 (85.7) 
 
Treatment 
  
Topical Steroid, n (%)  21 (77.7) 10 (76.9) 11 (78.6) 0.88 
Oral Steroids, n (%)  11 (40.7) 4 (30.8) 7 (50.0) 0.81 
2nd line agent, n (%)  3 (11.1) 2 (15.4) 1 (7.1) 0.88 
 
IQR = Interquartile range 
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3.4.2.2 The effects of granulomatous uveitis on choroidal morphology 
Haller’s large vessel layer of the choroid is thicker in eyes diagnosed with TB: The 
ratio of median Haller’s large vessel to median Sattler’s medium vessel layer was 
significantly greater in eyes diagnosed with tuberculosis (1.47 [=140.71µm/95.72µm] 
compared to eyes diagnosed with sarcoidosis (1.07 [=137.70µm/128.69µm]) at the 
TMC (p=0.001), but did not achieve statistical significance at the FCS (1.38 [=162.85 
µm/118.01µm] versus 1.15 [=166.09µm/144.43µm]) (p=0.02) (Figures 3.5, 3.6, and 
3.7). No significant differences were observed in the choroidal sublayers between 
active or quiescent, or anterior or posterior disease. Although total choroidal 
thickness measurements were correlated with age at the TMC (r=-0.51, p=0.007) and 
FCS (r=-0.50, p=0.007), no associations between the ratio of median Haller’s to 
median Sattler’s vessel layers were observed at the TMC [(r=-0.23, p=0.25) and FCS 
(r=-0.16, p=0.44)].  
 Visual acuity and choroidal thickness measurements: The median VA of all 
patients was 0.18 LogMAR (IQR=0.00 to 0.30 LogMAR) and there was no difference 
between eyes diagnosed with tuberculosis or sarcoid (Table 3.3). However, in the 
TMC, eyes with a VA equal to, or worse than 0.3 LogMAR, had a significantly thinner 
choroid (198.1µm [IQR=147.0µm to 253.4µm]), compared to eyes with a VA better 
than 0.3 LogMAR (292.4µm [IQR=240.1µm to 347.6µm]) (p=0.004) with factors 
including age and disease activity well matched between these sub-groups. However, 
at the FCS this did not reach statistical significance (p=0.02). Choroidal thickness 
measurements, showed a modest correlation with LogMAR VA (R2=-0.17, p=0.04) at 
the TMC and FCS (R2=-0.10, p=0.10), but did not reach statistical significance. There 
was no significant difference in age of the good VA (<0.3 LogMAR) group versus the 
poor VA (≥0.3 LogMAR) group (p=0.27). 
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Figure 3.5. Decreased hypo reflective areas in the choroidal vasculature in 
idiopathic panuveitis. 
Spectral domain optical coherence tomography using enhanced depth imaging. Arrowheads denote 
the hypo-reflective areas in Haller’s layer that correspond to choroidal vessels. a) Normal eye showing 
multiple hypo-reflective areas. Loss of these areas was evident in the majority of our study eyes, as 
illustrated in these examples:  b) Right eye of patient No 1, c) Right eye of patient No 2, d) Right eye of 
patient No 5, e) Right eye of patient No 18. 
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Figure 3.6. EDI OCT images of the choroid in A) Active sarcoidosis B) Active 
tuberculosis C) Inactive sarcoidosis and D) Normal eye 
Manual segmentation delineates Haller’s large vessel layer of the choroid from Sattler’s medium 
vessel layer. Figure 1A is from a patient with active sarcoid uveitis and Figure 1B is from a patient with 
active TB uveitis. Although the median total choroidal thickness measurements were not different 
between sarcoid and TB uveitis groups, the ratio of median Haller’s large to median Sattler’s medium 
vessel layers at the Total Macula Circle was significantly higher in eyes diagnosed with TB (1.47 
[=140.71µm/95.72µm] compared to eyes diagnosed with sarcoidosis (1.07 [=137.70µm/128.69µm]) 
(p=0.001). Figure 1C is from a patient with inactive sarcoid uveitis. At the Foveal Central Subfield, the 
choroid was thicker in eyes with active (336.8µm [IQR=272.3µm to 375.4µm]) compared to inactive 
granulomatous uveitis (239.3µm [IQR=195.3µm to 330.9µm]) but this failed to reach statistical 
significance at the stringent 0.004 level (p=0.04). Figure 1D is from a normal control eye to 
demonstrate the retina, retinal pigment epithelium, Haller’s large and Sattler’s medium vessel 
choroidal layers.  
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Figure 3.7. Box plot of ratio of Haller’s to Sattler’s vessel layers in eyes 
diagnosed with tuberculosis compared to sarcoid uveitis.  
This box plot demonstrates that the ratio of median Haller’s large to median Sattler’s medium vessel 
layers at the Total Macula Circle was significantly higher in eyes diagnosed with TB (1.47 
[=140.71µm/95.72µm] compared to eyes diagnosed with sarcoidosis (1.07 [=137.70µm/128.69µm]) 
(p=0.001). This did not achieve statistical significant at the Foveal Central Subfield (1.38 [=162.85 
µm/118.01µm] for TB versus 1.15 [=166.09µm/144.43µm] for sarcoid) (p=0.02). There was also no 
distinct cut-off in the ratio of these layers to reliably distinguish between the diseases. Quartiles 1 and 
3 are delineated by the borders of the box. The median is represented by the solid line within the box. 
The whiskers extend from quartile 1 to the minimum value and from quartile 3 to the maximum value. 
Because of the skew of the data, medians and interquartile ranges were presented.   
 
3.4.2.3 The effects of granulomatous uveitis on retinal morphology: 
In the 27 eyes analysed, the median retinal thickness measurement was 286.5µm 
(IQR=271.2µm to 309.1µm)) at the TMC and 235.9µm (IQR=216.6µm to 261.7µm) at 
the FCS. Retinal thickness measurements at the TMC and FCS showed good 
correlation within patients (R2=0.56, p=0.0001). There were no significant differences 
in retinal thickness measurements between the type of granulomatous uveitis – 
sarcoid or tuberculosis, disease activity, or anatomical site of uveitis. 
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3.4.3 Punctate inner choroidopathy 
3.4.3.1 Baseline Characteristics and Clinical Features 
46 patients with a clinical diagnosis of PIC were included. Thirty-five eyes, from 35 
patients, had EDI-OCT images, which met the inclusion criteria. The mean age was 
40.1 ± 9.4 years (mean ± standard deviation, range 21-60 years), with an 8:1 female 
to male ratio (82.8%). The mean refractive error was -4.5 ± 4.1 diopters, BCVA was 
0.33 ± 0.47 logMAR units (Snellen: 20/47 ± 4.7 lines) and mean duration of disease 
61.0 ± 48.6 months. Twenty-four patients presented with bilateral disease (68.5%), 
and 11 had unilateral disease (31.4%). Of the total cohort, 29 patients (82.8%) had a 
history of choroidal neovascular membranes (CNV). 22 had unilateral and 7 patients 
bilateral CNV. No differences were observed in CNV characteristics or location among 
the study groups. In the current study, no patients had active CNV at EDI-OCT 
acquisition, or in the preceding three months. Eighteen patients (51.4%) were on 
immunosuppressive therapies (14 on oral steroids (40.0%), 3 on oral steroids plus 
second-line agents (8.6%), 1 on second-line agents (2.8%)), and 17 patients (48.6%) 
were no longer on treatment. No significant differences between typical and atypical 
disease were seen for baseline characteristics, CNV frequency, CNV location or 
treatment modality. (Table 3.4) 
 
3.4.3.2 Qualitative Analysis of Retinal and Choroidal Morphology 
In total, 142 PIC lesions were counted from the NIR fundal images. Of these, 90 
lesions (63%) were also captured by the 20° x 5° OCT scanning protocol and included 
in the qualitative analysis.  Among the three lesion patterns analysed, 46.6% of all PIC 
lesions (42/90) showed focal atrophy of the outer retina, in particular the 
photoreceptor inner segment/outer segment (IS/OS) junction, and RPE (Figure 3.1). 
This focal disruption was also associated with atrophic changes affecting the 
overlying outer nuclear and outer plexiform layers. 34.4% of PIC lesions (31/90) were 
seen to consist of sub-RPE deposits (Figure 3.1C), and 18.8% (17/90) consisted of 
localized RPE elevations  
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Table 3.4. Baseline demographic and clinical characteristics of all patients, 
and in those with a diagnosis of punctate inner choroidopathy. 
  TOTAL TYPICAL 
PIC 
ATYPICAL 
PIC 
p value 
n  35 (100%) 16 (45.7%) 19 (54.28%)  
Age (years)  40.1+/-9.4 37.7+/-8.8 42.1+/-9.7 0.17 
Gender (M:F ; %Female)  6:29 (82.9%) 3:13 (81.3%) 3:16 (84.2%)  0.82 
Refraction (diopters) Total -4.5+/-4.1 -3.2+/-2.7 -5.6+/-4.9 0.09 
No HM -2.1+/-2.4 -2.3+/-1.8 -1.9+/-3.1 0.65 
HM -9.5+/-2.1 -8.0+/-1.4 -9.8+/-2.1 0.29 
BCVA( LogMAR)  0.33+/-0.47 0.17+/-0.27 0.45+/-0.52 0.06 
Duration of Disease 
(months) 
 61.0+/-48.6 43.6+/44.5 75.7+/-50.1 0.06 
Disease Inactive  35 NA NA NA 
Laterality Unilateral 11 (31.4%) 5 (31.2%) 6 (31.5%) 
0.98 
Bilateral 24 (68.5%) 11 (68.7%) 13 (68.4%) 
CNV Total 29 (82.8%) 14 (87.5%) 15 (78.9%) 0.50 
Unilateral 22 (75.8%) 10 (71.4%) 12 (80.0%) 
0.11 
Bilateral 7 (24.1%) 4 (28.5%) 2 (20.0%) 
CNV location Extrafoveal 7 (24.1%) 3 (21.4%) 4 (26.6%) 
0.86 Juxtafoveal 13 (44.8%) 6 (42.8%) 7 (46.6%) 
Subfoveal 9 (31.0%) 5 (37.5%) 4 (26.6) 
TreatmentA No 17 (48.6%) 7 (43.7%) 10 (52.6%) 
0.65 
Steroid 14 (40.0%) 6 (37.5%) 8 (42.1%) 
Steroid + ImmunosupB 3 (8.6%) 2 (12.5%) 1  (5.3%) 
Immunosup 1 (2.8%) 1 (6.2%) 0  (0.0%) 
Anti-VEGFC 16 (45.7%) 9 (56.3%) 7 (36.8%) 0.25 
(PIC= punctate inner choroidopathy, M= male, F= female, HM= high myopia, defined as refraction ≥-6 
diopters, BCVA= best corrected visual acuity, logMAR=logarithm of the minimum angle of resolution, 
CNV= choroidal neovascularization; A Treatment refers to systemic treatment at the moment of the 
scan (steroids/immunosuppresives) and previous intravitreal treatments with Anti-VEGF drugs; B 
combined treatment with systemic steroids + immunosuppressants; C>3 months free-of-injections 
before OCT scan date). Significance level: p<0.05. (NS: Not significant). 
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 (Figure 3.1A). In the subgroup analyses, untreated eyes had a trend towards 
a greater number of sub-RPE deposits (47.0% [16/34] untreated vs 26.7% [15/56] 
treated, p=0.05). Conversely, a trend towards a greater presence of outer retinal 
atrophy was observed in treated eyes (35.3% [12/34]) compared to untreated eyes 
(53.6% [30/56], p=0.09).  
Focal hyperreflective dots were seen in Sattler’s medium vessel layer in 68.5% 
(24/35) of patients (Figure 3.1 D). They were most commonly located directly 
beneath, or adjacent to, PIC lesions, but were also observed in areas distant to 
lesions (Figure 3.1 A to C). These hyperreflective dots appear to be located adjacent 
to vessel walls or on the luminal surface, and were not observed within the 
hyporeflective luminal vascular spaces (Figure 3.1 B). No hyperreflective dots were 
noted in Haller’s large vessel layer. This feature was more common in eyes with 
typical PIC (87.5% [14/16]) compared to atypical PIC (57.9% [11/19]) but this 
difference did not reach statistical significance level (p=0.05). Focal areas of thinning, 
spanning large and medium vessel layers of the choroid, were observed in 17.1% 
(6/35) of the eyes (Figure 3.1 E). In all cases, these areas were associated with PIC 
lesions containing outer retinal layer disruption and atrophy. 
 
3.4.3.3 Quantitative Analysis of Retinal and Choroidal Morphology: 
The mean retinal thickness was 256.04 ± 32.9 µm, whereas the mean choroidal 
thickness was 210.52 ± 103.44 µm. Mean retinal volume was 10.16 ± 1.41 mm3, and 
mean choroidal volume was 8.13 ± 3.60 mm3.  
The retina was significantly thinner in eyes with atypical (243.73 ± 35.36 µm) 
compared to typical PIC (270.66 ± 23.22 µm)(p=0.01). When high myopic eyes were 
excluded from analysis, this difference remained significant (246.65 ± 30.2 vs 270.05 
± 24.6 µm; p=0.04). In the subgroup analysis by refractive status, the retinal volume 
was significantly lower in low myopic than high myopic eyes (9.86 ± 1.20 mm3 vs 
10.90 ± 1.67 mm3 respectively, p=0.04). 
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The choroid was significantly thinner in eyes with atypical PIC (177.77 ± 
100.98 µm) versus eyes with typical PIC (249.42 ± 95.10 µm) (p=0.03). This difference 
was maintained in Haller´s large vessel layer (114.96 ± 61.93 µm in atypical PIC versus 
167.68 ± 65.92 µm in typical PIC, p=0.02). However, when high myopic eyes were 
excluded from analysis, this difference was not significant (229.09 ± 98.96 vs 268.85 ± 
84.75 µm, p=0.29). In eyes with high myopia, the choroid, Haller’s, and Sattler’s 
layers thickness and volume were significantly lower compared to eyes with low 
myopia (p<0.001). 
 
3.4.3.4 Clinical Significance of OCT-derived Parameters: 
A highly significant correlation was observed between the refractive state of eyes 
with PIC and both foveal and macular choroidal thickness (r= 0.72, p<0.001; r= 0.73, 
p<0.001) This correlation was also maintained with the choroidal volume 
measurements (r= 0.72, p<0.001; r= 0.60, p<0.001). After excluding high myopic eyes, 
disease duration showed a significant negative correlation between retinal thickness 
and volume measurements when controlling by age and refraction (r=-0.53, p=0.01; 
r=-0.47, p=0.04). A significant negative correlation was observed between foveal 
retinal thickness and BCVA (r=-0.40, p=0.03) and volume (r=-0.40, p=0.02).  
 
3.4.4 Vitreous inflammation 
3.4.4.1 Baseline Characteristics 
In the main study group (patients with uveitis and evidence of vitreous haze), 30 
patients (30 eyes) were evaluated in our study. In the control group, 30 patients (30 
eyes) were also evaluated, consisting of 12 patient (12 eyes) with uveitis but without 
vitreous haze, and 18 patients (18 eyes) without any evidence of uveitis or 
vitreoretinal disease. Clinical details of patients included are summarized in Table 
3.5. 
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Table 3.5. Baseline demographic and clinical characteristics of all patients, 
and in those assessed for vitreous inflammation. 
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3.4.4.2 OCT-derived Measurements of Vitreous Intensity: 
OCT-derived measurements of vitreous intensity for each group (“uveitis with 
vitreous haze” versus “uveitis with no vitreous haze” versus “normal eyes”), and for 
each grade of vitreous haze are summarized in Figure 3.8. A significant difference in 
VIT/RPE-Relative intensity was found between those eyes with “uveitis with no 
vitreous haze” or “normal eyes” (median=0.0767, interquartile range (IQR)=0.0478), 
when compared those with “uveitis with vitreous haze” (median=0.150, IQR=0.135) 
(p=0.0001), and between each grade of vitreous haze (p=0.001).  
 
 
 
Figure 3.8. Box plots illustrating Vitreous (VIT)/Retinal Pigment Epithelium 
(RPE) 
Relative Intensity measurements in “uveitis with vitreous haze” versus “uveitis with no vitreous haze” 
versus “normal eyes”. The horizontal lines within each box represent the median for each group; the 
ends of the boxes are the upper and lower quartiles, and the whiskers represent minimum and 
maximum values. 
 
167 
 
 
A significant correlation was found between VIT/RPE-Relative Intensity and 
clinical vitreous haze scores (r=0.566, p=0.0001, Spearman non-parametric testing), 
VA (r=0.573, p=0.0001), and clinical AC cells (r=0.613, p=0.0001) and AC flare scores 
(r=0.385, p=0.003). Of note, as the strength of the relationship between variables 
increases, so does the value of the correlation coefficient (r), with a value of 1 
showing a perfect relationship. When evaluated in a step-wise multivariable model 
examining factors governing media clarity (i.e. AC cells and flare) and other ocular 
characteristics such as VA and disease etiology (i.e. birdshot chorioretinopathy, 
Behçet's disease, and idiopathic panuveitis), location of inflammation (i.e. anterior, 
intermediate, posterior, and panuveitis), VIT/RPE-Relative Intensity remained 
independently associated with clinical vitreous haze scores (R2-adjusted=0.292, 
p=0.0001).  
 
3.4.4.3 Reproducibility of Vitreous Grading: 
Bland-Altman plots were used to illustrate the agreement between graders and 95% 
LoA are presented in Table 3.6 and Figure 3.9. It is expected that the 95% LoA include 
95% of differences between the two graders and this is represented for visual 
judgment in the Bland-Altman plot. The smaller the range between these two limits 
the better the agreement is.  
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Figure 3.8. Bland-Altman plot of difference in VIT-RPE-Relative Intensity 
Measurements obtained by Graders 1 and 2, versus the mean VIT/RPE-Relative Intensity score 
obtained by Graders 1 and 2. The solid horizontal line corresponds to the mean difference (−0.002 
arbitrary units) while the dashed horizontal lines correspond to the 95% limits of agreement (−0.019 to 
0.016 arbitrary units). 
 
Table 3.6. Reproducibility of VIT/RPE-Relative Intensity values in Patients 
with Vitritis and Controls as assessed by Bland-Altman plots. 
 
Interobserver 
Mean 
Difference  
95% CI 95% Limits 
of 
Agreement  
 
VIT/RPE - Relative intensity 
 
   Vitritis (n=30) -0.00164 -0.00593 to 
0.00264 
0.0450 
All Controls (n=30) -0.00158 -0.00373 to 
0.000566 
0.0226 
          Normal Eyes (n=12) 0.00301 -0.00193 to 
0.00795 
0.0305 
          Uveitis without vitritis 
(n=18) 
0.000633 -0.00129 to 
0.00255 
0.0151 
ALL (n=60) -0.00161 -0.00394 to 
0.000711 
0.0353 
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To examine whether the 95% LoA were significantly different between observers in 
controls and uveitic eyes, with and without vitritis, the variance of the interobserver 
measurement differences were calculated and the F statistic (variance ratio) 
presented (Table 3.7). The variance ratios between graders were not statistically 
significant in all groups, which suggest that VIT/RPE relative intensity measurements 
were reproducible in both controls as well as in eyes with vitritis. However, there was 
a trend towards a higher 95% LoA in eyes with vitritis compared to controls (0.0450 
versus 0.0226 respectively). 
 
Table 3.7. The Variance Ratio (F Statistic) of Intergrader Differences in 
VIT/RPE-Relative Intensity Measurements in Eyes with Vitritis and 
Controls. 
 
 
F Test p value 
   Vitritis (n=30) 1.06 0.88 
Controls (n=30) 1.07 0.86 
          Normal Eyes 1.00 1.00 
          Uveitis without vitritis 1.07 0.90 
ALL (n=60) 1.04 0.87 
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3.5 Discussion: 
 
3.5.1 Retinal and choroidal morphology in idiopathic panuveitis 
In this cross-sectional study, OCT images obtained from patients with idiopathic 
panuveitis were examined along with the effects of co-pathology, duration of disease 
and different treatment regimes. Their impact on visual acuity as well as OCT-derived 
parameters of the retina and choroid were analysed. Novel segmentation protocols 
for the choroidal sub layers were also described, which if confirmed in future 
longitudinal studies, may be a useful tool for the diagnosis and monitoring of 
inflammatory retinal disease. 
Choroidal thickness at the posterior pole, based on histopathological studies, 
has been historically reported as 220 μm.(332) However, it has been noted that 
fixation techniques can cause tissue shrinkage and underestimate the true thickness 
of the choroid. OCT-derived measurements of choroidal thickness, overcomes these 
artefacts, and has been reported to range from 262 to 332 μm.(270, 333, 334) Table 
3.2 summarises the normative values for normal eyes and those with panuveitis. The 
mean choroidal thickness in our patient cohort was 234 μm, thinner than that 
observed in normal subjects. In the current study, we found a thinner mean Haller’s 
layer thickness, (168 μm) and a lower ratio of Haller’s to total choroidal thickness, 
(0.72 ± 0.09) suggesting that the reduction of choroidal thickness observed in eyes 
with idiopathic panuveitis, occurs mainly in this layer. 
Recent publications on small patient cohorts of posterior uveitis, include, 
Vogt-Koynagi Harada (VKH) disease (6 and 8 cases respectively), (296, 335) and 
multiple evanescent white dot syndrome (MEWDS) in 2 patients. (336) Both studies 
observed an increase choroidal thickness measurements, ranging from 273 μm to 
805 μm. (Table 3.2) This is likely because 12 of the 16 reported cases had active 
disease, compared to our patients who were all clinically inactive. Alternatively it 
might reflect different pathological mechanisms between diseases.  
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Choroidal ischaemia has been suggested as a common pathophysiological 
pathway in different uveitic entities, and may be an explanation for the thinning of 
Haller’s large vessel layer observed in our study. The evidence for choroidal 
hypoperfusion, has been historically derived from studies using ICGA. In VKH, the 
choroidal stroma is thought to be the locus of inflammation. The associated ICGA 
features include delayed filling, loss of definition of stromal choroidal vessels, and a 
generalised disturbance of the choroidal vasculature.(337, 338) Similar features have 
been described in multiple inflammatory ocular conditions such as MEWDS, acute 
posterior multifocal placoid pigment epitheliopathy, sarcoid, Behçet's related uveitis, 
birdshot chorioretinopathy, and multifocal choroiditis.(339-344) 
There has been limited evidence from OCT studies, with only two reports 
implicating choroidal vessel damage in eyes with uveitis. The first study described a 
changes in Sattler’s medium vessel layer in 12 patients with VKH, and attributed this 
to structural changes in choroidal vessels.(296) The second study described a 
reduction of choroidal hyper-reflectivity using a longer wavelength swept source OCT 
(better penetration to the choroid) in a patient with multifocal choroiditis and 
panuveitis.(345) In our patient cohort, we similarly found reduced hypo reflective 
spaces and thinning occurring in Haller’s layer. We hypothesize that this reflects a 
loss of luminal spaces in the choroidal vasculature, and suggest Haller’s large vessel 
layer may be implicated in the pathophysiology of idiopathic panuveitis. These 
findings will need to be confirmed by immunohistopathological studies, which will be 
able to pinpoint the location of vessel wall damage, identify the nature of 
inflammatory infiltrate, and visualise vessel wall hypertrophy or fibrosis may shed 
some light into the aetiology of this disease. 
We observed no relationship between retinal or choroidal thickness with 
visual acuity. This is similar to previous studies in patients with posterior uveitis 
secondary to Behçet’s disease also found no correlation between choroidal thickness 
and visual acuity.(346) We did, however, observe a lower mean visual acuity in eyes 
with co-pathology such as cystoid macular oedema or epiretinal membrane. 
Furthermore, a relationship with visual acuity was identified when choroidal 
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thickness measurements were expressed as a ratio to retinal thickness. This suggests 
that the interplay between the retina and choroid, may be an important feature of 
uveitis-related visual loss. 
Limitations of our study include its retrospective nature and small sample size. 
Refractive error, a well-known confounder in studies of choroidal thickness, was not 
included in our data. However, we excluded eyes with greater than 6 diopters of 
ametropia from our study. Our cross-sectional study also does not provide any data 
regarding temporal changes, useful in a disease like Idiopathic panuveitis, which 
usually follows a chronic clinical course. Nevertheless, this study does provide novel 
analysis on OCT-derived parameters about a clinical entity that is poorly described in 
literature. 
In conclusion, patients with idiopathic uveitis were observed to have a loss of 
hypo reflectivity in Haller’s large vessel layer, and thinning of both Haller’s and the 
choroid as a whole. The ratio of Haller’s to retinal thickness was observed to 
correlate to visual acuity.  
 
3.5.2 Retinal and choroidal morphology in granulomatous panuveitis 
In this cross-sectional study, we assessed OCT-derived measurements of choroidal 
thickness, and its component Haller’s large and Sattler’s medium vessel layers, in 
eyes with sarcoid and TB-associated granulomatous uveitis. 
The ratio of Haller’s large to Sattler’s medium vessel layer was different in 
eyes with sarcoid compared to TB-associated uveitis. Although the median total 
choroidal thickness measurements were not different between both entities, the 
ratio of Haller’s to Sattler’s layers was significantly higher (37%) in TB (1.47 versus 
1.07 at the TMC). We speculate that this may reflect their different underlying 
pathogenesis. In 1976, Gass et al. in a clinicopathological correlative study of a 
patient with sarcoid posterior uveitis, found that lesions labelled as “focal choroiditis” 
were actually below the retinal pigment epithelium and not within the choroid.(347) 
Other studies have since confirmed these findings, observing that in sarcoid-
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associated uveitis, choroidal involvement is infrequent.(348, 349) This is in contrast 
to TB-associated uveitis where choroidal tubercles are commonly observed.(258, 
350) Furthermore, in a recent clinical study, it was observed that ocular TB in the 
posterior segment presents as a retinal vasculitis that not only predominantly affects 
venous structures, but also chorioretinal structures adjacent to involved vessels. In 
comparison, the classic feature of sarcoid-associated posterior uveitis, ‘candle wax 
drippings’, was found to be a periphlebitis primarily located in the inferior retinal 
periphery without adjacent vascular or choroidal involvement.(262) If future 
prospective studies confirm that the ratio of the sublayers of the choroid are indeed 
characteristic for either disease, EDI-OCT may prove a useful aid in the diagnosis of 
these granulomatous diseases. It should be noted that TB associated uveitis can have 
disparate retinal and choroidal manifestations and this study, with the relatively few 
cases available, cannot distinguish whether there are differences in choroidal 
thickness measurements according to the type of presentation. 
In this study, we observed an association between a thin choroid and poor VA 
at the TMC (p=0.004) but interestingly not the same degree of significance at the FCS 
(p=0.02). A possible explanation is that OCT images over the TMC cover a larger area 
compared to the FCS, and therefore more representative of the total choroidal 
thickness of the eye. It may be that occurrence of choroidal inflammation over 
extended periods ultimately leads to generalised choroidal atrophy and thinning, and 
it is this, rather than focal choroidal atrophy under the fovea which affects visual 
function. This raises the question as to whether choroidal thinning in chronic 
granulomatous disease is localised to the macula region or more widespread, 
especially since granulomatous uveitis can present with diffuse posterior segment 
signs.(259, 349, 351) In a recent study, extra-macular scans performed in eyes 
diagnosed with birdshot chorioretinitis demonstrated generalised choroidal thinning 
outside the macula.(271) Whilst factors including age and disease activity were well 
matched between the good (<0.3 LogMAR) and poor (≥0.3 LogMAR) visual acuity 
groups, other confounders are possible. 
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EDI OCT studies into other uveitic conditions such as Vogt-Koyanagi-Harada 
disease(276) and Behçet’s disease(352) have observed a thicker choroid in active 
compared to quiescent disease. A possible explanation for this observation is that in 
the presence of inflammation, the release of mediators such as prostaglandins causes 
blood vessels to dilate leading to increases in OCT-derived measurements of 
choroidal thickness.(353) This does not occur in the vessels of the retina as 
autoregulation maintains a constant perfusion pressure to the corresponding 
vascular tree.(354) However, in the highly vascular choroid no such autoregulatory 
mechanism is present.(355),(356) We hypothesize that the “spongiform” choroidal 
vasculature is highly reactive to changes in the inflammatory state of the immediate 
environment, with consequent changes to choroidal thickness measurements. 
Measuring choroidal thickness could therefore provide a non-invasive method to 
monitor disease activity within an individual over time. This would be important in 
addressing the difficult therapeutic question encountered in clinical practice - when 
and how quickly to taper immunosuppressive therapy, thereby allowing treatment to 
be better tailored to the individual patient.   
 
In this cross-sectional study, we observed a trend of a thicker choroid in active 
(median 336.8µm [IQR=272.3µm to 375.4µm]) compared to quiescent (median 
239.3µm [IQR=195.3µm to 330.9µm]) granulomatous uveitis (p=0.04) but this did not 
reach statistical significance at the stringent p≤0.004 level set to avoid the chance of 
type 1 errors. This might be explained by the observation that choroidal thickness is 
highly variable between individuals and is significantly dependent on variables such 
as age and sex which were recorded in this study and factors such as refractive error 
and axial length which were not recorded. However, looking for longitudinal changes 
within an individual may allow some of the natural choroidal variation between 
individuals to be accounted for.(357-360)  
Strengths of the study included the use of a validated segmentation protocol 
to analyse OCT images from patients with a relatively rare disease entity.(324) To the 
authors’ knowledge, this is the largest EDI-OCT study in granulomatous uveitis to 
175 
 
 
date. There are a number of limitations. Firstly, it included patients from a single 
tertiary referral centre that has a bias towards a more severe spectrum of disease. 
However, the data presented is likely to represent the patient cohort more likely to 
require immunosuppressive therapy and hence close monitoring. Secondly, the 
retrospective cross-sectional design carries inherent bias and longitudinal prospective 
studies involving larger patient cohorts will be required to confirm our findings. 
Thirdly, diagnoses were not all based on biopsy-proven cases. This reflects real world 
clinical practice. The clinical and laboratory diagnostic criteria, detailed in the 
methods section, have high specificity and sensitivity reported in the published 
literature.(313, 316) Fourthly, imaging with current OCT equipment was limited to 
the macula region, and as discussed above preliminary evidence suggests that extra-
macular scans may be more discriminatory for disease activity and visual function. It 
is likely that next generation OCT devices, with faster acquisition times will allow 
larger areas of the choroid to be assessed.(361) Lastly, we employed manual 
segmentation using custom software that is not currently available in the clinical 
arena. However, efforts are underway to provide automated choroidal thickness 
maps, similar to automated retinal thickness maps currently available, particularly 
with the coming next-generation OCT systems.(362)  
In conclusion, we observed that the ratio of Haller’s large to Sattler’s medium 
vessel layers was significantly higher in TB compared to sarcoid related uveitis, and 
there is a trend for the choroid to be thicker in active granulomatous uveitis. In 
addition, choroidal thinning was observed to be associated with reduced VA. These 
OCT-derived parameters of the choroid, if validated in larger prospective studies, may 
not only offer insights into diagnosis and visual prognosis for eyes with 
granulomatous uveitis, but also potentially be used to monitor disease activity within 
an individual over time or as an objective measure for clinical trials.  
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3.5.3 Retinal and choroidal morphology in punctate inner 
choroidopathy 
The aetiology of PIC is poorly understood. Although a genetic predisposition is 
thought to play a role (363), as with other white dot syndromes, the prevailing 
hypothesis is that of initial insult triggering an autoimmune response towards 
antigens in the outer retina and inner choroid. (364)(366)(354)(354)(356)(349) 
Previous studies have identified PIC lesions, located in the RPE, choriocapillaris, and 
in the inner choroid.(277, 279, 293, 365)  The natural history of the PIC lesions has 
been described as pale yellow spots, which evolve into deep, cylindrical, punched out 
scars with corresponding loss of tissue in the inner choroid, RPE and outer 
retina.(366) This is consistent with results obtained in the current study, where we 
observed that 46.6% of PIC lesions consisted of focal atrophy of the outer retina and 
RPE. In addition, 34.4% of PIC lesions consisted of sub-RPE hyperreflective deposits, 
and 18.8% of lesions presented as focal RPE elevations with underlying hyporeflective 
space. Other studies have suggested that this focal RPE elevation occurs in active 
disease.(294, 295) In our cohort of stable/inactive patients, this focal RPE elevation 
may be the presence of subclinical inflammation or reflect another 
pathophysiological process affecting the outer retina-RPE-inner choroid complex.  
In this study, we further examined choroidal morphology using EDI-OCT. In 
68.5% of patients, discrete hyperreflective dots were observed to be confined within 
the inner choroid. Previous studies using ICG have also shown involvement of this 
layer.(287, 365) It has been suggested that changes observed were indicative of 
choroidal vasculitis. It is possible that the inner choroidal hyperreflective clusters 
observed in our study reflect inflammatory changes in the choroidal vessel wall. This 
may include aggregation of inflammatory cells or pigment in the choroidal stroma. 
Histopathological studies will be required to confirm these speculations. In addition, 
focal thinning of the choroid (underlying PIC lesions) was also observed in our study. 
Studies carried out in other uveitic entities such as VKH disease have shown similar 
thinning during quiescent phase.(296, 367)  Lastly, we observed that patients with 
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greater duration of disease were found to have thinner retinas. This may reflect 
repeated inflammatory episodes or long-standing subclinical inflammations.  
In summary, the clinical value of OCT in evaluating patients with PIC was 
assessed. We suggest OCT may be used as a non-invasive tool for both qualitative 
and quantitative analysis of inflammatory lesions in these patients. 
 
3.5.3 Objective measurement of vitreous inflammation 
In patients with uveitis, the onset of inflammation commonly leads to permeation of 
the vitreous with inflammatory cells and protein-rich exudate.(368) These changes 
typically reflect the degree, and to an extent the location and character, of the 
underlying uveal inflammation. Vitreous inflammatory cells can be directly visualized 
using slit-lamp biomicroscopy and, more recently, using OCT.(304) However, in many 
cases of uveitis (e.g., pars planitis), vitreous cells may persist for extended periods 
even after resolution of their initiating inflammatory episode.(298) In contrast, 
protein-rich exudate is only seen in the presence of active inflammation. This exudate 
may also be seen on clinical examination in the form of vitreous “flare” (i.e., the 
scattering of light by fine particles suspended in solution as described by the Tyndall 
effect).(369, 370) As OCT is fundamentally a light scattering-based imaging modality, 
it is well suited to the visualization of this feature. Although OCT does not provide the 
exact composition of the vitreous compartment, higher vitreous signal intensity will 
be indicative of increased scattering of light and thus increased density of particles 
within the space. Conversely, lower vitreous signal intensity will reflect a relatively 
clearer vitreous composition with fewer suspended particles. 
 In this report, we first obtained an “absolute” measurement of vitreous signal 
intensity (“VIT-Absolute Intensity”), reflecting the mean intensity value for all image 
pixels contained within the vitreous compartment. In order to reduce the effects of 
OCT signal strength, anterior media opacities, and other confounding factors, we 
then compared this to a reference value (“RPE-Absolute Intensity”), and generated 
an optical density ratio with arbitrary units (“VIT/RPE-Relative Intensity”). The use of 
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OCT-derived optical density ratios has previously been described for the assessment 
of intra- and subretinal fluid.(305-310) In eyes with intraretinal fluid, increased signal 
intensity of cystoid spaces has been reported in diseases with active exudation (e.g., 
diabetic retinopathy) versus those without (e.g., cone dystrophies and idiopathic 
perifoveal telangiectasia).(306, 307) Similarly, subretinal fluid in eyes with 
neovascular age-related macular degeneration (AMD) shows an increased OCT signal 
intensity relative to that seen in central serous chorioretinopathy (a finding the 
authors hypothesize is related to increased breakdown of the outer blood-retinal-
barrier in the former condition).(308)  
In the current study, we demonstrate that: 1) VIT/RPE-Relative Intensity is 
significantly higher in uveitic eyes with known vitreous haze than in uveitic eyes 
without haze or in healthy controls, 2) VIT/RPE-Relative Intensity values are higher 
with each incremental increase in clinical vitreous haze score, 3) VIT/RPE-Relative 
intensity values show a significant, positive correlation with clinical vitreous haze 
scores, and 4) VIT/RPE-Relative Intensity scores can be calculated with a high degree 
of inter-grader reproducibility. These results are a preliminary, proof-of-concept, step 
in the validation of this OCT-derived biomarker as an outcome measure in uveitis. 
This OCT-derived biomarker has important theoretical advantages over the current 
gold standard in that it is objective (vs subjective), continuous (vs ordinal) and has a 
high level of inter-grader reproducibility. If validated in future studies, OCT-derived 
measures of vitreous inflammation may prove useful as an objective, quantitative, 
disease activity endpoint in clinical trials of posterior segment uveitis. One of the key 
limitations in such trials currently is the relatively poor ‘signal:noise ratio’ which 
renders a positive result unlikely except in the context of a highly effective treatment 
in a large-scale (and expensive) clinical trial. The reasons for this have been 
summarized elsewhere,(251) but include the lack of an objective outcome measure 
with a high degree of discrimination. If the OCT-derived measures described here are 
validated, and are demonstrated to robustly predict visual function and clinical 
benefit in patients with uveitis, it may be possible for trialists and regulatory bodies 
to adopt such a marker as a surrogate endpoint in clinical trials of this disease.(371, 
372) In this manner, OCT-derived measurements of vitreous inflammation may be 
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used to improve the sensitivity and efficiency with reductions in sample-size and cost 
for clinical trials in posterior segment uveitis.  
It should be noted that whilst this study demonstrated a statistically 
significant association of VIT/RPE-Relative Intensity with the NEI Vitreous Haze score, 
the correlation was relatively weak at r=0.566. It should be recognised that both 
these tools are imperfect surrogate measures for the ‘true’ gold standard of 
intraocular inflammation as manifest in the vitreous cavity, and thus discordance 
between the two indices may reflect the limitations of either. Limitations in this OCT-
derived vitreous reflectivity index will be explored further in subsequent studies and 
may be amenable to refinements in protocol, standardization in acquisition 
technique, and technical advances (discussed later). Some of the limitations in the 
NEI Vitreous Haze score have been assessed by Kempen et al.,(373) who noted an 
inter-observer agreement of k=0.53 (for exact agreement) and k=0.75 (for within 1 
grade) and by Davis et al.(301) Indeed, Davis et al., have addressed some of these 
issues by utilizing an extended nine-point graded photograph-to-photograph 
technique which was assessed in the MUST trial.(301) Similarly to our study, whilst 
they note excellent interobserver and intraobserver intraclass correlations 
(correlation coefficients 0.84 - 0.93), the correlation between the photographic and 
the NEI vitreous haze scores was much weaker (r=0.51; P<0.001). 
Our study has a number of strengths, combining detailed clinical assessments 
of ocular characteristics by uveitis specialists with novel, standardized qualitative and 
quantitative assessments of OCT images by a senior grader certified for image 
interpretation in clinical trials. Of note, our study was performed using standard 
volume scans obtained from the current generation of commercially available 
spectral domain OCT systems (i.e., without the need for specialized hardware). 
Although our study required the use of custom image analysis software employed at 
the Doheny Image Reading Center, similar forms of analysis are possible using free, 
publically available, image analysis tools (e.g., ImageJ, National Institutes of Health, 
Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html), or commercial 
software (Photoshop, Adobe Systems, San Jose, CA).(304, 310) As such, this form of 
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analysis may be applied retrospectively to any large-scale clinical trial of uveitic 
conditions where spectral domain OCT was employed. Although our study required 
manual segmentation of the vitreous boundaries on OCT images, development of 
automated segmentation solutions are unlikely to prove challenging (especially given 
the progress in recent years of automated analysis of more challenging morphology 
on OCT, such as choroidal neovascularisation (CNV)).(374-376) 
Our study also has a number of limitations. In particular, it involves cross-
sectional analysis of OCT image sets obtained from a small number of patients. In the 
future, longitudinal studies involving larger patient cohorts will be required to 
validate the clinical significance of our findings. Of note, no image sets were acquired 
using the EDI mode of the device – i.e., in all cases, the point of maximum imaging 
sensitivity was at the vitreoretinal interface rather than at the choroid, and only 
minimal B-scan averaging was performed.(322) In future studies, it will be interesting 
to examine the effects of increased B-scan averaging on VIT/RPE-Relative Intensity 
levels, and to determine whether the associated reductions in image speckle noise 
will result in increased accuracy of measurements.  
The design of the study was pragmatic in utilizing scans conducted under 
normal macular scanning conditions, rather than attempting to optimize for vitreous 
– for example, it is possible for the operator to increase the amount of vitreous 
imaged by pulling back on the joystick during image acquisition.(377) Even employing 
this technique, the depth of vitreous that can be imaged is still limited to the 
scanning range of the Spectralis OCT system (1.9 mm).(378) As a result, only the 
posterior aspect of the vitreous is directly visualized. Although this is a significant 
shortcoming for the assessment of vitreous cells, it may be less of a disadvantage 
when assessment is of diffuse vitreous permeation with protein-rich exudate. 
Moreover, the next generation of “swept source” OCT technology will allow for 
greatly increased scanning ranges.(379) In fact, the introduction of vertical cavity 
surface-emitting lasers (VCSEL) already allows “whole eye” OCT image sets with 
visualization of the vitreous in its entirety.(380) To date, these systems have only 
been used for simple applications such as ocular biometry;(381) their potential for 
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vitreous imaging in uveitic disease is intriguing, particularly if combined with 
measures such as VIT/RPE-Relative Intensity.  
In conclusion, in this pilot study, we describe a method for quantitative 
analysis of vitreous signal intensity on OCT. We apply this method to a cohort of 
patients with uveitis, both with and without vitreous haze, and to healthy controls. As 
a result, we describe a new OCT-derived biomarker: “VIT/RPE-Relative Intensity” with 
potential for use as an objective marker of disease activity in patients with uveitis. 
Measurements of this biomarker can be made using existing, commercially available 
OCT devices, both prospectively, and in image sets that have already been collected. 
The incorporation of automated vitreous measurements in commercial OCT software 
would allow use of this parameter in routine clinical practice. Moreover, assessment 
of the vitreous in patients with uveitis may be an important clinical application of the 
next generation of “whole eye” swept source OCT systems.   
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3.6 Chapter summary: 
 
In this chapter, novel methods for the assessment of inflammatory eye disease, in a 
clinical setting were examined.  OCT-derived images from four uveitic entities; 
idiopathic panuveitis, granulomatous uveitis, punctate inner choroidopathy, and 
vitritis, were qualitatively and quantitatively analysed. It was observed that by slight 
alterations in the way OCT images were acquired on commercially available devices; 
for example enhance depth imaging, extramacular scans, or vitreous imaging, it was 
possible in a clinical setting, to visualise ocular inflammation in far greater detail 
compared to conventional imaging techniques. Direct, in vivo visualisation of the loci 
of inflammation could be examined in the vitreous, retina, choroid, and furthermore, 
OCT images could be acquired across specific loci of inflammation. The non-invasive, 
rapid acquisition nature of OCT imaging lends itself to repeated scans and therefore 
longitudinal monitoring of inflammation. If confirmed and larger, prospective studies, 
these techniques may be used for not only the diagnosis of specific uveitic entities, 
but the assessment and monitoring of disease activity, and may be useful in 
individualising treatment strategies in the future. It may also be applied in the wider 
context, to visualise and assess inflammation in diabetic eye disease. 
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4. In vivo detection and monitoring of retinal inflammation 
 
4.1 Introduction:  
Resident and infiltrating leukocytes have an important role in sight-threatening 
diseases of the eye. Substantial evidence exists that activated or altered immune 
responses are not only present in uveitic syndromes (382), but also prevail in the 
form of parainflammation during age-related macular degeneration and diabetic 
retinopathy (383, 384), the two main causes of blindness in Western industrialised 
countries.  In these diseases the cellular components of inflammation can drive 
pathological angiogenesis causing sight threatening complications (385-388). A better 
understanding of the role of inflammation in pathological angiogenesis is not only 
essential for the development of disease modifying strategies but also for monitoring 
disease progression and assessing efficacy of treatments.  
The development of clinically viable imaging tools for in vivo visualisation of 
inflammation is a crucial step in this process. To date, live imaging of inflammation 
has been restricted to experimental animal models, with examples such as, magnetic 
particles - iron oxide and gadolinium chelates for magnetic resonance imaging, 
fluorescent nanoparticles which can be tagged with aptamers or peptides targeted 
against cell surface biomarkers, circulating factors or nucleic acid structures, or dyes 
such as Acridine orange - a known human carcinogen (389-393). The only application 
that is currently used to image inflammatory cells in humans is based on in vitro 
radionucleotide labelling of leukocytes from the patient’s own blood. Although this 
allows direct visualization of cell migration patterns, current imaging techniques do 
not allow sufficient resolution to track single cells (394).   
Here, we present the use of indocyanine green (ICG) for in vivo visualisation of 
myeloid cells in the mouse. ICG is a near infrared (NIR) fluorescence tricarbocyanine 
dye with a peak spectral absorption of 800-810 nm (in blood) that is approved by the 
US Food and Drug Administration (FDA) for clinical use. The introduction of ICG in 
ophthalmic angiography in the late 1960s was largely due to its minimal toxicity and 
favourable optical and biophysical properties (395). NIR light could penetrate the 
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ocular pigments of the eye such as melanin and xanthophyll, thereby allowing 
visualisation of the deep choroidal vasculature (not possible with conventional 
fluorescein angiography). In addition, its tendency for conjugation to plasma proteins 
meant that the dye did not readily leak from the fenestrated choriocapillaris (396).  
Despite the wide use of intravenous (iv) ICG, U.S. Food and Drug 
Administration approval, and good safety profile, there is limited evidence for its use 
in cellular imaging. This is probably due to its pharmacokinetic properties – ICG is 
rapidly removed from the circulation via hepatic clearance, and has a half-life of 
approximately 3-4 minutes, which precludes in vivo labelling of cells. However, we 
observed that by administering ICG as a depot injection, we could obtain 
reproducible labelling of peripheral CD11b+ circulating myeloid cells, establishing a 
novel method for in vivo tracking of these cells, at near single cell resolution as they 
invade the eye in response to inflammation and injury. Furthermore, we show in vitro 
evidence that human myeloid cells stain similarly which strongly supports the 
translation of this promising technique into clinical practice. 
Techniques for in vivo cellular imaging requires a biocompatible, non toxic 
agent, that is able to distinguish the resident macrophage population from invading 
circulating monocytes, allowing reproducible quantification of these cells. Our results 
clearly demonstrate that this can be achieved in mouse models by using a depot 
injection of ICG. Translation of ICG, which has been used clinically for over 50 years as 
an intravenous dye, to that of a depot preparation for use in humans, may be useful 
not only for monitoring ocular inflammation and pathological angiogenesis, but may 
also have applications further afield, for example, the detection of an immune 
response to more novel treatment strategies such as stem cell therapies or retinal 
implants. 
 
4.2 Aim: 
To develop a method to label and image myeloid cells infiltrating the mouse retina 
and choroid in vivo, using a Indocyanine green dye (ICG). The rationale for this 
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chapter is to develop a imaging biomarker for inflammation in murine models of 
where inflammation is well-established to play a role of disease pathology, in order 
to apply it to models of disease where the role of inflammation is less well 
understood. 
 
4.3 Materials and Methods: 
 
Technical acknowledgements: I would like to thank Dr Colin Chu, University College 
London for his assistance with Flow cytometry of murine splenic and blood cells.  
 
4.3.1 In vitro labelling of peripheral blood mononuclear cells and 
splenocytes with ICG. 
Mouse blood was drawn via cardiac puncture with a 0.5M EDTA-coated 23G needle, 
before either red cell lysis or Ficoll-gradient separation using Histopaque-1077 (Sigma 
Aldrich, UK) according to manufacturer’s guidelines. PBMCs were isolated from 
murine whole blood using Percoll-gradient separation. Mouse spleens were dissected 
and mechanical cell dissociation was performed in order to create single cell 
suspensions. The whole sample was passed through a 60μm cell strainer (Merck 
Millipore, Watford, UK) and washed with 1mL of PBS. The Eppendorf was centrifuged 
at 300g for 5 minutes and remaining cell pellet suspended in 6.25µg/mL ICG for 30 
minutes at room temperature. After the cells were stained with ICG, they were 
incubated with Fc-block (BD Biosciences, UK) before primary antibody staining at 
manufacturer’s recommended concentrations at 4°C for 20 minutes. PBMCs and 
splenocytes were washed and co-stained with CD45, CD11b, CD3 fluorescent 
antibodies. All antibodies were from BD Biosciences. Human PBMCs were isolated 
from 20mL whole blood using Ficoll-gradient. PBMCs washed and co-stained with 
CD45, CD11b, CD3 fluorescent antibodies (Miltenyi Biotech, Bisley, UK). 
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4.3.1.1 Optimisation of invitro ICG-labelling of peripheral blood mononuclear 
cells and splenocytes 
 
Human PBMCs were used for optimisation initially, in order to assess the 
concentration, timing of exposure, number of washes in phosphate-buffer saline, pH 
7.4 (PBS) that were required for cellular labelling with ICG. Serial dilutions of ICG 
were used and the most reproducible concentration, with the least indiscriminate 
labelling, was observed to be 6.25µg/mL. Cells were also labelled in room 
temperature and at 4 degrees Celsius with the former achieving optimal labelling and 
paradoxically minimal cell death. This was likely due to the length of time required for 
ICG-labelling at 4 degrees Celsius (60-90 min). Figure 4.1 showed a clear difference 
between control (Figure 4.1c’) compared to those incubated in 6.25µg/mL ICG for 30 
minutes at room temperature (Figure 4.1c). 99.4% of CD11b monocytes were stained 
with ICG using this protocol with 2 washes with PBS. In vitro staining of mouse PBMC 
yielded a lower percentage of monocytes stained with ICG. (Figure 4.2) After 
optimization, the largest proportion (43.3%) of CD45+ CD11b+ CD3+ cells staining 
was also achieved with 6.25µg/mL ICG for 30 minutes at room temperature. A similar 
protocol achieved optimal ICG-staining with splenocytes and reduction in proportion 
of cells labelled with serial dilutions of ICG. (Figure 4.3)  
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Figure 4.1. Gating strategy for in vitro labelling of human peripheral blood 
mononuclear cells (PBMCs).  
(a-d) Gating strategy to assess the proportion of CD11b-FITC+ CD45-PerCP+ cells stained by a 
concentration of 6.25µg/mL indocyanine green dye (ICG) when incubated for 30 minutes at room 
temperature. (a’-d’) represent the control sample where cells were incubated in phosphate-buffer 
saline, pH 7.4 (PBS)  under the same conditions. (c, c’) shows the proportion of CD11b-FITC+ CD45-
PerCP+ cells stained by ICG, and (d, d’) shows the proportion of all live cells stained by ICG.  
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Figure 4.2. Gating strategy for in vitro labelling of murine peripheral blood 
mononuclear cells (PBMCs).  
Gating strategy to assess the proportion of CD11b-FITC+ CD45-e450+ CD3- cells stained by a 
concentration of 6.25µg/mL indocyanine green dye (ICG) when incubated for 30 minutes at room 
temperature. The bottom panel represent the control sample where cells were incubated in 
phosphate-buffer saline, pH 7.4 (PBS)  under the same conditions. Histograms on the right show the 
proportion of CD11b-FITC+ CD45-e450+ CD3- cells stained by ICG compared to controls. 
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Figure 4.3. Gating strategy for in vitro labelling of murine splenoscytes  
Gating strategy to assess the proportion of CD11b-FITC+ CD45-e450+ CD3- splenocytes stained by a 
concentration of 6.25µg/mL indocyanine green dye (ICG) when incubated for 30 minutes at room 
temperature. The bottom panel represent the control sample where cells were incubated in 
phosphate-buffer saline, pH 7.4 (PBS) under the same conditions. Histograms on the right show the 
proportion of CD11b-FITC+ CD45-e450+ CD3- cells stained by ICG compared to controls. Bar chart 
showing the percentage of ICG-labelled cells with serial dilutions of ICG. 
 
190 
 
 
4.3.2 Flow cytometric analysis of ICG labelled cells 
ICG stained PBMCs, whole blood and splenocytes were analysed using a BD 
Bioscience LSRII flow cytometer as no commercial machine was available with a near 
infra-red laser for ideal excitation of ICG. Sub-optimal excitation by the 633nm red 
laser nonetheless still resulted in a reliable signal using a 780/60 bandpass filter. A 
minimum of 10,000 events was collected for each sample and fluorescence-minus-
one controls were used to determine the placement of gates. Medium or High flow 
rates were used. Compensation was performed using OneComp eBeads (eBioscience, 
San Diego, USA, 01-1111-42) and an ArC Amine reactive Compensation bead kit 
(Invitrogen Life Sciences, A10346) for the live-dead stain. Data was processed using 
FlowJo v10.1 (TreeStar. Ashton, Oregon, USA) 
 
4.3.3 Animal procedures 
All animals were handled in accordance with the UK Animals (Scientific Procedures) 
Act 1986. Female C57BL/6J mice (Harlan, UK) at seven to eight-weeks of age were 
used. For in vivo procedures, the mice were anesthetized with an ip injection of 
medetomindine hydrochloride (1 mg/kg body weight; Domitor; Pfizer Animal Health, 
New York, NU), and ketamine (60mg/kg body weight) in water. Post-procedure, 
anaesthesia was reversed by peritoneal injection of an equal volume of AntiSedan 
(Pfizer pharmaceuticals, USA). Mice were recovered overnight on heat mats and 
supplied with hydrated chow. Pupillary dilation was achieved with 1 drop of 1% 
Tropicamide (Bausch and Lomb, Surrey, UK).  
 
4.3.3.1 Induction of Endotoxin Induced Uveitis 
Female C57BL/6J mice (Harlan, UK) at eight-weeks of age received a single ip 
injection of 0.2mg of lipopolysaccharide (LPS) from Escherichia coli (Sigma-Aldrich, St 
Louis, MO, USA) in phosphate-buffered saline (PBS). 1mg ip bolus injection of ICG was 
given 24 hours prior to LPS treatment. Imaging was performed 48 hours later, at a 
previously determined time point where these is peak infiltration by myeloid cells. 
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4.3.3.2 Induction of laser choroidal neovascularisation 
In Female C57BL/6J mice (Harlan, UK) at seven to eight-weeks of age laser CNV was 
induced using a slit-lamp-mounted diode laser system (wavelength 680nm; Keeler, 
Windsor, UK). Laser settings used: 200 mW power, 100 ms duration, and 100µm spot 
diameter. Laser CNV lesions were applied at a distance of 3 disc diameters from the 
optic nerve avoiding any blood vessels. 
 
4.3.3.3 In vivo imaging 
Ocular imaging was performed using a scanning laser ophthalmoscope (SpectralisTM 
HRA, Heidelberg Engineering, Heidelberg, Germany). A 55° field of view lens was used 
and a mean of 100 consecutive frames was taken for each image. In order to visualize 
ICG-labelled cells, a near-infrared filter (790 nm diode excitation laser and 800 nm 
long-pass filter) was used. Cell labelling was achieved with various doses (1mg to 
0.0125mg) (Figure 4.6) of 5mg ICG (Pulsion Medical Systems AG) dissolved in 5mL of 
water and administered 3 days prior to laser induction of CNV, ip injection of LPS, 
imaging of the EIU model. The different routes of administration are summarized in 
Figure 4.7. To assist the identification of laser CNV lesions, infrared-reflectance 
imaging was performed with a 820 diode excitation laser and no barrier filter. For 
autofluorescence imaging and fluorescein angiography, a blue-light filter (488 nm 
solid state excitation laser and 500 nm long-pass filter) was used. Fluorescein 
angiography was performed 1 week after laser CNV induction with an ip injection of 
0.2 mL fluorescein sodium (2%). Images were acquired at 90 seconds and 7 minutes 
after injection. 
 
4.3.3.4 Quantification of ICG positive cells in the retina 
Images were exported from the Heidelberg eye explorer version 1.7.1.0. and 
processed in Adobe Photoshop CS5 (Adobe Systems Incorporated, San Jose, USA). 
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Details of image processing and quantification can be found in the results section and 
Figures 4.4, 4.5. 
 
4.4 Results: 
 
4.4.1. In vitro labelling of peripheral blood mononuclear cells (PBMCs) 
and splenocytes with ICG.   
To establish whether ICG can label circulating leukocytes we incubated whole blood 
with the dye in vitro for 30 minutes at room temperature. Visual inspection of a 
blood smear from human blood by fluorescent microscopy revealed a small 
population of fluorescent cells in the NIR channel (Figure 4.4, A, B). Next we exposed 
PBMCs isolated from human and mouse blood, and mouse splenocytes to ICG (30 
minutes at room temperature) and then analysed dye uptake and cell identity by flow 
cytometry. In human PBMCs, whilst many cells stained slightly with the dye, 6.5% (SD 
+/- 1.3%) of all cells were strongly stained with ICG (Figure 4.4, C, D). In this strongly 
stained population 90% were CD45+ CD11b+, suggesting ICG is primarily taken up by 
myeloid cells. Similarly, incubating mouse PBMCs with ICG strongly labelled 1% (SD 
+/- 0.3%) of cells and 64% of ICG+ cells were CD45+ CD11b+ (Figure 4.4, E, F). When 
mouse splenocytes were used for the same experiment 10.3% (SD 0.7%) of cells were 
labelled by ICG, of which 58% were CD45+ CD11b+ (Figure 4.4, G, H). 
We observed that although the proportion of ICG-stained cells increased 
when incubated in higher temperatures and concentrations of ICG, there was an 
increase in non-specific staining. We identified that a 30-minute incubation of ICG at 
a concentration of 6.25µg/mL at room temperature achieved reproducible staining of 
cells. Furthermore, we identified that the minimum dose in which some stained cells 
could be detected was 1.6µg/mL, although 5µg/mL was required for reliable and 
reproducible staining. For comparison, the 5mg ICG dose used in ophthalmic clinic 
equates to a plasma concentration of roughly 1.5µg/mL in an adult human. In 
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summary, the specificity of ICG-binding to PBMCs in vitro was dependent on 
concentration, ambient temperature, and period of incubation.  
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Figure 4.4. In vitro labelling of peripheral blood mononuclear cells (PBMCs) 
and splenocytes in human and mouse.  
(A) Blood smear of human blood incubated in a concentration of 6.25µg/mL indocyanine green dye 
(ICG) for 30 minutes at room temperature. A small proportion of cells stained with ICG were visualized 
on the near-infrared channel at 10X magnification and (B) 20X magnification. (C, D) An example of 
detecting ICG-stained human PBMCs by flow cytometry reveals labelling in around 5% of cells (mean 
6.5%, SD +/- 1.3%, N=4). (E, F) In mouse PBMCs a smaller proportion of ICG-labelled cells were 
detected (mean 1%, SD +/- 0.3%, N=4), (G, H) whereas mouse splenocytes labelled more readily with 
ICG (mean 10.3%, SD +/- 0.7%, N=4). (I to K) show the gating strategy used to identify ICG-stained 
CD45+ CD11b+ murine PBMCs, and (M-O) ICG-stained CD45+ CD11b+ CD3- murine splenocytes. (K, O) 
represent the forward and side scatter back gates. 
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4.4.2 In vivo labelling of infiltrating leukocytes by ICG.  
After establishing that ICG can label myeloid cells in vitro, we proceeded to test 
whether these cells can be labelled by ICG in vivo. We administered ICG to C57BL/6 
mice that were used in three different retinal disease models, known to have 
substantial leukocytic (including monocyte/macrophage) infiltration into the retina. 
The first model was endotoxin-induced uveitis (EIU), induced by systemic delivery of 
lipopolysaccharide (LPS) from Escherichia coli. A previous study has detected acridine 
orange labelled leukocytes in the subretinal space/deep retina, 2 days after LPS 
injection (187). In our study, animals were first injected with ICG (1mg) by 
intraperitoneal (ip) injection and after 3 days with LPS. In the subsequent days we 
found that ICG labelled cells were detectable in the retina in vivo using a fluorescence 
scanning laser ophthalmoscope in the ICG channel (near infrared).  The number of 
labelled cells peaked at 2 days after LPS administration (5 days after ip ICG, Figure 
4.5, A, B), with a weaker signal at 1 day and 4 days after LPS (not shown). No signal 
was seen in the fluorescein channel (FA), indicating that the ICG signal did not derive 
from autofluorescence. Control animals that were only injected with ICG but not with 
LPS showed only a few sporadic ICG positive cells (Figure 4.5, C, D). This suggests low 
levels of peripheral cells trafficking in the normal retina, as previously inferred via 
flow cytometric analysis (397, 398), which dramatically increases after LPS 
stimulation.  
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Figure 4.5. In vivo labelling of infiltrating leukocytes in a murine model of 
ocular inflammation. 
 (A) Inflammatory infiltration into the deep retina/choroid in an endotoxin-induced uveitis (EIU) eye, 
imaged with a scanning laser ophthalmoscope. In the ICG channel (ICG) white dots were visualized 
after ip injection of ICG (5 days prior to imaging), and induction of systemic inflammation (ip LPS 
injection 2 days prior to imaging). (B) Image of the same eye taken in the fluorescein channel (FA) 
shows no white dots. (C) A control mouse that only received ip ICG (3 days prior to imaging) but no 
LPS. Imaging in the ICG channel showed only a few sporadic ICG-labelled cells suggesting low level 
circulation of myeloid cells into the retina. (D) The same eye shows no signal in the FA channel.   
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Figure 4.6. In vivo labelling of infiltrating leukocytes in a laser-induced 
choroidal neovascularisation (CNV) murine model. 
 (A) Scanning laser ophthalmoscopy in the ICG channel showed no signal in an animal that received 
laser burns but no ICG. (B) In an animal which received ip ICG and laser simultaneously fluorescence is 
observed in retinal vessels and laser lesions, without obvious leakage of ICG into the surrounding 
retinal tissues. (C) An animal which received ip ICG (10 days prior to imaging) and laser burns (7 days 
prior to imaging) shows accumulation of ICG-labelled cells in and around laser lesions. (C’) Magnified 
image of laser lesion and surrounding cells shown in C. (D) 3 days later, in the same eye (as shown in C) 
ICG intensity was reduced (13 days after ip ICG) (D’) Magnified image of laser lesion and surrounding 
cells shown in D. (E) In an animal that received six laser lesions (7 days prior to imaging) and ip ICG (10 
days prior to imaging) ICG-labelled cells accumulated in and around all six laser lesions. (F, G) 
Corresponding fluorescein angiography (FA channel) of the superficial retina (F) and deep 
retina/choroid (G) taken 10 minutes after ip injection with fluorescein shows that only 2 of six laser 
lesions had developed choroidal neovascularisation, and none of these lesions display obvious 
fluorescein dye leakage, suggesting that inflammatory cellular infiltration occurs independently of 
neovascularisation.  
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The second model was the laser-induced choroidal neovascularisation (CNV) 
model, a widely used model to study pathological angiogenesis in the retina (399). 
The vascular response in this model is accompanied by an accumulation of infiltrating 
leukocytes in the laser lesion from the circulation and from within the retina (400, 
401). We hypothesised that the infiltrating leukocytes can be visualised by first 
labelling cells with ICG in the periphery and then inducing the lesion. Since laser 
injury can induce autofluorescence we first imaged laser-lesioned animals without 
ICG. In the ICG channel, no fluorescence was detected in the lesion (Figure 4.6, A). 
Next, we tested whether administration (ip) of ICG immediately after laser would 
result in ICG leakage into the retina. Although ICG could be visualised inside the 
retinal vasculature and laser lesions, overt leakage of ICG into the retina was not 
apparent (Figure 4.6, B). Since ICG is rapidly cleared from the circulation (within 
minutes in humans) we reasoned that administering ICG 3 days before laser should 
be sufficient for minimizing any ICG in the circulation that may directly leak into the 
retina from the blood stream and label resident retinal macrophages. Consistent with 
this, ICG could no longer be detected inside blood vessels 3 days after ICG injection 
(not shown). 7 days after laser (10 days after ICG) we observed a marked aggregation 
of clearly labelled cells in and around the laser lesions (Figure 4.6, C, C’). After a 
further 3 days (10 days after laser) the signal started to subside (Figure 4.6, D, D’). 
The invasion of ICG positive cells was a general response to laser injury and 
independent of neovascularisation. This is illustrated by an example shown in Figure 
4.6, E. Here 6 laser lesions were applied. Although all of them accumulated ICG 
positive cells, only 2 lesions showed signs of neovascularisation based on fluorescein 
angiography (Figure 4.6, F, G).  
We further tested whether cellular infiltration around the laser-induced CNV 
lesion could be monitored over time. As before, ICG was administered ip 3 days prior 
to laser, and animals were imaged sequentially 2, 5 and 8 days after laser (Figure 
4.7). The number of ICG-labelled cells in and surrounding the CNV lesion could be 
observed qualitatively to increase over time (Figure 4.7, C, D, E). We attempted to 
quantify these changes by using image analysis software (ImageJ) to count cells in 
thresholded images of CNV lesions (Figure 4.8); a method we have used successfully 
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for quantifying ICG-labelled cells in the EIU model. However, due to the narrow range 
of intensity values and the high number of cells within each lesion, it was not possible 
to visualize individual cells overlying CNV lesion. We therefore assessed the mean 
intensity values for a given pixel area using histograms in order to reproducibly 
quantify cellular infiltration in CNV lesions (Figure 4.8, G). Using this method, we 
demonstrate that ICG-labelled cellular infiltration can be quantified and monitored 
over time (Figure 4.7, B, C’, D’, E’). 
Because ICG is routinely used in clinical practice, we compared the dosage 
and delivery routes normally used in humans (5mg iv bolus injection) with our mouse 
protocol (1mg ip bolus injection). We reduced the ICG in a stepwise fashion from 1mg 
to 0.0125mg per mouse (the latter roughly equates to the human dose in current 
ophthalmic use).  Invading cells could still be readily detected after administration of 
0.5mg ICG ip but at 0.25mg they were fainter. With progressively reduced amounts of 
ICG (0.125mg, 0.05mg, 0.025mg and 0.0125mg), the lesions were faintly fluorescent 
but individual cells could no longer be detected (Figure 4.9). We also tested different 
delivery routes and found that ip injection was most efficient at labelling cells. A 
subcutaneous depot (1mg) produced weaker labelling, but individual cells could still 
be detected, whereas iv (1mg) delivery produced only very faint staining. Oral 
administration (by gavage or in drinking water) (n=6) did not lead to any labelling 
(Figure 4.10). 
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Figure 4.7. In vivo quantification of laser-induced CNV related infiltration. 
 (A) ICG was injected intraperitoneally at day 0 before laser-CNV induction at day 3 in C57BL/6 mice. 
Imaging in the ICG channel was performed on day 5, 7 and 10, (C-E) visualising increasing cellular 
infiltration in and surrounding the laser-CNV lesion. (B, C’-E’) We demonstrate that the mean intensity 
values and standard deviations can be quantified over a given area and show an increase in 
inflammation over time. The mean intensity value of the lesion at day 5 is represented by the black 
histogram (C’), day 7 the superimposed light grey histogram (D’) and day 10 the superimposed 
medium grey histogram (E’).  
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Figure 4.8. Quantification of ICG-labelled cells. 
Methods for the quantification of indocyanine green (ICG)-labelled cells in the laser induced choroidal 
neovascularisation (CNV) murine model were assessed 10 days after ip ICG and 7 days after laser 
(schedule shown in E). (A) Autofluorescence imaging in the FA channel shows the laser-induced CNV 
lesions, and (B) fluorescein angiography shows the vascular response. (C) Images of ICG-labelled cells 
in and around CNV lesions were acquired in the ICG channel. (D) An example of grey level thresholding 
demonstrates that individual cell counts are not possible with this approach. (F) An inverted image of 
(C) was used to quantifying (G a-e) ICG-labelled cellular infiltration by the use of histograms. This 
method could reproducibly quantify the mean intensity of each lesion for the purpose of tracking 
changes over time. Scale-bars = 1.5mm. 
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Figure 4.9. ICG dosing for the purpose of cellular labelling. 
The doses required for cellular labelling were tested in the laser induced choroidal neovascularisation 
(CNV) murine model. (A) The experimental protocol is shown diagrammatically with intraperitoneal 
(ip) indocyanine green (ICG) administered at day 0, laser-CNV induction at day 3, and subsequent 
imaging at day 10. (B) Table showing ICG doses in a stepwise reduction in mice from 0.5mg to 
0.0125mg in the left column, and the estimated equivalent human dose in the right column. (C, D) A 
deep retinal/choroidal image of animals that received 0.5mg and 0.25mg of ip ICG respectively. 
Although ICG-labelled cells can be detected, they were fainter compared to the higher dose of 1mg 
used in previous experiments (not shown). (E-H) A deep retinal/choroidal image of animals that 
received 0.125mg, 0.05mg, 0.025mg, 0.0125mg of ip ICG respectively. In these further dose 
reductions, CNV lesions were faintly fluorescent but individual cells could no longer be detected. 
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Figure 4.10. ICG dosing for the purpose of cellular labelling. 
Route of administration of ICG for the purpose of cellular labelling. Different delivery routes for ICG 
were tested in the CNV model. (A-C) 1mg of ICG was administered via the intraperitoneal, 
subcutaneous, and intravenous (tail vein) route at day 0 before laser-CNV induction at day 3 and 
imaging at day 13 respectively. (D, E) 1mg of ICG was given by daily oral gavage and the equivalent 
added to the drinking water for 7 days respectively, before laser-CNV induction, and subsequent 
imaging 10 days later. The intraperitoneal route of administration (A) was the most effective for 
cellular labelling. Faint labelling could be detected with the subcutaneous route (B) but not with the 
intravenous (C), or oral routes of administration (D, E). 
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4.4.3 Characterizing in vivo ICG-labelled cells 
In order to identify what cell types are labelled by ICG we analysed PBMCs and 
dissociated spleen by flow cytometry 72 hours after ICG administration (1mg ip). In 
control animals isolated PBMCs did not show any ICG signal, whereas PBMCs from 
ICG injected animals contained a small population (mean=0.74%, SD=0.31%, range 
0.47 to 1.01%) of strongly labelled ICG+ cells (Figure 4.11, A). Of these, a mean of 
75.9% (SD=9.64%) also stained for CD45+ CD11b+ (not shown). Similarly, the spleen, 
which is known for its role as a reservoir for circulating monocytes, contained a larger 
population of ICG-labelled cells (mean=2.42%%, SD=1.22%, range=0.86 to 3.48%), 
compared to circulating PBMCs (Figure 4.11, B). We observed that a mean of 70.1% 
(SD=6.66%) of the CD45+ CD11b+ splenocytes were stained with ICG. 
These findings reinforce our in vitro data showing that ICG is predominantly 
taken up by CD45+CD11b+ monocytes/macrophages. However, it also highlights that 
ICG may stain other inflammatory cells. We observed in our in vivo experiments that 
a very small proportion of CD4, CD8, and CD20+ cells which we included in our 
exclusion ‘dump’ channel (R-Phycoerythrin) were also stained with ICG. Furthermore, 
dissection of the mice 7 days after ICG ip revealed “green” staining of lymphatic 
tissue in the thoracic cavity (Figure 4.12, A, B), mediastinal lymph nodes (Figure 4.12, 
C), thymus (not shown) and the greater omentum in the abdominal cavity (Figure 
4.12, D, E, F). This suggests that inflammatory cells in the circulation, most likely both 
monocytes and lymphocytes that continuously circulate between the bloodstream 
and lymphoid organs can be labelled with ICG. 
To further test the identity of ICG positive cells invading the retina in the 
laser-induced CNV model we used an in vivo staining protocol. 7 days after laser (and 
10 days after ip ICG) the retina was imaged (Figure 4.13, A, B, C). Immediately after 
imaging a fluorescently labelled (FITC) antibody against CD11b was injected (iv). Over 
the course of 30 minutes this labelled a population of cells that spatially matched the 
ICG labelled cells (Figure 4.13, D, E, F). The CD11b signal was weaker than the ICG 
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signal and there was not a perfect overlap. Nevertheless, all CD11b positive cells 
were also ICG positive. The same approach was also taken with an anti CD45 
antibody with the same outcome. This further supports that the identity of most of 
the ICG labelled cells in the retina as infiltrating myeloid cells. 
 
Figure 4.11. Detection of in vivo ICG-labelled cells by flow cytometry. 
24 hours after ip injection of ICG dye, PBMCs and splenocytes were isolated from C57B6 mice in 
order to assess the proportion of cells labelled by ICG. (A) 1.01% of circulating mouse PBMCs 
were stained with ICG. This was statistically significant from control animals (p=0.001). 
(Mean=0.74%, SD=0.31%, range 0.47 to 1.01%). (B) A higher proportion of splenocytes (3.48%) 
were stained with ICG. This was also statistically significant from control animals (p=0.002). 
(Mean=2.42%%, SD=1.22%, range=0.86 to 3.48%). [Mann-Whitney U test, n=5] 
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Figure 4.12. Distribution of ICG within the abdominal and thoracic cavity 
after intraperitoneal administration. 
We performed dissection of mice 7 days after intraperitoneal administration of 1mg of 
indocyanine green (ICG). (A, B) In the thorasic cavity we observed green staining of lymphatic 
tissue along the thorasic wall and (C) mediastinal lymph nodes. (D-F) In the abdominal cavity, we 
observed a strong green stain of the greater omentum. 
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Figure 4.13. Characterization of in vivo ICG-labelled cells in the CNV model. 
Animals received laser 7 days prior, and ip ICG 10 days prior to imaging. (A) Infrared-reflectance 
imaging (IR) demonstrates the presence of laser-induced CNV lesions in the deep retina/choroid, and 
(B) a deep retinal/choroidal image taken in the ICG channel shows ICG-labelled cells surrounding two 
laser-induced CNV lesions. (C) A magnified view of ICG-labelled cells surrounding the CNV lesion from 
the upper lesion in (B). Immediately after IR and ICG imaging FITC-conjugated anti CD11b antibody was 
injected (iv) and imaged in the FA channel at 15 (D) and 30 minutes (E, F) post-injection. (F) A 
magnified view of CD11b-FITC-labelled cells demonstrates good correlation with ICG-labelled cells (C). 
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4.5 Discussion: 
We describe a novel technique for in vivo labelling of circulating cells with ICG dye. 
We found that in order to label these cells reproducibly in vivo, ICG must be 
administered as a depot preparation. Using this approach, we showed in three 
disease models of retinal inflammation that infiltrating leukocytes can be detected, 
tracked over time, and quantified in the murine retina.  
We found that the commonly used intravenous route of administration of ICG 
failed to label infiltrating leukocytes. However, by administering ICG as a depot, we 
have shown that infiltrating cells were clearly labelled in our disease models. A 
possible explanation for this is the increase period of ICG exposure that circulating 
cells have, in order to be labelled. In keeping with this, we observed in vitro, that an 
increased time of exposure to ICG resulted in increased cell labelling. Furthermore, 
we observed that in vivo and in vivo the majority of these labelled cells were of 
myeloid origin. 
Our technique will be useful in the above mentioned mouse models. In 
particular the laser-induced neovascularisation model is widely used to study 
pathological vessel growth in the retina. This model also contains an important 
inflammatory component, which so far has been mainly assessed by 
immunohistochemistry on postmortem tissue. With our ICG technique it will be 
possible to monitor inflammatory cell invasion longitudinally in these animals in 
parallel with vascular changes.  
More generally, in the field of inflammation the ability to monitor a sequence 
of events over time is particularly important in order to elicit cause-and-effect 
relationships. As such, recent developments have been focused on the ability to 
visualize inflammation in vivo using molecular imaging techniques such as intravital 
microscopy using fluorescent antibodies, nanoparticles and transgenic animals that 
express fluorescent proteins.(402, 403)  Although our ICG method does not target 
specific cell types or epitopes as specifically as transgenic animals or antibodies, we 
have nevertheless found that ICG is mainly taken up by CD45+CD11b+ 
monocytes/macrophages.  Moreover, our approach has the advantage that it can be 
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carried out very easily, does not depend on specific mouse strains and, most 
importantly, has the potential for immediate translation to human use.  
Current strategies for in vivo molecular imaging in humans include 
conjugation of NIR dyes, such as ICG, with ligands such as small molecules, 
antibodies, peptides, DNA and nanoparticles.  Nevertheless, none of these probes 
have been approved for human use because of their so far insufficiently 
characterized safety profiles. In particular nanoparticles suffer from poorly 
characterized distribution, accumulation and clearance from the human body, and 
potential cytotoxicity of heavy metal ingredients (382, 404).  
In contrast, ICG an inert, water-soluble organic dye, is rapidly bound to 
plasma proteins and solely removed from the circulation through the liver via a 
specific carrier-mediated transport system (405, 406). Furthermore, ICG is known not 
to provoke inflammation even when injected directly into tissues. The ICG dye was 
first developed in the mid-1950s to determine cardiac output and hepatic function. 
The dye is rapidly cleared, low in toxicity and well tolerated by patients; even at 
doses which exceed what is now routinely given by 10-fold (407, 408). This led to its 
application to a variety of clinical uses; with examples including sentinel node biopsy, 
tumour demarcation surgery, lymphatic vessel assessment and choroidal vasculature 
imaging in the eye.  Thus, ICG has a well-documented safety and tolerance track 
record of more than 60 years in clinical practice. Furthermore, instruments that are 
needed to visualize ICG are readily available in most ophthalmic clinics.  
 In conclusion, we have demonstrated cellular imaging of circulating 
monocytes invading the retina by using a depot injection of ICG. Translating this 
insight into clinic will involve the development of a formulation suitable for depot ICG 
application in humans. This may be useful not only for monitoring ocular 
inflammation, but may also have applications further afield, for example, the 
detection of an immune response to novel treatment strategies such as stem cell 
therapies or retinal implants, or serve as an imaging biomarker for predicting the 
onset of angiogenesis in age-related macular degeneration or diabetic retinopathy. 
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4.6 Chapter summary: 
 
We have developed a method to label and image myeloid cells infiltrating the mouse 
retina and choroid in vivo, using a single depot injection of Indocyanine green dye 
(ICG). This was demonstrated using different ocular mouse models of inflammation 
and angiogenesis – endotoxin-induced uveitis (EIU) and laser-induced choroidal 
neovascularisation (CNV). A near-infrared scanning laser ophthalmoscope was used 
for in vivo imaging of the eye and flow cytometry was used on blood and spleen to 
assess the number and phenotype of labelled cells. We found that in vivo intravenous 
administration failed to label any leukocytes, whereas depot injection, either 
intraperitoneal or subcutaneous, was successful in labelling CD11b+ myeloid cells. 
Progression of inflammation in the retina could be traced over a period of 14 days 
following a single depot injection of ICG. Additionally, flow cytometric analysis 
revealed that the predominant population of cells stained by ICG are circulating and 
splenic reservoir CD11b+ myeloid cells. The translation of this approach into clinical 
practice would enable visualisation of immune cells in situ. This will not only provide 
a greater understanding of pathogenesis, monitoring and assessment of therapy in 
many human ocular diseases but also open the ability to image immunity live for 
neurodegenerative disorders, cardiovascular disease and systemic immune mediated 
disorders. 
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5. The relationship between endothelial progenitor cells, 
circulatory monocytes, and diabetic eye disease 
 
5.1 Introduction: 
CD34+ EPCs derived from the peripheral circulation have the capacity to migrate, 
proliferate, and differentiate into mature endothelial cells.(59) Their potential for use 
in the treatment of ischaemic diseases lie in the ability of these cells to repair 
damaged blood vessels. However, the translation of EPC therapy into clinical practice 
has been limited by the ambiguity of its definition, relative rarity in the peripheral 
circulation, and duplicitous behaviour in cell culture. Established cell surface markers 
for EPCs, albeit inconsistently, have included CD34+; a stem cell marker, CD309+ (also 
known as KDR/VEGFR2); a marker for endothelial cells, CD133+; an early stem cell 
marker, and CD31; a mature endothelial cell marker.(70, 409, 410) There is increasing 
evidence that at least some of the cultured EPCs are derived from CD14+ monocytes, 
and furthermore, CD14+ monocytes themselves can give rise and behave functionally 
as endothelial cells.(74) It is therefore important to understand the relationships 
between these cells in both health and disease states. In this chapter, clinical 
evidence for the therapeutic efficacy of both EPCs and CD14+ monocytes is 
summarized and their relationship with diabetic eye disease examined. 
 
5.1.1. EPCs in clinical practice 
Clinical studies that explored the potential of EPC numbers as a biomarker have 
reported conflicting results. In cardiovascular disease, most studies demonstrate a 
reduced number of circulating EPCs.(411-413) However, reports have indicated that 
shifts in EPC levels were associated with disease severity; i.e. elevated levels in early, 
and lower levels in severe and late stages of coronary and peripheral arterial disease, 
and stroke.(414-418) These studies have also shown that low levels predict a poorer 
outcome of disease and response to treatment. In diabetes, reduced numbers of 
circulating EPCs with functional impairment have been observed, relative to age-
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matched healthy controls.(62-64, 419). Conversely, elevated levels have been 
reported to correlate with the presence and/or severity of diabetes-associated 
complications.(415, 420)  
The clinical relevance of the identity of EPCs lies in their relative rarity in bone 
marrow sample and even more so in the peripheral circulation. Ex-vivo expansion of 
these cells for the purpose of regenerative therapy is essential in order to obtain 
sufficient numbers for therapy. Moreover, the intermediate step “in culture” 
provides an opportunity to intervene; i.e. repair deficits or restore the regenerative 
potential of these cells, as observed in disease.(63) Strategies to enhance EPC 
function have included exposing these cells (both in vivo and in vitro) to numerous 
agents such as, tissue kallikrein (421), statins (a lipid lowering drug) (422, 423), 
losartan (an angiotensin II receptor antagonist drug used in hypertension) (424), and 
thymosin β4 (an actin sequestering protein) (425). In a diabetic mouse model, topical 
Sonic hedgehog gene therapy has been shown to improve wound healing by 
enhancing EPC function.(426) This was similarly observed with AMD3100, a CXCR4 
antagonist, in a mouse model of myocardial infarction.(427) Combination therapy of 
both Sonic hedgehog gene transfer and AMD3100 has also been observed to further 
enhanced EPC mobilisation from the bone marrow.(428)  
Pioneering clinical studies have shown that administration of EPCs can restore 
tissue vascularisation after ischaemic events in other parts of the body e.g. ischaemic 
limbs (60, 429), chronic ischaemic heart disease and heart failure (430), refractory 
angina (431), and stable angina (418). Pre-clinical studies in rat models have shown 
that transfusion of autologous peripheral blood derived EPCs can improve 
neurological functional outcome in stroke.(432) In diabetes, mobilisation of EPCs with 
negative-pressure wound therapy have shown efficacy in patients with foot 
infections or skin wounds (419), and a feasibility study using autologous G-CSF-
mobilised peripheral blood CD34+ for non healing diabetic foot ulcers shows 
promising results in 5 patients (433). The long-term efficacy of EPC therapy has yet to 
be demonstrated in randomised controlled clinical trials.  
 
213 
 
 
5.1.2. The identity of the EPC 
The identity of the EPC remains unknown. During embryonic development, it is 
thought that the both endothelial and haematopoietic cells arise from a common 
progenitor- the haemangioblast.(116, 434) In 1997, Asahara et al were the first to 
demonstrate the existence of circulating bone marrow derived cells that were able to 
form primitive vascular structures in culture. These cells displayed cell surface 
markers of early progenitor cells such as CD34 (59, 435), CD133 (69), and formed 
colonies of cells, which resembled endothelial cells; expressing CD31, CD309, and 
eNOS.  These colonies were described by Hill et al (436), whom cultured circulating 
EPCs by pre-plating peripheral blood mononuclear cells (PBMCs) to first remove 
circulating mature endothelial cells. The resultant colonies; called “CFU-Hill” colonies, 
were found to be reduced in those at greater risk of cardiovascular disease. However, 
it has since been shown that these CFU-Hill colonies are made up of not just EPCs but 
a mixed phenotype of cells, including monocyte and lymphocytes.(437-439) Many 
studies have also observed a large heterogeneity in cultured EPCs.(76, 440, 441) Two 
main phenotypes arose from short-term (less than 7 days), and long-term culture 
(more than 3 weeks) and were called early- and late-outgrowth EPCs respectively.(70, 
442, 443)  
The nomenclature surrounding these cells is confused; the early-outgrowth 
EPCs are more commonly known as circulating angiogenic cells (CACs) and late-
outgrowth EPCs termed endothelial colony forming cells (ECFCs). Both cultured EPCs 
subtypes differed in their proliferative and secretory behaviour, and their ability to 
integrate into existing vascular networks. CACs have low proliferative capacity but 
secrete growth factors in a paracrine fashion (70, 443, 444), and ECFCs are highly 
proliferative, producing cobblestone shaped monolayers resembling endothelial 
cells.(70, 76, 410). The sub-type of “cultured EPC” which most resembles the 
circulating EPC were thought to be CACs as they expressed surface markers of a 
haematopoietic lineage; CD34 and VEGFR2/KDR .(437, 445-447) Interestingly, 
myeloid lineage markers such as CD45 and CD14 have been found on CACs and these 
cells further express phagocytic ability (443, 448). Transcriptome analysis have 
further observed that CACs closely resemble myeloid cells showing similarity to 
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CD14+ monocytes.(449, 450) In contrast ECFCs expressed genes that are typically 
expressed by endothelial cells, such as Tie2 and eNOS.(449)  
 
5.1.3. The relevance of Monocytes 
Clinical studies utilising autologous EPCs to date, have been therefore been 
transfusing CACs, i.e. monocytes, with success in restoring perfusion to ischaemic 
tissue (74, 451), whereas direct transfusion of CD14+ monocytes do not show the 
same effect.(452) This suggests that a subset of CD14+ monocytes is enriched in the 
process of culture. The difference between an unselected population of circulating 
CD14+ monocytes and CACs (selected by culture) has been observed to be the 
upregulation of antioxidant genes such as superoxide dismutase, glutathione 
peroxidase, and catalase.(453) CACs have further been observed to be more resistant 
to hydrogen peroxide induced oxidative stress than unselected CD14+ monocytes 
and endothelial cells.(453) Schirmer et al observed in a patient population with 
coronary artery disease that the transcriptomes of monocytes and CD34+ cells 
differed in those that responded to treatment compared to non-responders.(454) 
This was most marked when the cells were stimulated with LPS with cells from non-
responders showing inhibited arteriogenesis. It is therefore important to consider 
changes in the circulating monocyte population in conjunction with EPC status when 
examining their differences in health and disease. 
 Changes in monocyte subsets have been discussed in the Chapter 1.3.2. In 
this chapter, we further examine the co-expression of CD309+ and CD163+ in an 
effort to elucidate their differential expression in different diabetic eye disease 
phenotypes. CD309 is expressed in monocytes and have been observed to be 
upregulated as a response to pro-angiogenic stimuli such as tissue injury, or 
ischaemia in the context of myocardial infarction and heart failure.(455, 456) CD163 
is a member of the scavenger receptor cysteine-rich superfamily, whose expression is 
restricted to the monocyte/macrophage lineage.(457, 458) CD163 expression is also 
upregulated in response inflammatory stimuli but only in the latter “resolution 
phase” of the insult. (459, 460) Monocytes that express CD163 are therefore 
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considered an anti-inflammatory, akin to medics in a battlefield tending to injured 
soldiers when the gunfire has slowed.  
 
 
 
5.2 Aim:  
In this study, therefore, we propose to characterise circulating EPCs in conjunction 
with CD14+ monocyte subtypes, in cohorts of patients with different phenotypes of 
diabetic retinopathy. The rationale for this chapter is to identify biomarkers in the 
peripheral circulation that may increase the understanding of the pathogenesis of 
diabetic eye disease and its relationship with ocular phenotypes. 
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5.3 Materials and Methods: 
5.3.1 Patient recruitment, image analysis, and blood collection 
Peripheral blood samples were collected from 20 healthy adult donors and 18 
patients with diabetic eye disease. Collection of samples was approved by the 
institutional Health Research Ethics Authority and signed informed consent obtained 
from all donors. Inclusion criteria included patients with Type 2 Diabetes aged 18 
years or more. Exclusion criteria included 1) coexisting retinal or optic nerve 
pathology (e.g. age-related macular degeneration (AMD), glaucoma), 2) media 
opacities precluding accurate retinal imaging (e.g. dense cataract). Patient 
demographics and clinical information were collected from electronic and paper 
records, including age, sex, body-mass index, HbA1c, history of hypertension and 
hypercholesterolemia, diabetic retinopathy and maculopathy severity grade, and 
visual acuity. Progression data regarding diabetic retinopathy and maculopathy 
severity grades were collected in 2011 and 2015 from electronic patient records. 
Retinal imaging, including fluorescein angiography and optical coherence 
tomography scans were analysed as previously described in chapter 2.3. Between 40 
to 60mL of blood was obtained from each donor using glass BD Vacutainer system 
containing Sodium Heparin (BD Biosciences, 366480). 
 
5.3.2 Isolation of Peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from the peripheral blood samples using Ficoll-Paque (PAA 
laboratories, LSM1077), a long established method for depleting red blood cells 
(RBC), and platelets.(461-463). Briefly, 50 mL conical tubes were used and blood 
samples were diluted with an equal volume phosphate-buffer saline, pH 7.4 (PBS) 
prior to layering over 20 mL of Ficoll-Paque. This was centrifuged at 800 X g for 30 
minutes in a swinging-bucket rota without the brake applied and the top layer of 
plasma removed. The PBMC layer was carefully removed by pipetting and washed 
with PBC by centrifugation at 250 x g for 10 minutes. PBMC pellets were re-
suspended in ammonium chloride potassium lysis buffer (Invitrogen) for 10 minutes 
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at room temperature with gentle mixing to lyse remaining red blood cells before a 
final wash with PBS. Cell numbers were recorded using a cell counter under a light 
microscope and trypan blue used to determine proportions of cell viability. PBMCs 
were cryopreserved in liquid nitrogen using fetal calf serum (FCS) (Invitrogen) 
containing 10% dimethyl suloxide (DMSO) (Thermo Fisher Scientific) and stored until 
analyses. 
 
5.3.2.1 Optimisation protocols for PBMC isolation 
Red cell lysis was used initially to isolate leukocytes from whole blood. Although this 
yielded a high number of cells and therefore reduced the volume of blood draw 
required for each patient, cell death with this technique alone was much higher than 
when combined with Ficoll separation, which yielded an average of 1 x 106 cells/mL 
of whole blood. (Figure 5.1) 
 
Figure 5.1. Red cell lysis to isolate leukocytes from human whole peripheral 
blood.  
(A) Colour photograph demonstrating red cell contamination despite red cell lysis. (B,C) Forward and 
side scatter flow cytometry plots using Ficoll separation and red blood cell (RBC) lysis protocols 
showing reduced contamination in the former. (D) light microscopy after RBC lysis demonstrating red 
cell contamination.  
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5.3.3 Primary antibodies 
Directly conjugated monoclonal antibodies were selected to minimise the risk of non-
specific binding and to increase experimental efficiency. Surface markers were 
selected with the aim of defining EPC proportions and monocyte subsets of in the 
PBMC samples in normal and patients with diabetic eye disease.  
At the time of when these experiments were conducted, the accepted 
definition of an EPC, albeit controversial, was CD45, CD34, CD133, and CD309.(69) 
These markers were therefore selected for the EPCs. Surface markers CD45, CD14, 
CD16 were selected to define for the monocyte population and were divided into 
three subtypes according to surface expression; classical monocytes (CD14++ CD16-), 
intermediate (CD14++ CD16+) and non-classical/inflammatory (CD16++ CD14 low). Of 
note percentages of these subsets have been reported as 83-85%, 4-5%, and 7-11% in 
healthy human PBMC samples.(464, 465)  
In addition, co-expression of CD309 (a pro-angiogenic marker)(456, 466, 467)  
and CD163 (an “anti-inflammatory” marker) (468-470) were assessed on monocyte 
subsets. The inclusion of other markers was limited by the availability of suitable 
fluorophores for conjugation at the time of experimental design and the 4 channels 
possible on the FACScalibur. The PE fluorochrome, with a high quantum yield, was 
reserved for CD133 staining, as the CD133 antigen was known to be weakly 
expressed in human PBMCs. 
 
5.3.3.1 Titration assay of primary conjugated antibodies used for flow 
cytometry 
Titration assays were performed for all antibodies to identify the antibody amount 
and concentration that resulted in the highest signal of the positive population and 
the lowest signal of the negative population. Titration assays were performed using 
frozen cells derived from blood cones due to the lack of fresh blood cells available. As 
such, this was a high proportion of non specific binding in dead cells. Figure 5.1 is 
illustrative a titration assay performed on CD34-FITC, an important marker for this 
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thesis that was used to identify a relatively rare cell population. Enriched samples for 
CD34+ should have been used for titration. However, at the time of these 
experiments, the cost of enrichment for CD34+ was deem to high for use for antibody 
titration. 
 
  
 
Figure 5.2. CD34-FITA titration assay 
Histograms showing the fluorescence intensity for CD34-FITC antibody on frozen peripheral blood 
mononuclear cells with 10, 6, 4, 2, and isotype control. 
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Table 5.1. Primary conjugated antibodies used for flow cytometry. Unless 
stated otherwise, all antibodies were raised against human tissues. 
 
Reactivity Clone Conjugate Company 
Volume 
used 
(L) 
Catalogue 
number 
CD34 AC136 FITC Miltenyi Biotec 6 130-081-001 
CD34 AC136 PE Miltenyi Biotec 4 130-081-002 
CD133 AC133 PE Miltenyi Biotec 10 130-105-225 
CD309/KD
R/VEGFR2 
ES8-20E6) APC Miltenyi Biotec 10 130-093-601 
CD45 5B1 PerCP Miltenyi Biotec 6 130-094-975 
CD14 TÜK4) FITC Miltenyi Biotec 6 130-098-063 
CD14 TÜK4) PerCP Miltenyi Biotec 10 130-094-969 
 
 
CD16 REA423 FITC Miltenyi Biotec 10 130-106-703 
CD163 GHI/61.1 PE Miltenyi Biotec 10 130-097-628 
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5.3.4 Flow cytometry  
PBMCs were removed from liquid nitrogen storage and thawed in a water baths. Cells 
were transferred into 15 mL conical tubes and incubated in RMPI-1640 medium 
(Invitrogen) and 10% FCS for an hour to allow recovery of the cells. PBMC counts and 
cell viability were assessed as above.  
 The flow cytometer used for all experiments was FACScalibur (BD 
Biosciences), which was regularly maintained and used according to manufacturer’s 
instructions. Low flow rates were used for EPC analyses and 1,000,000 events 
collected for each sample. Medium flow rates for monocyte analyses with a minimum 
of 100 000 event collected. Compensation was performed using single-stain samples 
and Propidium Iodide (PI) (eBioscience, 00-6990) used as a live-dead stain. 
Fluorescence-minus-one (FMO) controls were used to determine gate position. 
Analysis was performed using FlowJo (Treestar, Ashland, OR, USA). 
 
5.3.4.1 Optimisation protocols for CD34+ cell analysis 
Positive selection for CD34+ with magnetic –activated cell sorting (MACS) (MACS 
CD34 MicroBead Kit, human, Mitenyi Biotech) was used to enrichment this rare cell 
population from PBMCs. Figure 5.3 shows an increase in CD34+ fraction from 0.203% 
to 9.88% using MACS with freshly isolated PBMCs, with no cell loss observed in the 
MACS negative fraction and minimal contamination.  With frozen PBMCs, the 
enrichment was less effective, with an increase from 0.155% to 2.75%. (Figure 5.4) 
Although this was a good protocol for the enumeration for CD34+ cells, it was ideally 
performed with freshly isolated PBMCs. In addition, an important technical constraint 
was the protocol from recruiting patients to sample preparation exceeded the 
working hours of the host institution. Therefore samples could not be process on the 
same day and PBMCs had to be frozen. It was for this reason that MACs was not used 
for the enumeration of CD34+ cells. 
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Figure 5.3. Optimisation experiment using magnetic-activated cell sorting 
in freshly isolated human peripheral blood mononuclear cells.  
(A,F) Scatter plot of isotype control (B,C) CD34-FITC plotted again forward scatter showing CD34+ cells 
in light blue, and back gated endothelial progenitor cells (EPCs) from (D, E). (B, D) represent PBMC 
samples analysed with flow cytometry without MACS enrichment (unMACS), and (C,E) after MACS 
enrichment. 
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Figure 5.4. Optimisation experiment using magnetic-activated cell sorting 
in frozen human peripheral blood mononuclear cells.  
Scatter plot of CD34-FITC plotted again forward scatter showing CD34+ cells in light blue. (A) No MACS 
enrichment was carried out prior to flow cytometry (unMACS) and (B) MACS enrichment was carried 
out prior to flow cytometric analysis of PBMCs. 
 
5.3.4.2 Introduction of a cell culture step prior to for flow cytometric analysis 
of cells 
Hill et al in 2003 observed that the colony forming potential of peripheral blood 
mononuclear cells were strongly correlated to the subjects’ Framingham 
cardiovascular risk factor score.(436) We therefore explored the possible use of this 
pre-culture step prior to flow cytometric analysis of PBMCs in our patient cohort.  
20mL of whole blood was collected from five healthy volunteers and cultured 
according to the methods described by Hill et al. Briefly, a n initial pre-plating step 
step in a fibronectin-coated six-well plate using 5 million PBMCs per well was 
performed, which the author reasoned as to remove mature circulating endothelial 
cells. After 48 hours, the nonadherent cells were collected and 1 million cells were 
replated onto fibronectin-coated 24-well plates for a final assessment of the number 
of colonies. Growth medium consisting of consisting of Medium 199 (GIBCO BRL Life 
Technologies) supplemented with 20 percent fetal-calf serum, penicillin (100 U per 
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milliliter), and streptomycin (100 μg per milliliter). was changed every three days, and 
cells analysed at seven days. Cells were dissociated using trypsin for 3 minutes at 
room temperature. Both adherent and nonadherent cells were analysed by flow 
cytometry both immediately after plating and at 7 days respectively. 
Figure 5.5 shows the proportion of CD34+ cells present in the initial PBMC 
sample, adherent, and nonadherent cells. The pre-plating and culture step failed to 
enrich the PBMC sample for CD34+ cells. Interestingly, monocytes were greatly 
enriched by this culture step, with an expansion of the intermediate and non-classical 
populations. (Figure 5.6) The shift in monocyte characteristics and volume of whole 
blood required for this experiment made this culture step unsuitable for this project, 
which sort to analyse EPC as well as Monocyte phenotypes in diabetic eye disease. 
 
Figure 5.5. Optimisation experiment: flow cytometric analysis CD34+ cells 
from peripheral blood mononuclear cells (PBMCs) cultured for seven days.   
The left panel shows CD34+ cells expressed as a percentage of PBMCs 7 days after culture. The right 
panel are representative scatter plots showing CD34+ cells plotted against side scatter. 
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Figure 5.6. Optimisation experiment: flow cytometric analysis CD14+ cells 
from peripheral blood monocyte cells cultured for seven days.   
The left panel shows CD14+ cells expressed as a percentage of PBMCs. The middle panel are 
representative scatter plots showing a monocyte gate place on a forward and side scatter plot. The 
right panel shows scatter plots with CD14-PerCP on the Y-axis and CD16-FITC on the X-axis, and 
relative proportions of classical monocytes (CD14+ CD16-), intermediate monocytes (CD14+ CD16+), 
and non classical monocytes (CD14+ CD16++). 
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5.3.5 Statistical Analysis  
Patient demographic and imaging data were analysed with frequency and descriptive 
statistics. Normality of the variables was examined using histograms. The Mann-
Whitney U test was used to compare continuous variables, whereas the χ² test was 
used for categorical variables. Spearman’s rank correlation was used to test for 
associations between variables. Snellen visual acuities were converted to LogMAR 
(logarithm of the minimum angle of resolution) visual acuity for the purposes of 
statistical analysis. Statistical analyses were performed using statistical software SPSS 
software version 16 (SPSS, Inc, Chicago, IL).  
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5.4 Results: 
5.4.1 Patient Demographic and Clinical Characteristics 
The mean age of patient included was 50 years (SD=13.3) with a male to female ratio 
of 1.5. The mean body mass index was 29 (SD=8.8), mean diabetes duration was 20 
years (SD=9.1), and mean HbA1c 7.6 (SD=1.59). 15/20 patients (75%) had a history of 
treated hypertension and 15/20 treated hypercholestrolaemia. 
 Regarding diabetic retinopathy and maculopathy severity grades (assessed 
during clinical examination), the eye with greater severity was included. 6 patients 
had mild non-proliferative diabetic retinopathy, 7 moderate to severe non-
proliferative diabetic retinopathy, and 7 treated proliferative diabetic retinopathy in 
the more severely affected eye. 6 patients had no evidence of diabetic maculopathy 
in either eye, and 14 clinical evidence of diabetic maculopathy in one or more eyes. 
There was a wide range of visual acuity measurements in all patients, with a mean of 
0.41 logMar (or 6/15 Snellen equivalent) (SD=0.49). 10 patients had fluorescein 
angiograms at the time of this study, and of these, 3 patients had none to mild, 2 
moderate, and 5 severe diabetic macular ischaemia. All patients had OCT scans, and 
these were used to assess for the presence of diabetic macular oedema (7/20 
patients [35%]). 
 
  
5.4.2 EPCs and monocytes in diabetes and in healthy controls 
5.4.2.1. EPCs 
FMOs were used along with a published gating strategy in order to ascertain the 
percentage of CD34+ cells and their subsets.(471) These were compared between 
patients with type 2 diabetes and healthy controls. No difference was observed 
between groups with mean of 0.34% of live cells (SD=0.32) in control compared to 
0.28% of live cells (SD=0.16) in diabetes. (Table 5.1, Figure 5.7) However, when 
subsets of CD34+ cells were analysed, a significant difference was observed in the 
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CD34+ CD309+ subset between those with controls (2.14% of CD34+ cells [SD=2.00]) 
compared to diabetes (5.77% of CD34+ cells [SD=2.15]). (Table 5.1) No difference was 
observed in CD34+ subsets with CD133+ surface marker. (Figure 5.1) 
 
Table 5.2. Comparing the proportions of EPCs in patients with type 2 
diabetes and normal controls 
EPC (CD34+) analysis  Control Diabetic  
  Mean SD Mean SD p-value 
 %      
CD34+ Live 
cells 
0.34 0.32 0.28 0.16 0.87 
CD34+ CD133+ CD34+ 32.71 22.41 24.25 17.37 0.41 
CD34+ CD 309+ CD34+ 2.14 2.00 5.77 2.15 0.001** 
CD34+ CD309+ CD133+ CD34+ 2.47 1.86 1.69 2.02 0.15 
p values significant at 5% level are indicated with (*), and (**) at 1% level. 
 
 
 
Figure 5.7. Comparing the proportions of EPCs in patients with type 2 
diabetes and normal controls 
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Table 5.3. Comparing circulating monocytes and their subsets in patients 
with type 2 diabetes and normal controls 
  Control Diabetic  
  Mean SD Mean SD p-value 
Monocyte analysis %      
All Monocytes 
CD45+ CD14++  
Live 
cells 
13.63 3.46 18.19 8.06 0.15 
Classical Monocyte (M2)       
CD14++ CD16- Live 
cells 
71.47 8.38 63.00 12.59 0.12 
CD14++ CD16- CD309+  M2 20.32 21.35 1.98 1.17 0.001** 
CD14++ CD16- CD163+ M2 29.75 27.13 50.18 10.23 0.14 
CD14++ CD16- CD309+ CD163+ M2 37.74 17.73 37.01 11.46 0.49 
Intermediate Monocyte (iM)       
CD14+ CD16+ Live 
cells 
4.75 0.69 6.75 3.85 0.58 
CD14+ CD16+ CD309+ iM 29.34 29.68 0.57 0.68 0.03* 
CD14+ CD16+ CD163+ iM 42.60 44.94 77.61 13.61 0.38 
CD14+ CD16+ CD309+ CD163+ iM 16.54 10.62 15.76 13.87 0.72 
Non-Classical Monocyte (M1)       
CD16+ CD14 low Live 
cells 
7.71 3.38 10.71 5.18 0.31 
CD16+ CD14 low CD163+ M1 1.65 1.67 0.16 0.26 0.28 
CD16+ CD14 low CD309+ M1 31.99 19.64 43.66 15.43 0.15 
CD16+ CD14 low CD309+ CD163+ M1 1.16 1.13 3.09 11.82 0.06 
       p values significant at 5% level are indicated with (*), and (**) at 1% level. 
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Figure 5.8. Comparing the proportions of monocyte subsets in patients with 
type 2 diabetes and normal controls.  
* denotes a p-value of <0.05, and ~ denotes a p-value=0.06 
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5.4.2.2. Monocyte Subtypes 
Published gating strategies were used to identify the proportion of circulating 
monocytes and their subsets in PBMCs from patients with type 2 diabetes and 
controls.(472) In this study, the “rectangular” gating strategy was used. Monocytes 
were defined by cell surface markers CD45 and CD14 and subsets further categorised 
using CD16. (Table 5.3) No statistically significant difference was observed in all 
monocytes, or their subsets as described above in diabetes compared to controls. 
(Table 5.3) However, the trends observed in the proportion of these subsets in 
diabetes (compared to controls) were (1) reduced classical monocytes (63.0% vs 
71.5%) (p=0.12), (2) increased intermediate monocytes (6.8% vs 4.8%) (p=0.58), (3) 
increased non-classical monocytes (10.7% vs 7.7%) (p=0.31). (Figure 5.8) 
Interestingly, the total proportion of monocytes in the live cell population was 
greater in diabetes (18.2%) compared to controls (13.6%) however, this was not 
statistically significant (p=0.15). (Table 5.3) Co-expression of CD309 on all three 
subsets were further analysed and a statistically significant reduced expression was 
observed in diabetes compared to controls; classical monocyte population; controls 
(mean=20.3% of M2 cells [SD=21.4]) and diabetes (mean=1.98% of M2 cells 
[SD=1.17]) (p=0.001), and intermediate monocyte population; controls (mean=29.3% 
of iM cells [SD=29.7]) and diabetes (mean=0.57% of iM cells [SD=0.68]) (p=0.03). 
(Table 5.3, Figure 5.8) 
Co-expression of CD163 on all three subsets was also analysed. No significant 
difference in expression was observed all monocyte subsets. A trend of increased 
expression was observed in classical monocyte population in patients with diabetes 
(mean=50.2% of M2 cells [SD=10.2]) compared to controls (mean=29.8% of M2 cells 
[SD=27.1]), (p=0.14). (Table 5.3, Figure 5.8) 
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Figure 5.9. Comparing the co-expression of CD309 and CD163 on monocyte 
subsets in patients with and without diabetic macular oedema.  
 
 
Figure 5.10. Comparing the co-expression of CD309 on monocyte subsets in 
patients with and without diabetic macular ischaemia.  
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5.4.3 The effects of diabetic macular disease 
No difference was observed in EPCs or their subpopulations in either phenotype of 
diabetic macular disease or retinopathy severity levels. 
Monocyte subsets and co-expression of CD309 and CD163 were assessed in 
patients with diabetic macular oedema (DMO) and diabetic macular ischaemia (DMI). 
In DMO, a significant increase was observed in classical monocytes which co-
expressed both CD309 and CD163 in patients (mean=43.0% of M2 cells [SD=9.0]) 
compared to controls (mean=32.4% of M2 cells [SD=11.4]), (p=0.03). (Figure 5.9)  
In DMI, a significant increase was observed in intermediate monocytes, which 
co-expressed CD309 in patients (mean=1.04% of iM cells [SD=1.07]) compared to 
controls (mean=0.15% of iM cells [SD=0.21]), (p=0.05). (Figure 5.10) 
 
5.4.3 The effects of age and body mass index (BMI) 
No relationships were observed between EPCs or their subpopulations with age or 
body mass index or retinopathy severity levels. In addition, no relationship was 
observed between both age and BMI with monocytes subsets in different retinopathy 
severity levels.  
Monocyte subsets and co-expression of CD309 and CD163 were assessed in 
patients 60 years and older and those with a BMI of greater than 30. In patients 60 
years and older, a significant increase was observed in classical monocytes which co-
expressed both CD309 and CD163 (mean=41.9% of M2 cells [SD=8.8]) compared to 
those younger than 60 years (mean=30.2% of M2 cells [SD=11.8]), (p=0.04). (Figure 
5.11) In addition, there was a positive correlation with age and classical monocytes 
that expressed both CD309 and CD163. (r=0.56, p=0.03). 
In patients whose BMI was greater than 30, a significant increase was 
observed in non-classical monocytes, which co-expressed CD309 in patients 
(mean=31.7% of M1 cells [SD=5.08]) compared to those with a BMI less than 30 
(mean=51.9% of M1 cells [SD=8.6]), (p=0.036). (Figure 5.11) 
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Figure 5.11. The effect of age and body mass index on classical monocytes. 
Comparing the co-expression of CD309 +/- CD163 on monocyte subsets in patients aged greater or less 
than 60 (left), and with a BMI of greater or less than 30 (right).  
 
5.4.4 Biomarkers for progression of diabetic eye disease 
In the 4-year intervening period, one patient died in 2014. 9/17 (52.9%) patients 
showed progression over the 4 year intervening period of either retinopathy or 
maculopathy severity; 9/17 (52.9%) retinopathy only, and 8/17 (47.1%) maculopathy 
only. Patients had progression in either phenotype had a significantly smaller 
proportion of classical monocytes (mean=58.4% of all monocytes [SD=9.96]) vs stable 
(mean=73.3% of all monocytes [SD=8.35]), (p=0.02); a larger proportion of 
intermediate monocytes (mean=8.25% of all monocytes [SD=3.98]) vs stable 
(mean=4.95% of all monocytes [SD=3.11]), (p=0.05) and a larger proportion of non-
classical monocytes (mean=13.0% of all monocytes [SD=5.38]) vs (mean=6.83% of all 
monocytes [SD=2.31]), (p=0.04). (Figure 5.12) Binary multivariable logistic regression 
was performed, and the changes observed in classical and non-classical monocytes 
remain significant, independent of age.  
No significant differences were observed with maculopathy progression 
alone. However, in retinopathy progression alone, the proportion of non-classical 
monocytes was double that of those who were stable. (mean=14.3% of all monocytes 
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[SD=5.33]) compared to those who were stable (mean=7.25% of all monocytes 
[SD=2.39]), (p=0.02). 
There were no differences in the EPC profiles between patients who had 
stable or progressive diabetic eye disease in all groups. 
 
 
Figure 5.12. Monocyte subsets and diabetic eye disease progression.  
Comparing monocyte profiles in patients who had progression in either diabetic retinopathy or 
maculopathy to those that remained stable over a 4 year period. Classical monocytes (Left); 
Intermediate monocytes (Middle); Non-classical monocytes (Right). 
 
 
  
236 
 
 
5.5 Discussion: 
In this chapter, we examined the relationships between EPCs, monocytes and their 
respective subpopulations, with clinical phenotypes of diabetic eye disease and 
clinical demographics such as age, BMI, and glycaemic control. No difference was 
observed with both cells type in diabetic retinopathy severity levels but in different 
phenotypes of macular disease. Additionally, age and BMI were the only parameters 
in which a significant difference was observed in monocyte populations. 
 
5.5.1 EPCs in diabetic eye disease 
The concept of EPC therapy for repairing blood vessels in the adult has continuously 
received attention since its discovery by Asahara et al. (59) Previous studies have 
observed reduced numbers and decreased function of circulating EPCs in diabetes. 
(62-64) In our cohort, we observed no difference between CD34+ or CD34+ CD133+ 
cells between patients with type 2 diabetes and healthy controls. However, we did 
observe more than double in the proportion of CD34+ CD309+ cells in diabetes.  
In 2005, Fadini et al found in 24 patients with type 2 diabetes, a significant 
reduction in circulating CD34+ cells (33%) as well as CD34+ CD309+ cells (40%). A 
possible explanation for this difference may lie in dissimilarity between the cohorts of 
patients examined. There were a sizable number of patients (8/24 [33%]) in that 
cohort with peripheral vascular disease compared to none in our study. Loomans et 
al in 2004 similarly observed a 44% reduction in cells in 20 patients with type 1 
diabetes. However, this study was not comparable as “EPCs” were quantified after 
PBMCs from 60 mL of whole blood were cultured for 4 days, and mature endothelial 
cells markers CD31, DiI-labeled acLDL, and UEA-1 were used. It is now well known 
that cell culture conditions create an artificial phenotype in EPCs, and it is not even 
known whether this culture phenotype correlates with any cells actually existing in 
the bloodstream.(473) Tepper et al, examined 20 patients with type 2 diabetes (63) 
and also observed a 48% reduction of “EPCs” that were defined by CD34+ surface 
marker. Here, mature endothelial cell markers such as vascular endothelial (VE)-
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Cadherin, CD31 (474) were used again. It is likely these cells represented circulating 
endothelial cells (CECs) rather than EPCs. 
 Recent evidence from polychromatic flow cytometry with rigorous gating 
protocols have observed that CD34+ CD309+ cells were not detectable in peripheral 
blood samples from healthy volunteers.(475) This comes against much of the 
published literature to date, which though controversial, established a widely 
accepted the EPC marker combination; (CD34+CD133+CD309+) in the bone marrow. 
These cells also expressed CD31 at bright levels, suggesting that they were at an early 
stage of endothelial differentiation. To add to the controversy, there have also been 
inconsistent reports of CD133 as an identifier for EPCs that are able to differentiate 
both in vitro and in vivo along the endothelial lineage.(409, 410, 476)  The identity of 
the EPC remains controversial, even after a decade of examination. It is noteworthy 
that these observations were made on healthy volunteers. The diversity of EPCs 
numbers and phenotype observed in the literature may simply reflect different 
disease states. Elevation levels of EPCs, as defined by CD34+ CD309+, have been 
reported in head and neck cancer, hepatocellular carcinoma, haemangioma, and 
small cell lung cancer; suggesting their involvement in tumour vasculogenesis and 
tumour growth.(477-480) We similarly observed increased levels of CD34+ CD309+ 
cells in diabetes compared to controls. This may reflect the possible pro-angiogenic, 
pro-inflammatory role played by these cells in the development of diabetic eye 
disease, be it impaired vasculogenesis (retinal ischaemia) or neovascularisation 
(proliferative diabetic retinopathy.(477) Our results however, did not identify any 
difference in EPC profiles between different clinical phenotypes of diabetic eye 
disease, nor served as a biomarker for predicting the progression of disease severity. 
 A potential confounder in this study was the use of statins in 75% of our 
patients. A recent systematic review of both preclinical and clinical studies has shown 
that statins improve the number and function of both mesenchymal stromal cells and 
EPCs in cell-based regenerative therapy.(481) Of relevance to this thesis, the 13 
preclinical studies reviewed that involved the administration of stains alone to 
animals, an increase in the number and function of EPCs and improved organ 
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function was observed in 85% and 92% respectively. In the 7 clinical studies that used 
statins alone (without cell therapy), all similarly described an increase in EPC numbers 
and function and improved organ function. The concurrent use of statins in patients 
recruited to this study may therefore mask differences between disease and normal 
in our cohort. 
 
5.5.2 Monocytes in diabetic eye disease 
In this chapter, we observed no difference in monocytes proportions or their subsets 
in diabetes compared to controls. This is consistent with a study which examined a 
larger cohort of patients with type 2 diabetes (n=53) (111), but converse to another 
study in Type 1 diabetes that observed elevated levels of non-classical and 
intermediate monocytes.(110) This may reflect the pathophysiological differences 
between type 1 and type 2 diabetes and the role of the autoimmune response in 
former. CD16+ subsets of monocytes have been observed to be elevated in other 
autoimmune diseases, and thought to be involved in the induction of an 
inflammatory autoimmune response.(104, 482, 483) Of note, in type 1 diabetes, 
CD16+ monocytes (both non-classical and intermediate) were further associated with 
an increased risk of developing diabetic retinopathy. (110) 
We found significantly decreased CD309+ expression on classical (Figure 5.8 
top) and intermediate monocytes (Figure 5.8 middle), and a trend toward increased 
CD309+ expression in non-classical monocytes (Figure 5.8 bottom) in diabetes 
compared to controls. We propose that this reflects the reduced angiogenic capacity 
and pro-inflammatory state of patients with type2 diabetes. Under physiological 
conditions, CD309+ (also known as VEGFR2) expression is mostly limited to 
endothelial cells. It acts by binding (with greatest affinity) to VEGF-A to transduce a 
signal for angiogenesis via a tyrosine kinases pathway.(484) However, many reports 
have indicated that bone marrow derived “EPCs” are mostly of myeloid origin.(485) 
Moreover, in the peripheral circulation, CD309 expression has been mainly observed 
in monocytes, not CECs or EPCs (475), and is upregulated after tissue injury.(455) 
Also, it is these CD309+ monocytes that have been observed to contribute to re-
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endothelialisation of balloon-injured femoral arteries in mice.(486). Monocytes have 
angiogenic properties and participate in both physiological and pathological 
angiogenesis (485), either by orchestrating the process through it secretory activity 
or directly incorporating into blood vessels.(74, 487-489) Circulating monocytes have 
further been reported to express the mature endothelial marker CD31 in tumour 
angiogenesis.(490) Therefore, in this study, it is possible that reduced expression of 
CD309 observed in the classical and intermediate monocytes of patients with type 2 
diabetes, reflect the impaired reparative process in the microvasculature of the 
retina.  
This theory is supported by our findings that in DMI (retinal capillary loss) we 
observed a significant increase in intermediate monocytes that co-expressed CD309. 
(Figure 5.10) This may be a dynamic alteration of the monocytic phenotype in 
response to tissue injury in the retina (up regulation of pro-angiogenic monocytes), or 
it may reflect an impaired physiological homeostatic repair of the retinal 
microvasculature resulting in retinal capillary loss. It has been suggested that 
intermediate monocytes may represent a journey of transition from classical to non-
classical monocytes (103), and increased in different disease states. (104-106) It is 
therefore more likely that the increase in pro-angiogenic intermediate monocytes 
observed in this study, is a response rather than the cause of macular ischaemia. 
Interestingly, in DMO (leaking retinal capillaries), we observed a significant 
increase in classical monocytes which co-expressed both CD309 and CD163. (Figure 
5.9) Classical monocytes are known to direct pro-inflammatory responses to injury. 
CD163 is a member of the scavenger receptor cysteine-rich superfamily, whose 
expression is restricted to the monocyte/macrophage lineage.(457, 458) CD163+ 
monocytes have been observed to develop in the “healing phase” of an acute 
inflammatory reaction (459, 460), and shown to produce both anti-inflammatory and 
angiogenic factors (491, 492). In addition, IL-6 and IL-10 (anti-inflammatory cytokines) 
and dexamethasone have been shown to induce CD163 mRNA expression in 
monocytes.(470) CD163 expression has therefore been associated with an anti-
inflammatory response. The differential expression CD163+ monocytes may be one 
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of the explanations as to why different phenotypes of diabetic eye disease occur. In 
DMO, it may be a response to chronic low-grade inflammation caused by the gradual 
accumulation of fluid in the intra-retinal and sub-retinal spaces of the macula. 
Furthermore, CD163+ cells have been observed in significant numbers in both dry 
and neovascular age-related macular degeneration (AMD).(493) In dry AMD, CD163+ 
cells were restricted to the inner retina, whereas in neovascular AMD (where 
neovascularisation from the choroid is present and leakage of fluid occurs into the 
retina), CD163+ cells were markedly increased in all layers of the retina. This suggests 
that CD163+ cells are recruited from the peripheral circulation into the retina and 
confirms the association between pathological fluid accumulation in the retina and 
these cells. These support the hypothesis that CD163+ cells play a role in the 
pathophysiology of DMO. 
We observed that older patients (>60 years) also had a significantly higher co-
expression of both CD309 and CD163 classical monocytes. Although frequency of 
total monocyte counts in PBMC has been observed to increase with age (494), the 
relationship of CD163+ monocytes with age has not been previously described in 
diabetes. This difference may also reflect the chronicity of disease in the older 
patients. In the United Kingdom, obesity is defined by a BMI of greater than 30. In 
these patients, we observed a significant increase in non-classical monocytes, which 
co-expressed CD309. Increased proportions of the “pro-inflammatory” non-classical 
monocytes have been observed in previous studies, though the expression of CD309 
in these cells have not been previously described. The increased expression of CD309 
in obese patients may contribute to their severity levels of diabetic eye disease. This 
study was not powered to assess this question, but large population-based studies 
have observed an association between BMI and the presence and severity of diabetic 
eye disease.(495-497) 
 Perhaps our most clinically relevant results were the differences observed in 
monocyte subsets when we compared patients who progressed in diabetic eye 
disease severity with those who remained stable over a period of 4 years. (Figure 
5.12) The proportion of classical monocytes was depressed and non-classical 
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elevated in those who progressed in diabetic eye disease severity independent of 
age. Differences in the relative proportions of monocytes subsets have been reported 
in a myriad of other chronic conditions such as coronary artery disease, liver cirrhosis, 
and obesity.(498-500) If validated in a larger cohort of patients, relative proportions 
of monocytes subsets may be used as a biomarker for diabetic eye disease. 
 
5.6 Chapter summary: 
 
In this chapter, EPC and monocyte profiles were examined in patients with type 2 
diabetes and compared to controls. Associations between these, and clinical 
demographic information and diabetic eye disease phenotype were compared. 
Although no difference between EPC and monocyte subsets was detected between 
groups, a greater proportion of EPCs that co-expressed the pro-angiogenic marker 
CD309+ was observed in diabetes compared to controls. Conversely, in monocytes 
(classical and intermediate), the proportion of cells expressing CD309+ was reduced 
in diabetes compared to controls. CD309+ expression was raised however, in patients 
with macular ischaemia (on intermediate monocytes), and those who were greater 
than 60 years of age (on classical monocytes). In DMO, elevated co-expression of 
CD309+ and the anti-inflammatory CD163+ surface marker was observed on classical 
monocytes, similar to those with a BMI greater than 30 (M1). Finally, a low 
proportion of classical monocytes and a high non-classical monocytes were both 
associated with progression of diabetic eye disease, independent of age. 
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6. Final discussion and Outlook 
 
6.1. Final Discussion: 
The aim of this work was to better understand diabetic macular ischaemia (DMI); 
identify novel methods of quantifying this disease entity and explore its relationship 
to circulating of cellular mediators of angiogenesis and inflammation, with the view 
to developing therapy in the longer term. The reasons behind this goal were the 
paucity of literature in the area, largely due to the lack of treatment for this 
condition, and the devastating effects observed in some patients in clinical practice. 
Not only were retinal specialists unable to offer treatment, there was no knowledge 
of prognosis for these often working-age patients. At the time of conception of this 
thesis, there were promising early results from clinical trials using EPCs for the 
treatment of ischaemic conditions. There was also evidence to show EPC dysfunction 
in diabetes, arguing against the feasibility of autologous cell therapy, and indications 
that inflammation played a vital role in impairment angiogenesis observed in diabetic 
microvascular disease. For these reasons, novel methods of retinal imaging analyses 
were performed on data collected from human and animal models of vascular and 
inflammatory disease. Circulating EPCs and monocytes were further examined for 
associations with severity and progression of diabetic eye disease. 
 In the second chapter, data regarding the visual impact of diabetic ischaemia 
was presented. Visual loss was observed to occur only in moderate to severe disease, 
and preserved in questionable and mild ischaemia. (Table 2.4) Capillary non 
perfusion of the nerve fibre layer of the papillomacular bundle was also found to be a 
strong independent risk factor for visual loss. The natural history of the disease was 
further described; with the foveal avascular zone expansion rate of 5-10% increase in 
area per year. (Figure 2.10) This data allows identification of a window of opportunity 
for therapy; ideally before visual acuity is affected, but where disease can be 
detected. The limitations of this study were inherent to its retrospective design. Data 
collection was dependent on the frequency with which patients had fluorescein 
angiography - the main retinal imaging modality used to assess diabetic macular 
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ischaemia. This procedure requires an intravenous injection of a fluorescein dye, and 
takes approximately 20-30 minutes to complete. It further carries a small risk of 
anaphylaxis thus precluding its frequent use in patients. Since the commencement of 
this work, the first commercially available OCT angiography device, since its first 
description in 1991(26), has become available (in the latter half of 2014). OCT 
angiography allows for a rapid (~6 seconds), non-invasive (dye injection not required) 
means to visualise not only the superficial retinal capillary plexus, but also the deeper 
layers down to the choriocapillaris.(501) (Figure 6.1) The ease with which these 
images can be acquired will enable patients with DMI to be monitored more closely 
and will further provide information regarding deep retinal capillary perfusion, and 
nerve fibre layer perfusion (Figure 6.2) not possible conventional fluorescein 
angiography. Moreover, quantification of capillary density has been automated 
(Figure 6.3) unlike the manual delineation performed in this study, which will make it 
more amenable to clinical use. In future, data generated from this study will inform 
assessment performed in patients using OCT angiography, will be useful in identifying 
patients with progressive macular ischaemia who may be ideal candidates for 
regenerative therapy. 
 In chapters 3 and 4, novel methods for quantifying inflammation in the 
vitreous and retina were described. For the purposes of monitoring inflammation in 
clinical practice, techniques used much fulfil the following criteria; it must be safe, 
efficient, and sufficiently comfortable for the patients for the purpose of repeated, 
longitudinal imaging, and it must not alter the behaviour of cells being measured (i.e. 
incite inflammation). Current methods for measuring inflammation include indirect 
analyses such as levels of CRP in blood, visualising the leakiness of a vessel or swelling 
of the retina. Cellular imaging has also been limited to ex-vivo labelling that has 
inherent limitations such as phenotypic and genotypic alterations that occur when 
cells are taken out of the circulation, and being only able to observe cells that are  
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Figure 6.1. An example of an OCT angiogram of a normal eye and an eye 
with diabetic macular ischaemia.  
Superficial (left) and deep (right) capillary plexus in the macula of a normal subject (Top row) and in 
diabetic macular ischaemia (Bottom row) 
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Figure 6.2. An example of an OCT angiogram of an optic nerve head. 
Superficial (left) retinal nerve fibre layer capillary plexus and deep (right) ganglion cell layer capillary 
plexus from a patient with type 2 diabetes. 
 
 
Figure 6.3. Quantification of capillary density on OCT angiograms. 
Different severities of diabetic macular ischaemia; none (left) moderate (middle) and severe (right). 
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re-infused into the circulation. In this work, we developed more direct measures for 
inflammation in the eye using state-of-the-art retinal imaging technology-OCT, and 
further developed a simple method using ICG to label cells in vivo. In the field of 
regenerative medicine, this latter technique may further allow direct visualisation of 
cell-mediated inflammation regardless of the type of cell or tissue transplanted. 
In chapter 5, we assessed EPC and monocyte profiles in the context of 
diabetic eye disease. Although we observed elevated levels of EPCs as defined by 
CD34+ CD309+, we failed to find any differences between subsets of diabetic eye 
disease as previously reported (93), or identify any associations with the progression 
of disease. This may reflect the limitations of and difficulties encountered when 
analysing a rare cell population; comparing proportions as low as 0.001% of the total 
PBMC population. The use of different technique for examining EPCs will, in future, 
improve our ability to accuracy detect differences between groups. Transcriptome 
analysis is one example that has been successfully used to characterise different 
culture-derived EPC subsets.(449, 450) Gene-expression profiling has highlighted the 
changes in which EPCs undergo during culture, and it was further able to detect 
changes in gene transcription in the context of disease. Results were consistent in 
both groups, demonstrating high similarities between a population of cultured EPCs 
and CD14+ monocytes. However, these studies did not examine the circulating EPC 
(without a culture step), possibly due to the rarity of this cell population in peripheral 
blood and potential difficulties obtaining sufficient numbers for analysis. A limitation 
of this method is that biological effects do not take place at a transcriptional level; 
and future efforts will likely require the integration of proteomic and metabolomics 
approaches in order to perform comprehensive profiling of the EPC. 
In this chapter, differences in monocytes subsets were observed in the 
context of progression. Interestingly, there were no initial associations between 
monocyte subsets and eye disease severity at the outset. The expansion of CD16+ 
monocytes in the context of inflammation has been previously reported several 
publications (502-505), and is consistent with our observations, which further 
supports the notion of diabetes being a disease of inflammation. A recent large 
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population-based cohort study has further underlined the importance of 
inflammatory and immune response in the development of type 2 diabetes; revealing 
elevation of biomarkers such as C-reactive protein (CRP), total leukocyte count, IL-1, 
and IL-18 years before the onset of diabetes. A limitation of our monocyte analysis 
was the potential presence of confounding cells which express CD16+ i.e. neutrophils 
and natural killer cells. Although, published gating strategies were used for the 
quantification of flow cytometry data, we did not perform multiparameter imaging 
cytometry or use high-dimensional automated clustering algorithms to confirm the 
robustness of our gating strategy. Further, there is debate regarding Ficoll-based 
purification techniques of blood monocytes resulting in expansion of the CD16+ 
fraction.(462, 506) Ideally, whole-blood FACS analysis should have been performed to 
confirm our findings.  
 
6.2. Outlook: 
Fictitious clinical scenario: 
“Mrs Smith has had type 2 diabetes for over 25 years, she arrives in the eye clinic for 
her 6th appointment this year for an anti-VEGF intravitreal injection for diabetic 
macular oedema. This has improved anatomically but her vision has not recovered. 
OCT angiography reveals concurrent diabetic macular ischaemia with moderate 
severity and quantitative analysis shows an increase in FAZ area of 20% from 
baseline. Whole blood analysis for monocyte subsets has confirmed alterations in her 
monocyte fractions. She is offered targeted intravitreal immunomodulatory therapy, 
which she can receive at the same time as her anti-VEGF injection. If this fails, an 
alternative is discussed, which will involve an intraocular injection of autologous 
monocytes repaired ex-vivo. Regeneration of foveal capillaries will be monitored using 
OCT angiography, and location of transplanted cells visualised with ICG labelling” 
 
Important barriers toward bringing this fictitious clinical scenario into the 
realms of reality include; the lack of understanding of the role of monocytes in the 
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retina, its microcirculation, and the difficulties encountered in visualising these cells 
in in vivo. Nonetheless, there is evidence to suggest that monocytes play a key role in 
microvascular diseases, and their relative larger numbers in the peripheral circulation 
(compared to EPCs) make cells more suitable for autologous transplantation. 
However, its plasticity in culture, i.e. displaying endothelial-like genes when co-
cultured with endothelium, or changes in antigenic phenotype when co-cultured with 
lymphocytes, and propensity to stick to plastic within minutes, are all factors that 
could arguably be considered equally as strengths or weaknesses in its campaign for 
candidacy in the field of regenerative therapy. In cell therapy, the challenges faced by 
monocytes lies not only in determining what subset to transplant, but also where to 
place it. Fortunately, monocytes have the pragmatic ability to home to sites of 
“injury” and there is evidence from hindlimb ischaemia models that intramuscular 
injections of these cells are equally effective as the intravenous route.(118) Another 
option for new treatment is intravitreal immunomodulatory therapy. The mainstay of 
which continues to be corticosteroids, which works via broad spectrum of action, 
potentially inhibiting both “good” and “bad” cells. More recently, newer-steroid 
sparing such as sirolimus, adalimumab, and gevokizumab, targetting specific 
inflammatory cytokines have been developed for intravitreal use in non-infectious 
uveitis and may be explored in the context of diabetic eye disease. In fact, systemic 
gevokizumab has entered phase 2 studies for the treatment of diabetic nephropathy.  
It is likely that a form of immune regulation will play a role in the treatment of 
diabetic eye disease in the future. Whether it will be a game changer the way anti-
VEGF therapy has been over the past 5 years remains to be seen. Lastly, the 
importance of establishing meaningful clinical end-points and surrogate markers for 
efficacy must not be overlooked and defined at the outset of trials. These end-points 
should reflect clinical significance beyond statistical significance. 
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